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Influenza is a significant cause of morbidity and mortality worldwide. Individuals 
with underlying immune conditions, including the very young, are particularly vulnerable. 
Infection elicits lasting antibody and T cell-mediated immune responses although 
antibody-mediated protection is limited due to the mutagenic nature of influenza viral 
surface antigens. T cell responses, in contrast, target conserved viral proteins and can 
protect from highly disparate strains. Compared to circulating memory, non-circulating, 
lung tissue-resident memory T cells (TRM) generated following influenza infection 
mediate enhanced viral clearance and protection following challenge. Thus, vaccination 
strategies promoting TRM may convey enhanced protection from disease compared to 
those relying on circulating responses. The factors governing TRM generation, 
however, are unclear and whether individuals most susceptible to infection, such as the 
very young, generate functional TRM is not known.  
This body of work investigates the nature of T cell responses and TRM 
establishment following influenza vaccination and infection in early life and adulthood. 
We have identified distinct capacities of commercially available inactivated influenza 
virus (IIV) and live-attenuated influenza virus (LAIV) vaccines to elicit protective 
responses with IIV inducing strain-specific neutralizing antibodies and LAIV generating 
lung-localized, virus-specific TRM capable of providing heterosubtypic protection upon 
	  
viral challenge. We have further found that infants generate robust primary T cell 
responses following influenza infection or LAIV vaccination comparable to adults. 
However, mice infected or vaccinated in infancy fail to efficiently generate TRM and are 
less protected from subsequent infection in adulthood. We have identified enhanced 
expression of T-bet, known to promote effector differentiation while limiting memory T 
cell establishment, by primary infant effectors and further demonstrate that 
heterozygous infants expressing reduced T-bet generate lung TRM comparable to 
adults. Together, these findings have implications in influenza vaccine design, 
highlighting differing mechanisms of protection between IIV and LAIV, establishing TRM 
as a correlate of vaccine-mediated protection to influenza, as well as identifying cell-
intrinsic dysregulation of a transcriptional pathway early in life necessary for effective 
lung TRM generation. 
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CHAPTER 1: Introduction 
 
Life is tough, my darling, but so are you 
- Stephanie Bennett Henry 
 
Section 1.1: Influenza viruses and the burden of disease 
Influenza infection is a significant cause of morbidity and mortality worldwide 
which disproportionally affects individuals at the extremes of age, including the very 
young and very old, as well as pregnant women, immunocompromised individuals and 
those with underlying medical conditions. Influenza virus is spread primarily via 
inhalation of aerosolized large-droplet respiratory particles as well as direct contact with 
respiratory secretions or contaminated fomites. Following exposure, the viral incubation 
period is approximately 1 to 4 days and progresses to moderate to severe acute 
respiratory illness characterized by fever, myalgia and malaise. Influenza infection 
results in an estimated one billion cases of disease worldwide and an average of 
300,000-500,000 deaths annually. In the United States alone, influenza illness results in 
200,000 hospitalizations each year with an associated economic burden of over 10 
billion dollars (1-3). 
The highest rates of illness and hospitalization occur in children younger than 2 
years of age and in adults older than 65 years (4). Children typically have the highest 
attack rates during community outbreaks of influenza and also serve as a major source 
of transmission of influenza within communities partially due to prolonged viral shedding 
compared with adults. Influenza illness is responsible for 13% of total cases of pediatric 
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acute lung injury and 2-7% of associated deaths (5). Older children from 2 to 5 years of 
age are at less risk of hospitalization than younger children, but are at increased risk for 
influenza-associated clinic visits and children with comorbidities, including asthma and 
cystic fibrosis, have a risk of hospitalization and illness-associated complications similar 
to very young children (6).  
While vaccines for influenza are available, due to multiple factors, including 
variations in viral strains and variable induction of protective immune responses in 
vaccine recipients, current vaccines are not completely protective against infection with 
seasonal strains and are ineffective at protecting against emerging or pandemic strains 
(7). Furthermore, protective vaccine responses among infants and children are reduced 
compared to adults (8). Significantly, the increased disease burden early in life 
necessitates our increased understanding of disease processes and immune responses 
in this age group as well as the factors necessary to generate effective vaccine 
responses. 
 
Section 1.1.1: Influenza viral structure and strains 
In order to study the immune response to influenza, it is essential to understand 
viral pathogenesis and the nature of infection. Influenza viruses are a collection of 
enveloped, single-stranded, negative-sense segmented RNA viruses belonging to the 
group Orthomixoviridae. There are three major viral types; A, B and C. The vast majority 
of disease in both humans and animals is associated with influenza A viruses (IAV). 
Influenza B viruses (IBV) cause disease only in humans, but illness is generally milder 
and widespread outbreaks are less common than with IAV. Influenza C viruses are 
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somewhat structurally distinct from IAV and IBV with seven, rather than eight, genomic 
RNA segments (9). Like IBV they also infect only humans but cause only mild upper 
respiratory disease.  
The genome of IAV (henceforth referred to as ‘influenza’) consists of eight RNA 
segments encoding 11 proteins as described in Table 1.1 (10). Mature viral particles 
consist of a ribonucleoprotein core containing genomic single-stranded RNA segments 
complexed with nucleoprotein (NP) monomers packaged with the three viral polymerase 
proteins; polymerase basic protein 1 (PB1), polymerase basic protein 2 (PB2) and 
polymerase acidic protein (PA). This core is surrounded by a host-derived lipid bilayer 
membrane studded with matrix 2 (M2), hemagglutinin (HA) and neuraminidase (NA) 
proteins. Viral matrix 1 (M1) sits just below the lipid bilayer while nuclear export 
protein/nonstructural protein 2 (NEP/NS2) is contained within the viral particle between 
the core and the enveloped membrane. Nonstructural protein 1 (NS1) is not contained 
within the mature virion, but has pleiotropic functions during the intracellular phase of 
the viral lifecycle including viral mRNA translation, as well as antagonism of host type I 
interferon (IFN) responses (11). The remaining viral protein PB1-F2 is also not 
contained within the mature viral particle but is expressed during replication and plays a 
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Table 1.1: Influenza A virus (IAV) proteins and function 
Proteins encoded by the influenza A viral genome including their localization 
within the mature virion and their function during infection. Table adapted from (13). 
 
	  
Viral Protein Location Function 
Hemagglutinin Envelope Viral binding to host sialic acid receptors 
Neuraminidase Envelope Cleavage of host sialic acid upon viral budding 
Matrix Protein-1 Matrix Structural 

























Export of viral 
ribonucleoproteins 
PB1-F2 Expressed in Host Host cell apoptosis 
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Figure 1.1: Influenza A virus (IAV) proteins and structure 
Schematic representation of a mature influenza A viral particle denoting surface 
and structural proteins as well as accessory proteins contained within the virion 
following budding from the host cell. Mature viral particles have a ribonucleoprotein core 
containing viral single-stranded RNA segments wound around nucleoprotein (NP) 
monomers packaged with the three viral polymerase proteins; polymerase basic protein 
1 (PB1), polymerase basic protein 2 (PB2) and polymerase acidic protein (PA). The 
ribonucleoprotein core is surrounded by a host-derived lipid membrane studded with 
matrix 2 (M2), hemagglutinin (HA) and neuraminidase (NA) proteins. HA and M2 are 
necessary for host cell binding and entry, respectively. NP mediates viral release. Viral 
matrix 1 (M1) lines the internal side of the lipid bilayer. Nuclear export 
protein/nonstructural protein 2 (NEP/NS2) is contained within the viral particle. The 
remaining viral proteins nonstructural protein 1 (NS1) and PB1-F2 are not contained 
within the mature virion. NS1 has pleiotropic functions during the intracellular phase of 
the viral lifecycle including antagonism of host type I interferon (IFN) responses. PB1-F2 
is expressed during replication and plays a role in enhancing viral virulence 
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Influenza A viruses are further divided into subtypes based on the expression of 
various HA and NA surface glycoproteins. Currently, there are 16 serologically distinct 
HAs and 9 distinct NAs recognized (Table 1.2). Humans are commonly infected with 
viruses containing H1, H2 or H3 hemagglutinin and N1 or N2 neuraminidase serotypes 
(Table 1.2). However, H5, H7 and H9, which are derived from avian strains, have been 
identified in humans in outbreak situations (14). Strains are further classified based on 
WHO nomenclature guidelines according to host, geographic location of isolation, 
lineage number and year of isolation (15) (e.g., A/duck/Alberta/35/76 (H1N1)). 
 
Section 1.1.2: Infection of host cells 
Influenza HA and NA represent the major viral antigenic determinants and are 
critical for entry to and budding from host cells. Viral HA binds to 2,3-linked or 2,6-linked 
sialic acid residues expressed by airway and alveolar epithelial cells and mediates viral 
endocytosis by host cells in conjunction with M2. As a result, primary infection and viral 
replication occurs within the epithelial cells of the upper and lower respiratory tract. 
Following replication and budding, NA cleaves sialic acid residues from the surface of 
the host cell, thus preventing their interaction with HA present on newly synthesized 
viral particles and allowing for release of new mature virions. 
  
	  
	   8	  
Table 1.2: Influenza Hemagglutinin and Neuraminidase subtypes 
Currently described HA and NA serotypes including host type(s) which they are 




Subtype Human Equine Swine Avian 
Protein 
Subtype Human Equine Swine Avian 
H1 +  + + N1 +  + + 
H2 +  +/- + N2 +  + + 
H3 + + + + N3    + 
H4    + N4    + 
H5 +/-   + N5    + 
H6    + N6    + 
H7 +/- +  + N7  +  + 
H8    + N8  +  + 
H9 +/-  +/- + N9    + 
H10    +      
H11    +      
H12    +      
H13    +      
H14    +      
H15    +      
H16    +      
 
+ indicates frequently isolated from members of a group 
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Due to the error-prone nature of the viral polymerase during replication, viral 
genes are susceptible to mutation (16). The selective pressures of the host immune 
system upon the antigenic HA and NA molecules make these molecules particularly 
subject to variability. The accumulation of such point mutations over time is referred to 
as antigenic drift. Furthermore, the segmented nature of the influenza genome allows 
for the exchange of entire genome segments between viruses coinfecting a single cell. 
Infection with more than one strain can result in the generation of novel ressortant 
strains, a phenomenon referred to as antigenic shift.  
 
Section 1.1.3: Pandemic influenza infection 
The introduction of new influenza strains as a result of antigen drift and shift can 
result in pandemic disease. Pandemic strains differ from seasonal strains in that 
transmissibility and morbidity are higher, often due to a lack of host immune memory to 
novel strains. Several examples of severe influenza pandemics have been documented 
in the last century beginning with the 1918 influenza pandemic. The 1918 H1N1 strain 
has been shown to be a recombinant strain derived from an avian H1N1 influenza virus 
(17, 18) and resulted in an estimated 50 million deaths worldwide (19). Interestingly, 
direct descendants of the 1918 virus are still in circulation today (11). In 1957 an H2N2 
ressortant virus derived from a recombination event involving the 1918 H1N1 virus and 
an additional avian strain was responsible for a pandemic event. Similarly, a pandemic 
in 1968 was caused by a ressortant H3N2 virus generated from a circulating H2N2 virus 
and an avian virus (11). Most recently, in the 2008-2009 influenza season the novel 
2009 H1N1 pandemic virus caused an estimated 60 million illnesses and greater than 
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12,000 deaths in the United States alone. Interestingly, this virus was a fourth-
generation descendant of the 1918 virus (20). 
In addition, multiple, limited outbreaks of highly pathogenic avian influenza 
viruses of H5, H7 and H9 subtypes have been recently observed. These viruses have 
been primarily associated with extensive infection of poultry species but can cause 
disease in individuals handling infected animals. Such disease may be severe and even 
fatal although human-to-human transmission is rare. Seasonal influenza strains which 
circulate widely in humans typically contain HA molecules with specificity to 2,6-linked 
sialic acid residues present in the upper respiratory tract while HA derived from avian 
strains preferentially bind 2,3-linked sialic acid residues which predominate in the lower 
respiratory tract (21).  
HA molecules of highly pathogenic avian influenza strains contain additional 
protease cleavage sites (protease cleavage is necessary for HA to become active) 
allowing them to be cleaved by endogenous proteases throughout the body, whereas 
normal HA can only be cleaved by trypsin-like proteases that are primarily found in the 
respiratory and gastrointestinal tracts (22) thus allowing the virus to act more 
systemically rather than remain localized to the respiratory tract. Such differences in 
viral localization may account, to some extent, for the enhanced disease, but reduced 
transmissibility associated with these avian influenza strains. The highly pathogenic 
nature of these viral strains, however, has raised the concern that additional mutations 
resulting in improved viral transmission, such as changes in sialic acid specificity of HA, 




Section 1.2: Innate immunity 
The innate immune response, in general, is characterized by rapid recognition 
and responses against pathogen components with limited capacity to establish 
conventional long-term immune memory. Important functions of the innate immune 
system include 1) initiating inflammatory responses and recruitment of innate and 
adaptive immune cells to the site of infection through the release of cytokines and 
chemokines, respectively, 2) direct lysis and directed phagocytosis of invading 
pathogens via activation of the complement cascade, and 3) activation of the adaptive 
immune system through antigen presentation. 
 
Section 1.2.1: Components of the innate immune system 
The most fundamental components of the innate immune system include 
physical and chemical barriers which serve to inhibit initial pathogen entry to the body. 
In the nasopharyngeal and respiratory tracts the epithelium represents a physical barrier 
to pathogen entry. The beating action of cilia in the respiratory tract and mucus in the 
nasopharyngium similarly help to remove pathogens prior to invasion. Chemical agents 
such as lysozyme present in mucus and surfactant in the lungs help to lyse or kill 
pathogens, preventing the establishment of productive infection. 
The innate immune system further hosts several specialized cell types present 
throughout the body, both within the blood and in the tissues, which further function to 
eliminate pathogens bypassing primary physical and chemical barriers. Innate immune 
cells include phagocytic cells such as neutrophils, macrophages and dendritic cells 
(DCs) that engulf and digest pathogens and pathogen-infected cells; natural killer (NK) 
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cells which target and lyse virally-infected cells; and granulocytes (including neutrophils) 
such as eosinophils, basophils and mast cells which are characterized by the presence 
of cytoplasmic granules containing antimicrobial agents which vary by cell type. Most 
innate cells are derived from common myeloid progenitors (CMP) during hematopoiesis 
with the exception of NK cells which are derived from common lymphoid progenitors 
(CLP). In addition to direct antimicrobial functions macrophages, DCs and neutrophils 
are important producers of inflammatory cytokines and chemokines which further direct 
localized inflammation and recruitment of additional immune cell types to the site of 
infection. Inflammatory cytokines important in innate immune responses include IL-1, IL-
6, IL-10, IL-18, TNF-alpha, granulocyte–macrophage colony-stimulating factor (GM-
CSF), and Type I Interferons (IFN, IFN-alpha and IFN-beta) (23, 24). 
 
Section 1.2.2: Pathogen recognition by innate immune responders 
One of the most critical functions of the innate immune response is its ability to 
initiate the activation of the adaptive response, including pathogen-specific B cells and T 
cells. Cells within the innate immune system recognize defined molecular moieties 
referred to as pathogen-associated molecular patterns (PAMPs) derived from foreign 
invaders. Examples of PAMPs include conserved pathogen-derived molecules such as 
lipopolysaccharide (LPS), flagellin, peptidoglycan or double-stranded RNA. Detection of 
PAMPs is mediated by pattern recognition receptors (PRRs). The most well-defined 
PRRs include 1) Toll-like receptors (TLRs) (25, 26), which are membrane-bound 
proteins present on the cell surface or within endocytic vesicles that signal through NF-
kappa-B and MAP kinase pathways to induce cytokine secretion or co-stimulatory 
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molecule expression, 2) NOD-like receptors (NLRs) (27, 28), which are cytoplasmic 
proteins that generally regulate apoptotic responses, and 3) retinoic acid inducible 
gene-1-like receptors (RLRs)(29), which recognize viral genomic RNA and DNAs and 
promote antiviral gene programs and signaling, generally mediated by Type I IFNs. 
Recognition of PAMPs by PRRs in specialized phagocytic cells termed antigen 
presenting cells (APCs) results in their activation and maturation. Although several 
immune cell subsets can act as APCs, DCs are the most potent, processing antigen 
derived from both the extracellular environment as well as intracellular antigens derived 
from infection of the DC itself and displaying peptide fragments on the cell surface in the 
context of major histocompatibility (MHC) molecules. Classically, MHC class I 
molecules display peptides derived from cell-intrinsic sources to activate CD8+ T cells 
while MHC class II molecules display peptides derived from cell-extrinsic sources to 
activate CD4+ T cells. However autophagy (30) and cross-presentation (31) pathways 
allow for the generation of CD4+ T cells specific to intracellular antigens, such as those 
derived from virally infected APCs, and CD8+ T cells specific to extracellular antigens, 
such as those derived from phagocytosis of dead or dying virally-infected cells. 
Following activation, APCs express increased levels of MHC, allowing them to display 
pathogen-derived peptides for recognition by cognate antigen-specific T cells, as well as 
increased levels of co-stimulatory molecules necessary for T cell activation, including 
CD40 and CD80/CD86, and cytokines, which provide an additional T cell activation 
signal (Figure 1.2). Upon activation, DCs upregulate the lymph node homing marker 
CCR7 facilitating their migration from the tissues to the tissue-draining lymph nodes 
where naïve T cells are localized (32, 33). 
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Figure 1.2: Activation of antigen presenting cells (APCs) 
Recognition of pathogen-associated molecular patterns (PAMPs) by APCs 
results in their activation and maturation. Dendritic cells (DCs) are the most potent 
APCs, processing antigens derived from both cell-extrinsic and cell-intrinsic sources 
and displaying peptide fragments from these antigens on the cell surface in the context 
of major histocompatibility (MHC) molecules. Following activation, APCs upregulate 
expression of MHC and T cell co-stimulatory molecules including CD40 and 
CD80/CD86 as well as begin to secrete cytokines, including IL-12, all factors necessary 
for T cell activation. Activated DCs further upregulate the lymph node homing marker 
CCR7 allowing them to exit the tissues and migrate to the tissue-draining lymph nodes 
where naïve T cells are localized. 
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Section 1.2.3: Innate immune responses to influenza  
Influenza initially infects and replicates within airway epithelial cells. As infection 
progresses, phagocytic cells including alveolar macrophages and lung-resident DCs 
represent secondary targets for infection. Within infected cells, influenza is recognized 
by at least three distinct PRR classes: TLR3 and TLR7, retinoic acid inducible gene-1 
(RIG-1), and the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) 
inflammasome (34).  
TLRs 3 and 7 recognize double-stranded RNA and single stranded RNA, 
respectively, present within the endosomes. The endosomal localization of these 
receptors suggests that they detect viral RNA that has been taken up from the 
environment (cell-extrinsic recognition) rather than from within the responding cells 
themselves (cell-intrinsic recognition). TLR3 and 7 signal through the adaptor proteins 
TRIF and MyD88 leading to the activation of MAP kinases and nuclear factor-kappa B 
(NF-kappa-B) which promote inflammatory cytokine responses (24, 26). TLR3 
additionally signals through IRF3 and TLR7 through IRF7 to induce type I IFN 
responses (35) (Figure 1.3a and b). Although influenza does not have a dsRNA stage in 
its lifecycle, TLR3 signaling is important in primary proinflammatory responses to 
influenza infection (36, 37) and chemokine expression in the lungs is reduced and T cell 
migration is delayed in Tlr3−/− mice compared to WT mice (38). In the absence of 
TLR7, bone marrow derived macrophages produce reduced levels of the inflammatory 
cytokine IL-1-beta (39) and antibody responses in sublethally infected mice are reduced 
compared to WT although mice are protected. However, the same mice were unable to 
mount protective antibody responses to split-virus vaccine (40), demonstrating the 
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importance of this molecule in the generation of subsequent humoral immune 
responses. 
In contrast to TLRs, RIG-I detects virus that is present within the cytosol of 
infected cells (cell-intrinsic recognition). RIG-I recognizes influenza ssRNA 5′-
triphosphates (41) allowing it to interact with the adaptor mitochondrial antiviral signaling 
protein (MAVS). MAVS signaling, in turn, results in NF-kappa-B activation and the 
production of proinflammatory cytokines as well as type I IFN via IRF3 (Figure 1.3c). 
Induction of type I IFNs in response to influenza infection has been shown to be 
predominantly mediated through RIG-I (42, 43), and influenza virus-induced IFN 
expression in airway epithelial cells is RIG-I-dependent (37).  
Like RIG-I, NLRP3 detects intracellular virus. Detection of influenza infection by 
NLRP3 has been shown to depend on activity of the viral M2 protein upon infection (39). 
NLRP3 is expressed by myeloid cell types, including DCs, neutrophils and 
macrophages and forms an inflammasome complex in association with the adaptor 
ASC and cleaves pro-caspase-1 leading to subsequent activation of IL-1-beta and IL-18 
(27, 28). Inflammasome activation can additionally elicit pyroptosis of infected cells. In 
the context of influenza infection, NLRP3 promotes the recruitment of leukocytes into 
the lungs (44). Mice deficient in NLRP3 additionally suffer from increased mortality 
compared to WT (45). 
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Figure 1.3: Recognition of influenza viral particles by pattern recognition 
receptors (PRRs) 
Within host cells, influenza infection is recognized by PRRs including TLR3 and 
TLR7, retinoic acid inducible gene-1 (RIG-1) and the NACHT, LRR and PYD domains-
containing protein 3 (NLRP3) inflammasome (not shown). (A) TLR3 recognizes the 
presence of double-stranded RNA within the endosomes. Although influenza does not 
have a dsRNA stage in its lifecycle small amounts of dsRNA intermediates are thought 
to be generated during the process of replication. TLR3 signals through the adaptor 
protein TRIF leading to the activation of nuclear factor-kappa B (NF-kappa-B) which 
promotes inflammatory cytokine responses as well as IRF3 to induce type I IFN 
responses. (B) TLR7 recognizes viral genomic ssRNA within the endosomes. TLR7 
signals through the adaptor protein MyD88 leading to the activation of NF-kappaB to 
promote inflammatory cytokine responses and IRF7 to induce type I IFN responses. (C) 
RIG-I recognizes influenza ssRNA 5′-triphosphates, generated during the process of 
viral replication, in the cytosol of infected cells. RIG-I then interacts with the adaptor 
mitochondrial antiviral signaling protein (MAVS). MAVS signaling, in turn, results in NF-
kappa-B activation and the production of proinflammatory cytokines as well as type I 




































Following recognition of viral infection by PRRs, infected cells and phagocytic 
cells that have engulfed and processed virally-infected cells, begin to secrete 
proinflammatory cytokines, chemokines and type I IFN as described. Infected 
respiratory epithelial cells release inflammatory cytokines and chemokines including 
tumor necrosis factor-alpha (TNF-alpha), type I IFN, IL-6, IL-8, IFN-gamma-inducible 
protein-10 (IP-10), monocyte chemoattractant protein-1 (MCP-1, also known as CCL2) 
and CCL5 (46, 47). These molecules trigger a localized antiviral state within neighboring 
cells with type IFNs, in particular, stimulating the expression of a large collection of 
genes known as IFN-stimulated genes which have potent antiviral effects. In addition, 
secretion of chemokines recruits innate immune effectors including neutrophils and NK 
cells, as well as APCs, including macrophages and DCs, to the site of infection. 
Among the first innate immune cells to respond to infection are tissue-localized 
alveolar macrophages and neutrophils which are rapidly recruited to the site of infection. 
Both alveolar macrophages and neutrophils are critical for clearance of virally-infected 
cells during infection and act as important additional sources of inflammatory cytokines 
and chemokines recruiting additional cell types to the site of infection (48-50). 
Neutrophils have been demonstrated to protect from the severity of influenza infection in 
several mouse models (51-53) and their specific depletion results in increased 
morbidity, particularly in the context of infection with highly virulent virus (54). The 
presence of alveolar macrophages during influenza infection has been shown to protect 
against morbidity due to reduced lung pathology (55). Their depletion during influenza 
infection results in reduced production of proinflammatory cytokines, including TNF-
alpha, as well as reduced antibody production and recruitment of cytokine-producing 
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CD8+ T cells to the lung (49). Furthermore, alveolar macrophages have been shown to 
play a protective role in protection against secondary bacterial pneumonia following 
influenza infection (56). 
During influenza infection, NK cells recruited to the lung play an important role in 
the lysis of virally infected cells by recognition of MHC class I downregulation as 
‘missing self’ and additionally by the recognition of viral HA (57, 58). In addition, NK 
cells are important secretors of cytokine and help to promote virus-specific T cell 
responses through the release of IFN-gamma during infection (59, 60). Depletion of NK 
cells during influenza infection results in delayed viral clearance and worsened disease 
in mice (60) and reduced levels of NK cells correlate with exacerbated disease in 
humans (61).  
DCs are a diverse group of phagocytic cells present in the blood and throughout 
the tissues of the body that are routinely divided into two major subsets including 
include plasmacytoid DCs (pDCs) and myeloid or conventional DCs (cDCs). Within the 
respiratory tract, pDCs can be identified by their expression of B220 and are CD11c(lo). 
Conventional DCs, however, express high levels of CD11c and can be further 
subdivided by expression of the mucosal alpha-E integrin CD103 and the myeloid 
marker CD11b to generate CD103+CD11b(lo) (CD103+) and CD103-CD11b(hi) 
(CD11b(hi)) subsets (62). Following influenza infection, pDCs represent a major source 
of the anti-viral type I IFN, IFN-alpha. and may play important roles in T cell activation 
and polarization during infection through the production of cytokines (63-65).  
In addition to pDC responses, there is also an accumulation of both CD103+ and 
CD11b(hi) subsets within the lung interstitium following influenza infection (66-68). 
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Within the infected lung, both subsets take up viral particles and influenza-derived 
antigens, resulting in their activation and maturation. CD103+ DCs seem to have an 
increased capacity to migrate to the lung-draining MdLN and subsequently activate 
virus-specific CD8+ T cells relative to the CD11b(hi) subset which remains in the lung to 
produce inflammatory cytokines (68). CD11b(hi) DCs, however, may subsequently 
migrate and become the predominate antigen presenting population later in infection 
(69). Both CD103+ DC and CD11b(hi) DC subsets produce RANTES, important in 
effector T cell migration and IL-12, important in generating Th1-type immune responses, 
in response to influenza infection (70). 
 
Section 1.3: Adaptive Immunity 
In contrast to the rapid responses of the innate immune system, adaptive 
immunity is characterized by a delayed, but highly specific response that is tailored to a 
specific invading pathogen. Furthermore, adaptive immune responses have the capacity 
to generate immunological memory after initial pathogen encounter, which results in 
rapid and robust responses upon subsequent encounter with the same pathogen. The 
major cells types of the adaptive immune response include B and T lymphocytes, while 
APCs - DCs in particular - serve as and important link between the innate and adaptive 
immune systems and are necessary for lymphocyte activation. 
 
Section 1.3.1: Initiation of adaptive immune responses 
Adaptive immune responses are initiated to small molecules, generally proteins, 
but sometimes polysaccharides or lipids, termed antigens. Antigens are generally 
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derived from pathogens, but may also be derived from endogenous sources which may 
lead to autoimmunity. B and T cells both recognize antigens via the expression of 
antigen receptors. For B cells, this receptor is surface-bound antibody, called a B cell 
receptor (BCR), which can recognize antigen directly. In the case of T cells, antigen is 
recognized by the T cell receptor (TCR), but only in the context of MHC class I or class 
II molecules on the surface of other cell types.  
 
Section 1.3.1.1: Primary B cell activation and humoral immune responses 
Adaptive immune responses can be divided into two broad classes based on 
lymphocyte type: humoral responses, which are mediated by B cells and associated 
antibody responses, and cell-mediated responses, which are dominated by T cell 
responses. B cell responses are initiated in the spleen and lymph nodes in response to 
encounter with cognate antigen via its BCR. The responding B cell takes up this antigen 
via endocytosis, digests it, and displays peptide fragments on its surface in the context 
of MHC class II molecules. Antigens which require T cell help for complete B cell 
activation are termed ‘T-dependent’ antigens and represent the majority of protein 
antigens. Following display of peptide antigen on the B cell surface, specialized T cell 
subsets, termed T follicular helper (Tfh) cells, activated against the same antigen 
recognize cognate antigen on the B cell surface and bind MHC class II-peptide 
complexes via their TCRs. During this process, CD40 on the surface of the B cell 
interacts with CD40L (CD154) on the surface of the T cell providing costimulation (71). 
The antigen-specific T cell further provides cytokine stimulation including IL-4 and IL-21, 
promoting B cell proliferation, antibody class-switching, somatic hypermutation and the 
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formation of germinal centers (GCs) as a specialized microenvironment for activation to 
proceed. Help provided by Tfh also promotes GC B cells to differentiate into long-lived 
memory B cells and plasma cells (72). 
Plasma cells generated following resolution of infection or in response to 
vaccination represent the predominate source of long-term antibody production (73). 
They are a terminally differentiated B cell subset and highly express the transcription 
factor Blimp-1, which is also robustly expressed by terminally differentiated T cells (74, 
75). Plasma cells home to and remain localized predominantly within the bone marrow 
in a process mediated by CXCL12 and vascular cell adhesion molecule-1 (VCAM-1) 
(74). There are able to persist within this niche for prolonged periods allowing them to 
convey protection from reinfection that can be life-long (76). 
 
Section 1.3.1.2: Primary T cell activation and cell-mediated immune responses 
Similar to B cells, primary activation of naïve T cells occurs in the secondary 
lymphoid tissues where antigen-specific T cells encounter activated, mature APCs, 
generally DCs, displaying their cognate antigen in the context of MHC. CD4+ T cell 
activation requires peptide antigen displayed on MHC class II while CD8+ T cell 
activation requires antigen displayed on MHC class I. In addition to binding of the TCR 
and MHC-peptide complexes, T cells further require costimulation through the 
interaction of CD28 expressed on the surface of the T cell with CD80/86 expressed on 
the surface of the activated APC (77). Additional molecules such as OX40 and Inducible 
costimulator (ICOS) expressed by the T cell may also provide costimulation via 
interaction with ICOS-L and OX40-L, respectively, on the surface of activated APCs (71, 
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77). APCs further provide cytokine signals to T cells during the process of activation 
which promote their proliferation and survival, as well as influence their subsequent 
function and activated CD4+ T cells additionally provide cytokine signals, predominantly 
in the form of IL-2, which promote CD8+ T cell activation. 
 
Section 1.3.2: Primary effector T cell subsets 
Newly activated CD4+ T cells further differentiate into discrete T helper (Th) 
lineages with Th1, Th2, Th17, Tfh and inducible T regulatory (iTreg) subsets being the 
best defined (72, 78). The differentiation of distinct effector CD4+ T cell subsets is 
thought to depend on several factors but the cytokine environment in which cells are 
activated plays a fundamental role as cells activated in vitro in the presence of various 
cytokines develop into different lineages (78). The process is more complicated in vivo 
with factors such as the nature of the infecting pathogen, the combination of PAMPs 
encountered and the cytokine environment engendered by responding innate immune 
cells additionally playing roles. Though despite some understanding of these factors, 
much of this process remains incompletely defined. 
It is understood, however, that in response to these environmental influences 
newly activated T cells upregulate one or two ‘master’ transcriptional regulators through 
various signaling pathways, which, in turn, drive defined transcriptional programs 
varying by subset (78, 79). Consequently, each subset has distinct functions mediated 
by a defined set of effector cytokines. Th1 cells are induced by IL-12 and ensuing 
STAT4 signaling drives the expression of the Th1 lineage-defining transcription factor T-
bet. Expression of T-bet, in turn, drives inflammatory responses mediated by IFN-
	  
	  26	  
gamma and TNF-alpha that are particularly effective in protection from viral infection 
and influenza infection results in a Th1 biased response. Analogously,Th2 differentiation 
is mediated by IL-4 activation of STAT6 signaling which induces the transcription factor 
GATA3. IL-4, IL-5 and IL-13 are the major Th2 effector cytokines which promote 
antibody responses and protection from extracellular bacteria and parasites. Th17 cells 
can be generated by IL-6 and TGF-beta-mediated STAT3 signaling and produce 
several cytokines including IL-17A and F, IL-21 and IL-23. The Th17 subset has been 
implicated in several inflammatory conditions, but is thought to be necessary for 
effective clearance of extracellular bacteria and fungi. Tfh cells are generated following 
IL-6 and IL-21 signaling resulting in upregulation of Bcl6. Tfh cells secrete IL-4 and IL-
21 and provide B cell help and promote germinal center (GC) formation, which is 
necessary for antibody generation during infection. Peripheral or inducible Tregs are 
generated by IL-2 and TGF-beta which signal through STAT5 to promote FoxP3 
expression. Tregs promote immune tolerance via the production of IL-10 and TFG-beta 
(78, 79). 
A summary of currently described CD4+ T cell subsets, the cytokines and 
transcriptional regulators which induce them and their function during infection are 
depicted in Figure 1.4. 
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Figure 1.4: CD4+ T cell subset differentiation and function 
The cytokine microenvironment in which naïve CD4+ T cells are activated results 
in the generation of various T helper (Th) cell subsets including Th1, Th17, T follicular 
helper (Tfh), T regulatory (Treg) and Th2 populations. Each subset is controlled by one 
or two ‘master’ transcriptional regulators which drive the expression of defined cytokine 
subsets within responding cells. Effector CD4+ subsets can be characterized by 
discrete patterns of cytokine secretion and have distinct functions that facilitate different 
types of immune responses. The induction of the Th1 subset occurs in response to IL-
12 and IFN-gamma signaling during activation which drives the expression of T-bet. T-
bet, in turn, promotes the secretion of TNF-alpha and IFN-gamma which are protective 
during infection with intracellular pathogens. The Th17 subset is induced by IL-6 and 
TGF-beta and mediated by ROR-gamma-t. Th17 cells produce IL-17A and F, IL-21 and 
IL-23 which promote the clearance of extracellular bacteria and fungi. Tfh cells are 
generated following IL-6 and IL-21 signaling which results in upregulation of Bcl6. Tfh 
cells secrete IL-4 and IL-21 and provide B cell help and promote germinal center (GC) 
formation, which is necessary for antibody generation during infection. IL-2 and TGF-
beta signaling during T cell activation result in the generation of peripheral Tregs which 
promote immune tolerance via the production of IL-10 and TFG-beta. Finally, the Th2 
subsets is generated by IL-4-mediated induction of GATA3 resulting in the generation of 
IL-4, IL-5 and IL-13 which promote immune responses to parasites and antibody 
production.  
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Less heterogeneity is thought to exist for effector CD8+ T cells and following 
activation, naïve CD8+ T cells differentiate primarily into cytotoxic effectors (CTLs) with 
the ability to lyse target cells expressing cognate antigen and to produce inflammatory 
cytokines including TNF-alpha and IFN-gamma (80, 81). As with CD4+ T cell activation 
and differentiation, this process is dependent on cytokine signaling and the induction of 
distinct transcriptional regulators. In many cases, IL-2 derived from CD4+ T cells is 
necessary in this process, although not strictly, and promotes CD8+ T cell proliferation 
and survival. Additionally, IL-12, derived from activated APCs, promotes the expression 
of the transcription factor T-bet, which is necessary for the generation of CTLs as well 
as their function (82, 83). T-bet-mediated differentiation of CTLs also requires the 
additional T-box transcription factor, Eomesodermin (Eomes) (84). T-bet is rapidly 
induced following activation and is necessary for early cytokine production (85), while 
Eomes is induced later during differentiation and, in conjunction with runt-related 
transcription factor 3 (Runx3), regulates the later expression of IFN-gamma, as well as 
the additional CTL effector molecules granzyme B and perforin which mediate lysis of 
target cells.  
 
Section 1.3.3: Primary adaptive immune responses to influenza infection 
Section 1.3.3.1: T cell activation 
As discussed, primary infection of respiratory epithelial cells following exposure 
to influenza virus leads to the activation, maturation and migration of DCs which have 
taken up viral antigens from the lung to the MdLN as part of the innate immune 
response to infection (Figure 1.5a). Mature naïve T cells expressing lymphoid homing 
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receptors, including CD62L (also known as L-selectin) and CCR7, traffic through the 
MdLN where they interact with activated, mature DCs bearing viral antigen and this 
interaction results in the activation of virus specific T cells (Figure 1.5b). Newly activated 
T cells begin to upregulation canonical activation markers including CD44 and CD69 as 
well as CD25, the high-affinity IL-2 receptor. They also begin to produce effector 
cytokines, beginning with robust production of IL-2, particularly in activated CD4+ T 
cells. The presence of IL-2 combined with increased expression of CD25 by responding 
cells results in substantial proliferation. Priming, activation, and expansion of naive 
influenza-specific CD8+ T cells in the MdLN occurs in the first 3 to 4 days following 
infection (86, 87) and similar results have been observed with virus-specific CD4+ T 
cells (88). Initiation of T cell responses in the MdLN corresponds approximately with 
peak viral titers in the lung which occur between D3 and D5 (89). 
The cytokine environment during influenza infection is dominated by IL-12 and 
IFN-gamma and T cells activated during infection will generally be of the Th1-type. Both 
responding CD4+ and CD8+ T cells upregulate expression of T-bet and secrete the 
characteristic Th1 effector cytokines TNF-alpha and IFN-gamma (90). CD4+ T cells 
additionally continue to secrete high levels of IL-2. Very few IL-4 producing T cells are 
present in the lung during influenza infection suggesting the absence of a robust Th2 
response (88). Consistent with this, transfer of Th2-polarized influenza-specific T 
effectors offers little to no protection during infection (91). Despite the dominance of 
Th1-type responses in infection, studies have demonstrated the robust generation of 
Tfh populations in the MdLN as well as the spleen following influenza exposure (92) and 
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these responses drive B cell activation and the generation of robust T-dependent 
antibody responses to influenza (92). 
 
Section 1.3.3.2: T cell homing to the lung 
Concomitant with their differentiation into primary effectors, newly activated virus-
specific T cells downregulate expression of CD62L and CCR7 allowing them to exit the 
MdLN and traffic to the lung (Figure 1.5c). While in the tissue-draining lymph node, T 
cells receive additional signals from DCs which induce the expression of a particular set 
of chemokine receptors and integrins in a process termed ‘imprinting’. Expression of 
these molecules allows for the tissue-specific homing of newly activated cells. While 
imprinting of skin and gut tissue-homing T cells is best understood (93-95), T cell 
migration to the lung during influenza infection is mediated by the expression of CCR4. 
This process is further driven by activated lung-derived DC subsets (96). CCR4 binds 
the ligands MCP-1, RANTES (CCL5) and MIP-1-alpha (CCL3). Both MCP-1 and 
RANTES are expressed by infected lung epithelial cells during influenza infection (97, 
98), allowing for localization to the site of viral infection. MIP-1-alpha is also expressed 
in the lung during influenza infection and is further necessary for normal viral clearance 
(99, 100). Lung DC-imprinted T cells protect against influenza infection more effectively 
than do gut or skin DC-imprinted T cells demonstrating the tissue-specific nature of this 
process, with tissue-derived DCs mediating the migration of activated T cells back to 
their tissue of origin. Various factors, including site-specific inflammatory cytokines or 
the presence of various combinations of pathogen-associated molecular patterns 
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(PAMPs) during DC activation may potentially influence this process, providing a 
molecular “barcode” which T cells may use to identify and migrate to sites of infection. 
 Following the process of imprinting, activated virus-specific T cells must home to 
the lung. This process depends on expression of chemokine receptors and integrins 
which promote their chemokine-directed migration to and transmigration into the 
inflamed lung tissues, respectively. The initial downregulation of CD62L and CCR7 
allows newly activated T cells to exit the MdLN into the circulation. Activated CD4+ and 
CD8+ T cells express the integrin Lymphocyte Function-Associated Antigen-1 (LFA-1, a 
dimer of CD11a and CD18), which binds to Intracellular Adhesion Molecule-1 (ICAM-1) 
present on endothelial cells, allowing their tissue transmigration (101). During influenza 
infection expression of LFA-1 has been shown specifically to be important in the 
migration and retention of effector CD8+ T cells to the lung (102) and may play a similar 
role in CD4+ T cell migration. The chemokine receptor CXCR3 has been similarly 
shown to be required for localization of CD8+ effector T cells to the lung epithelium 
during influenza infection (103, 104) and one of its ligands, IP-10, is notably upregulated 
by infection (47). Expression of CXCR3 is also important in the migration of CD4+ T 
cells to the lung during primary influenza infection (105, 106).  
Virus-specific CD4+ and CD8+ T cells begin to arrive in the lung between 5 and 7 
days post-infection (88, 107) and peak levels of activated effector T cells in the lung are 
reached approximately 10 days post-infection which correlates with lung viral clearance, 
occurring between 7 to 10 days post-infection (89). Significantly, lung localization of 
responding T cells is essential for their effector function and associated protection (88, 
108, 109) (Figure 1.5d). 
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Figure 1.5: Primary T cell response and memory generation following influenza 
infection 
 (A) Following Influenza infection, naïve DCs in the lung take up virus and virally-
derived particles, driving their maturation and migration to the lung-draining mediastinal 
lymph node (MdLN). (B) Mature, activated DCs in the MdLN activate influenza-specific 
naïve CD4+ T cells as they traffic through the lymph nodes (a CD4+ T cell is shown 
here). (C) Newly activated effector T cells exit the MdLN and traffic to the lung and can 
also reach the spleen via the circulation. (D) Effectors in the lung secrete effector 
cytokines and directly lyse virally-infected epithelial cells. (E) CD4+ effectors also play 
roles in the activation of virus-specific B cells and CD8+ T cells in lymphoid tissues 
(including the MdLN and the spleen), allowing them to assume effector functions. (F) 
Responding effectors are retained as long live memory populations at diverse sites. 




















































Section 1.3.3.3: T cell effector function during infection 
 Extensive studies in mice have been conducted using knockout models and 
antibody depletion assays to evaluate which adaptive immune cell subsets and what 
effector functions are essential for protection during primary influenza infection. These 
studies are described for CD4+ and CD8+ T cells and B cells below. The contribution of 
CD4+ and CD8+ T cell and B cell response to protection from primary influenza 
infection are additionally outlined in TABLE 1.3) 
 
Section 1.3.3.3.1: CD8+ T cells 
The main effector function of CD8+ T cells during primary influenza infection is 
the killing of virally infected cells bearing cognate influenza-derived antigen (Figure 
1.5d). Effector CD8+ T cells mediated this process in two ways: 1) ligation of Fas 
molecules expressed on the surface of target cells by FasL expressed by the CD8+ CTL 
resulting in caspase-mediated apoptosis, or 2) release of cytotoxic granules containing 
perforin, which polymerize on the target cell surface to form membrane pores, and 
granzymes, which are serine proteases which enter through these pores and activate 
apoptosis (111). CD8+ effectors also secrete proinflammatory cytokines including TNF-
alpha and IFN-gamma which further augment the local inflammatory response.  
In animal models of influenza infection adoptively transferred virus-specific CD8+ 
T cells can provide protection from severe infection in naïve mice (112). Additionally, 
CD8+ T cells are the primary mediators of protection in mice lacking B cells and 
antibody responses (113, 114). CD8+ T cell responses, however, are not strictly 
essential for elimination of influenza virus as CD8+ T cell-deficient mice are able to clear 
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virus from the lungs following infection (115, 116). These mice do experience delayed 
viral clearance, though, and CD8-deficient mice are more susceptible to lethal challenge 
compared to controls (116) suggesting that, while not essential, CD8+ T cell responses 
are important in limiting the severity of primary influenza infection. 
 
Section 1.3.3.3.2: CD4+ T cells 
During the primary response to influenza infection CD4+ T cells play important 
roles in providing cytokine stimulation to responding CD8+ T cells and B cells during 
activation (Figure 1.5e). In CD4-depleted mice CD8+ T cell expansion and lung 
recruitment are reduced, and viral clearance is delayed compared to CD4-replete mice 
although these differences were modest in some studies (117, 118). In the absence of B 
cells, mice treated with CD4-depleting antibodies rapidly succumb to influenza infection 
(119) highlighting the importance of CD4+ cells in the function of CD8+ effectors. 
However, in infected B cell-deficient mice treated with CD8+-depleting antibodies, the 
remaining CD4+ T cells are unable to clear virus and succumb to infection (120, 121) 
demonstrating that CD4+ effectors alone are not sufficient for protection from influenza 
infection. 
In addition to cytokine production, CD4+ T cells have been further shown to 
mediate lysis of virally-infected cells through a perforin/granzyme-dependent 
mechanism, similar to CD8+ T cells (122-124). Interestingly, a dichotomy in the function 
of activated virus-specific CD4+ T cells seems to occur dependent on localization. While 
some effectors migrating to the lung others remain within the MdLN or migrate to the 
spleen. Virus-specific T cells in the MdLN predominantly produce IL-2 and have 
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undergone fewer rounds of division compared to cells in the lung and bronchoalveolar 
lavage (BAL) fluid which produce TNF-alpha and IFN-gamma and have undergone 
more extensive replication (88, 125) suggesting that MdLN-localized CD4+ effectors 
may preferentially activate B cells and CD8+ T cells while lung-localized CD4+ effectors 
may enhance inflammation through secretion of proinflammatory cytokines. 
 
Section 1.3.3.4: Primary B cell activation and responses in influenza infection 
Like T cells, the MdLN serves as the major site of B cell response induction 
during influenza infection although activation also occurs to some extent in the spleen 
(126). B cells are localized to the so-called B cell zones of secondary lymphoid organs 
and here they encounter influenza-derived antigen circulating through the lymph. 
Following recognition of cognate antigen, B cells endocytose, degrade and display 
antigen-derived peptides on their surface in the context of MHC class II for recognition 
by cognate virus-specific Tfh, which are also localized to the B cell follicles due to their 
expression of CXCR5. The interaction of B cells with Tfh results in the formation of GCs 
where B cells proliferate and differentiate into antibody secreting cells (ASCs). Such 
ASCs can be identified in the MdLN as early as 3 days following influenza infection 
(127). Virus-specific ASCs further traffic to the lung and the spleen where they can be 
detected approximately 7 days post-infection (128, 129).  
The primary protective role of B cells in influenza infection is mediated through 
the generation of virus-specific antibodies (Figure 1.5e). Serum antibodies to influenza 
can be detected approximately 6 to 7 days following infection or primary influenza 
vaccination and continue to increase for approximately 1 month, at which point they 
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continue to be maintained at relatively high levels for extended periods (130-132). 
Responses against viral HA and NA are the most robust and considered to be 
particularly important in protection. In studies of B cell-deficient mice, viral clearance is 
delayed and overall survival is reduced compared to control mice (116, 133, 134). 
However, B cells alone are not sufficient for protection during influenza infection and 
require the presence of either CD4+ or CD8+ T cells for effective viral clearance (135). 
This is likely due to requirements for T cell help in the initial phases of B cell activation 
or in promoting the quality of the antiviral antibody response as passive transfer of virus-
specific antibodies alone can completely protect naïve hosts from infection (90). 
However, only HA-specific antibodies are able to mediate complete viral clearance 
following transfer to infected naïve hosts. Antibodies to NA and M2 which are also 
expressed on the viral surface control lung viral titers but do not result in complete viral 
clearance. In contrast, passive transfer of antibodies specific for the internal viral 
proteins NP and M1 conveys no detectable protection in otherwise naïve hosts (90). 
Significantly, passive transfer of anti-viral antibodies can protect only against 





Table 1.3: Protection by primary adaptive immune cell subsets during influenza 
infection 
Protection from severe or lethal influenza infection in mice sufficient for or lacking 
the following adaptive immune cell subsets. Immune cell subset depletion was achieved 
either by genetic knockout models or by use of depleting antibodies or by a combination 
of both methods. Selected references for each model are also given. 
 
	  





+ + + Yes ---- 
+ + - Yes (120) 
+ - - No (136) 
+ - + Yes (137) 
- + + Yes (113) 
- + - No (121) 
- - + No (119) 
- * - - No (138) 
 






Section 1.4: Memory T cell generation and maintenance 
Following the resolution of primary infection, responding CD4+ and CD8+ 
effector T cell populations undergo a rapid and substantial contraction during which 
approximately 90-95% of responding effector cells die by apoptosis. Subsets of 
pathogen-specific CD4+ and CD8+ T cells, however, survive this contraction and are 
retained as long-lived memory T cells which can persist for life, conveying protective 
immunity upon secondary pathogen encounter. While the mechanisms underlying the 
transition from primary effectors to memory T cells are incompletely understood, roles 
for the magnitude and duration of inflammation, cytokine signaling and the balanced 
expression of various transcription factors have been specifically investigated.  
 
Section 1.4.1: Exposure to inflammatory signals 
Several studies have demonstrated that differentiation of memory T cells 
following primary infection depends on the inflammatory context in which naïve T cells 
are initially activated, both in terms of duration and magnitude. These studies suggest 
that limited inflammation during priming generally supports the generation of memory 
while enhanced inflammation results in reduced long-term persistence of activated T 
cells. In one set of studies, pre-treatment of mice with antibiotics prior to inoculation with 
Listeria monocytogenes to reduce the duration of infection and overall levels of 
inflammation led to an overall decrease in antigen-specific CD8+ T cell expansion, but 
contraction was also reduced and these cells rapidly acquired memory phenotypic and 
functional characteristics (139, 140). Furthermore, antigen-specific CD4+ and CD8+ T 
cells recruited and primed late in infection tend to more efficiently establish memory 
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compared to those that are primed early on (141-143). In addition, the nature of the 
pathogen appears to influence this process as transfer of antigen-specific CD8+ T cells 
into hosts infected with Vesicular Stomatitis Virus (VSV), which elicits a moderate 
inflammatory response results in greater proportions of memory compared to transfer 
into hosts infected with Listeria monocytogenes which elicits a more robust 
inflammatory response (144). 
Additionally, prolonged cytokine exposure during priming and the acquisition of 
effector function, per se, may not be necessary for the generation of memory T cells as 
CD4+ T cells primed for short periods of time and lacking effector function still develop 
into memory cells in vivo following adoptive transfer (145). However, CD8+ T cells 
primed in the absence of CD4+ T cell signals differentiate into effectors (146, 147), but 
fail to generate robust memory T cell populations capable of expansion upon secondary 
antigen exposure (137, 148), illustrating that the signals during priming necessary for 
memory generation between CD4+ and CD8+ subsets are distinct. Further 
understanding of inflammatory signals necessary for robust memory T cell generation 
will be important in the generation of vaccines or therapeutics promoting lasting, 
protective T cell responses.  
 
Section 1.4.2: Survival cytokine signals 
Another key factor required for memory T cell generation is signaling via 
homeostatic and survival cytokines such as IL-7 and IL-15. Naïve CD4+ and CD8+ T 
cells express IL-7R (a dimer of CD127 and the common gamma chain receptor CD132), 
which is required for their survival and homeostatic proliferation prior to initial activation 
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(149, 150). Following T cell activation the expression of IL-7R expression is initially 
downregulated but is then reexpressed by memory CD4+ and CD8+ cells (151, 152). IL-
7 signaling is important for the transition from effector to memory in CD4+ cells during 
infection as memory CD4+ cells fail to develop in IL-7-deficient hosts (153). A similar 
requirement for IL-7 signaling in memory generation in CD8+ T cells has also been 
identified (154, 155); however, IL-7 signaling alone is not sufficient to promote memory 
T cell generation (156). In addition, IL-15 signaling further plays an essential role in 
CD8+ memory formation (157), although it is dispensable in the generation of memory 
CD4+ T cells (158).  
During infection, a population of responding effector CD8+ cells delineated by 
high expression of CD127 and low expression of the co-inhibitory receptor killer-cell 
lectin like receptor G1 (KLRG1) was identified as a precursor to memory T cells (151, 
159). Cells of this phenotype (CD127(hi)KLRG1(lo)) are referred to as memory 
precursor effector cells (MPECs). In contrast, CD127(lo)KLRG1(hi) CD8+ T cells are 
considered to be terminally-differentiated and do not persist long-term after the 
resolution of infection and are thus referred to as short-lived effector cells (SLECs) (151, 
152). In an analogous fashion, Ly6c expression appears to delineate terminally-
differentiated CD4+ effectors with those cells expressing low levels of this molecule 
progressing to memory (160). In total, however, few molecules distinguishing memory T 
cell subset precursors have been described although identification of a more 
comprehensive set of such molecules could have powerful applications in future studies 




Section 1.4.3: Balance of transcriptional regulators 
Mounting evidence suggests that differences in cell fate decisions may be 
mediated at the transcriptional level by the relative expression of various transcriptional 
regulators. These transcriptional regulators often function in pairs with reciprocal 
activity. One such pair includes the T-box transcription factors T-bet and Eomes. High 
levels of T-bet are associated with Th1-type T cell responses and drive a strong 
proinflammatory gene expression profile (85, 161). It has further been demonstrated 
that robust expression of T-bet by CD8+ T cells during the primary immune response is 
associated with the generation of CD127(lo)KLRG1(hi) SLEC T cells (159). Similarly, 
the development of CD4+ T cells with high cytotoxic potential, analogous to terminally 
differentiated CD8+ effectors, is dependent on IL-2 mediated induction of T-bet (162). 
Expression of T-bet and Eomes are inversely controlled by IL-12 signaling (163) and 
work in a reciprocal manner to control CD8+ T cell activation and transition to memory 
with higher relative expression of Eomes biasing cells toward an MPEC phenotype and 
memory generation (164, 165) (Figure 1.6). Furthermore, cell populations expressing 
the highest levels of Eomes are biased toward the generation of central memory T cells 
(159) (Figure 1.6), suggesting, perhaps, that this is the most ‘quiescent’ memory T cell 
subset.  
Other transcription factor combinations have similarly been demonstrated to 
influence T cell fate decisions. Expression of the transcriptional regulator Blimp-1, which 
is best known for its role in plasma cell development, driven by IL-2 signaling promotes 
the generation of SLEC CD8+ T cells in the primary response to infection (75, 166), 
partially through transcriptional repression of DNA-binding inhibitor Id3 (167). A role for 
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Blimp-1 in the reciprocal antagonism of Bcl6 expression during Tfh development has 
also been described (168). Activity of the DNA-binding inhibitor Id2 is necessary for the 
survival of CD8+ effectors and the generation of SLECs during infection (169, 170). In 
contrast, upregulation of the transcription factors Id3 (167, 170), Bcl6 (171), Foxo1 (172, 
173) and TCF-1 (125, 174) have been shown to positively regulate memory T cell 
formation, both in CD4+ and CD8+ T cells (Figure 1.6). As the relative expression of 
these transcription factors is controlled by inflammatory signals during the course of the 
effector response, the nature of the effector response may serve to control memory T 
cell generation. A schematic representation of these transcription factors and their 




Figure 1.6: Expression of transcriptional regulators controls T cell subset 
differentiation and memory establishment 
The inflammatory context in which naïve T cells are activated influences the 
expression of fate-determining transcription factors which promote either terminally-
differentiated, short-lived effector T cells (SLECs) or memory precursor effector cells 
(MPEC). Enhanced inflammation and IL-12 signaling during activation result in the 
generation of proportionally more SLECs relative to MPECs based on the enhanced 
expression of transcription factors including T-bet, Blimp-1 and Id2. In contrast, MPECs 
express higher levels of Eomes, Bcl6, Id3, Foxo1 and TCF-1. Following resolution of 
infection, in the contraction phase of the response, SLECs will predominantly eliminated 
by apoptosis while a proportionally greater subset of MPECs will be retained as long-
lived memory. Additionally, the relative expression of transcription factors which initially 
defined SLEC versus MPEC subsets within the remaining MPEC population may dictate 
the type of memory cells they will become, with increased expression of T-bet, Blimp-1 
and Id2 favoring TEM and increased expression of Eomes, Bcl6, Id3, Foxo1 and TCF-1 
favoring TCM subsets. TRM appear to be intermediate for T-bet relative to TEM and 
TCM and express very low levels of Eomes, suggesting they fall between TEM and 











































Section 1.4.4: Long-term maintenance of memory T cells  
Following their establishment, memory T cells are retained at relatively stable 
numbers for long periods of time, potentially for life (175-177), in a dynamic process 
mediated by slow, consistent proliferation termed homeostatic turnover. Consistent with 
their integral roles in the establishment of memory T cells, IL-7 and IL-15 signaling have 
been shown to be important in the long-term maintenance of CD4+ and CD8+ memory 
T cells. The relative contributions of these cytokines to survival, however, appear to be 
distinct. Whereas IL-7 signaling in necessary for the initial establishment and sustained 
survival of memory CD8+ T cells (154, 178) these cells can be generated in the 
absence of IL-15 signals but are lost over time due to a failure to undergo homeostatic 
division (179). Roles for IL-15 and continued IL-7 signaling in the survival and 
homeostatic proliferation CD4+ memory T cells have also been described (153, 180-
182).  
In addition to cytokine survival signals, the long-term maintenance of CD4+ 
memory T cells has been further shown to require MHC class II expression (183, 184), 
as well as additional TCR stimulation (185, 186). In contrast, memory CD8+ T cells 
appear to be sustained in the absence of MHC class I expression (187) and do not have 
a requirement for additional TCR stimulation for their long-term maintenance (188), 
highlighting differential requirements for the persistence of these two memory subsets. 
While roles for these factors have been well-established, our understanding of the 





Section 1.5: Memory T cell subset heterogeneity 
Memory CD4+ and CD8+ T cells are heterogeneous in terms of phenotype, 
localization and function. Like effector T cells, memory T cells retain high-level 
expression of CD44 and human cells generally continue to express the CD45RO 
isoform. Memory T cells are, however, heterogeneous in their expression of the 
lymphoid homing molecules CD62L and CCR7 which led to delineation of two subsets: 
CD62L+/CCR7+, central memory T cells (TCM) which localize to secondary lymphoid 
tissues, and CD62L-/CCR7- effector memory T cells (TEM) present in peripheral tissues 
(189-191). Both subsets were presumed to circulate with TCM migrating through the 
secondary lymphoid tissues and TEM acting to survey the peripheral tissues.  
In addition to discrete localization patterns, TEM and TCM subsets are thought to 
have similar, but distinct functions upon restimulation. While both TEM and TCM CD8+ 
T cell subsets have similar abilities to produce effector cytokines, including IFN-gamma 
and TNF-alpha, following restimulation TCM are the predominate producers of IL-2 
(192, 193). In addition, TCM appear to have enhanced proliferative ability relative to 
TEM and have the capacity to generate greater numbers of secondary effectors upon 
secondary activation (193). A similar increased proliferative capacity following 
stimulation has been observed for CD4+ TCM relative to TEM. CD4+ TCM and TEM 
further produce similar levels of IFN-gamma and TNF-alpha, however, in contrast to 
CD8+ TCM, CD4+ TCM do not appear to have an enhanced ability to secrete IL-2 
(194).  
In addition to TEM and TCM subsets, a distinct population of non-circulating 
memory T cells termed tissue-resident memory (TRM) has been recently identified to 
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persist long-term in peripheral tissues, including brain, skin, vaginal mucosa and lung, 
following infection (195-200). TRM can be distinguished from circulating TCM and TEM 
subsets by intravascular administration of fluorescently labeled anti-T cell antibodies. 
This process results in the specific labeling of circulating T cells while TRM remain 
protected from labeling due to lack of antibody access to the tissue site (201, 202).  
Phenotypically, TRM can be identified by high expression of CD44 and low 
expression of the lymph node homing receptors CCR7 and CD62L, similar to TEM. 
They additionally reexpress the early activation marker CD69 and CD4+ TRM further 
express CD11a, the alpha chain of the integrin LFA-1 (198, 203), while CD8+ TRM 
express CD103, the alpha chain of the alpha-E-beta-7 integrin (204), which is not 
significantly upregulated by CD4+ TRM in mice (205). A proportion of CD4+ and CD8+ 
T cells localized within the tissues and protected from intravascular antibody labeling do 
not express CD69 and protected CD8+ memory T cells lacking expression of CD103 
have been described in some tissue sites (201, 206, 207). This variability in CD69 and 
CD103 expression suggests heterogeneity in function and/or localization of TRM. The 






Table 1.4: Phenotype of naïve, effector and memory T cell subsets 
Expression of key phenotypic molecules by naïve, effector and memory T cell 
subsets including TCM, TEM and TRM. The migratory properties of each subsets are 
additionally given. Table adapted from (110). 
 
 
Property Naïve Effector TCM TEM TRM 
CD44 Low High Intermediate High High 
CD62L High Low High Low Low 
CCR7 High Low High Low Low 
CD45 Isoform 
(Humans) CD45RA CD45RO CD45RO 
CD45RO/ 
CD45RA* CD45RO 
CD69 Low High Low Low High 
















* TEMRA subsets found in humans reexpress the CD45RA isoform 
 





Section 1.5.1: Tissue retention of TRM 
Following the resolution of infection, maintenance of a pathogen-specific memory 
T cell population at the site of pathogen encounter may represent an effective strategy 
for protection against secondary challenge. Similar to initial tissue homing, prolonged 
retention of T cells within the peripheral tissues appears to be regulated by the 
expression of various combinations of chemokine receptors and integrins. Recently, the 
TRM-specific markers, CD69 and CD103, have been demonstrated to contribute to 
TRM maintenance in tissues. During T cell activation, CD69 suppresses the expression 
of sphingosine 1-phosphate receptor-1 (S1PR1), likely through the transcription factor 
Kruppel-like factor 2 (KLF2), preventing lymph node egress (208). A recent study 
demonstrated that CD8+ TRM express low levels of S1PR1 and that forced expression 
of S1PR1 or KLF2 prevented the establishment of TRM following infection (209). These 
findings suggest that the increased expression of CD69 by TRM may represent a non-
canonical role for this molecule in the retention of activated T cells in peripheral tissues 
following infection rather than lymph node retention during activation. Interestingly, in 
CD4+ cells, low levels of KLF2 in effectors promoted Tfh differentiation whereas forced 
overexpression of KLF2 resulted in enhanced T-bet expression leading to Th1 
differentiation (210).  
For CD103, a role in tissue localization has been previously demonstrated via its 
ability to bind to E-cadherin on epithelial cells, including airway epithelial cells (211). 
The expression of CD103 by lung memory CD8+ T cells is induced by TGF-beta during 
respiratory infection (212) and CD103-deficient CD8+ T cells are inefficiently retained in 
the lungs after resolution of infection, suggesting an important role for CD103 in the 
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establishment of lung CD8+ TRM populations (213). Furthermore, CD103 has been 
similarly shown to be similarly upregulated in CD8+ memory cells in the skin and gut in 
response to TGF-beta signaling suggesting a conserved mechanism across tissues 
(214, 215).  
Although CD4+ TRM do not express CD103 at significant levels (205), the 
expression of other integrins, such as LFA-1 (198, 203), may instead function in the 
tissue-retention of this subset. Expression of LFA-1 and the alpha-1-beta-1 integrin Very 
Late Antigen-1 (VLA-1), which binds collagen, have been shown to contribute to the 
retention of memory CD8+ T cells in the lung following infection (102, 216), potentially 
indicating a similar role for CD4+ T cells. Taken together, these findings suggest that 
integrin expression by memory T cells may play an important role in their long-term 
retention within the lung, potentially by binding structural molecules present within the 
airway epithelium. A schematic representation of TRM establishment from activation to 





Figure 1.7: Tissue homing and retention of TRM precursors 
 (A) Following Influenza infection, naïve CD4+ and CD8+ T cells are activated in 
the lung-draining mediastinal lymph node (MdLN) which results in the upregulation of 
the activation and memory marker CD44 and CD69, which results in retention in the 
MdLN during activation. Expression of the LN-homing molecular CD62L is coordinately 
downregulated, as is expression of the LN egress molecule S1PR1, which is controlled 
by the transcription factor KLF2. (B) Newly activated effectors reduce expression of 
CD62L and CCR7, allowing egress from the lymph node. In addition, molecules which 
mediate lung homing, including CCR4, CXCR3, CCR5 and LFA-1 are upregulated, 
allowing cells to traffic to the lung by following a chemokine gradient. Integrins, such as 
LFA-1, facilitate tissue entry. (C) Activated effectors remain in the lung via expression of 
integrins, including LFA-1 and VLA-1. Factors such as inflammation and TCR signaling 
may trigger reexpression of CD69 and downregulation of KLF2 and S1PR1. TGF-β 
signaling results in enhanced expression of CD103 by CD8+= TRM. Expression of these 
factors mediates the long-term retention of these cells within the lung following 
resolution of infection. Figure adapted from (110). 
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Section 1.5.2 Transcriptional regulation of TRM  
As in the initial generation of memory T cells, the balance of key transcription 
factors may also play an important role in the establishment of TRM versus circulating 
TCM and TEM subsets. As discussed, the enhanced expression of T-bet, Blimp-1 and 
Id2, by T cells during the primary response favor the development of terminally 
differentiated effector cells while increased relative expression of Eomes, Id3, Bcl6, 
Foxo1 and TCF-1 promote memory precursor T cells with enhanced ability to generate 
lasting memory subsets (Figure 1.6). Furthermore, within memory precursor cell 
subsets, the relative dominance of ‘effector’ or ‘memory’ transcription factor expression 
is additionally thought to favor the establishment of TEM versus TCM, respectively. 
Hence, increased expression of ‘effector’ transcription factors in the memory stage is 
though to promote TEM while increased expression of ‘memory’ transcription factors 
favors TCM.  
Recent studies have demonstrated that CD8+ TRM are derived from precursors 
lacking KLRG1 (214) and seem to require the coordinate downregulation of both T-bet 
and Eomes for their establishment (104, 217). Interestingly, once established, TRM 
express intermediate levels of T-bet relative to naïve T cells or TCM, which express low 
levels, and effectors or TEM, which highly express this transcription factor. TRM 
continue to express only low levels of Eomes, similar to TEM, while TCM express 
Eomes to a greater extent (217). Transcriptional programs defining CD4+ TRM have not 
yet been elucidated. Whether a master transcription factor, or set thereof, defines TRM 
lineage commitment or maintenance for both CD4+ and CD8+ subsets remains to be 
identified. A recent study has suggested that the balance of transcription factors Blimp-1 
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and Homolog of Blimp-1 in T cells (Hobit) may control transcriptional programs for 
tissue residency inlymphocytes, NK T cells and NK cells (218).  
 
Section 1.5.3: TRM function 
The functional importance of TRM in protection from reinfection has been 
demonstrated in a number of different tissue sites in several pathogen models (195, 
198, 219-221). The enhanced protective ability of TRM is thought to be mediated by 
several different mechanisms. Significantly, TRM are localized to the sites of pathogen 
encounter providing the opportunity to respond immediately upon reinfection, rather 
than first relying upon local innate inflammatory responses to initiate their activation and 
recruitment to the site of infection. In one example using parabiotic hosts, the host 
having only circulating memory T cells exhibited greatly reduced viral clearance to a 
skin infection compared to the host with virus-specific TRM (221). In addition to direct 
cytotoxic activity TRM may mediate pathogen clearance through immune cell 
recruitment. TRM have been demonstrated to rapidly produce proinflammatory 
cytokines following antigen reexposure including IFN-gamma and TNF-alpha. Such 
cytokine production by TRM has been shown to induce the maturation of local DCs and 
NKs cells and recruit circulating cells, including circulating memory CD8+ T cells and B 
cells, to the site of infection (222-225). Importantly, TRM are also able to induce the 
mobilization of local tissue innate immune responses, such as induction of type I IFN, 
which can protect from specific reinfection as well as provide ‘bystander’ protection 




Section 1.5.4: Protective memory responses to influenza infection 
Section 1.5.4.1: Long-term antibody responses 
The generation of neutralizing antibodies directed toward the viral surface 
glycoproteins HA and NA during an influenza infection is a major mechanism of 
protection in both the primary and secondary responses to infection. Following the 
resolution of primary influenza infection, plasma cells producing virus-specific antibodies 
are retained long-term in the bone marrow, consistently secreting low-levels of antibody 
which circulate in the blood (76, 226). Production of influenza-specific antibodies in this 
manner can occur for life. Indeed, sera from individuals born prior to the 1918 influenza 
epidemic were still cross reactive to antigens from the 1918 virus even 90 years later 
and many individuals still had circulating memory B cells which secreted antibodies 
binding to 1918 influenza HA (131). Significantly, well-matched HA-neutralizing 
antibodies provide sterilizing immunity, whereby the virus is completely prevented from 
infecting the host, likely due to inhibition of HA binding to host sialic acid receptors as 
required for cellular entry. However, due to the mutagenic forces of antigenic drift and 
shift, HA and NA, the additional major antigenic protein in influenza, exhibit profound 
variations in protein sequence and antigenicity between distinct influenza strains over 
time. As a result, antibody responses typically provide limited cross-protection between 
viral serotypes and immunity to influenza infection wanes over time (227).  
 
Section 1.5.4.2: Memory T cell responses 
Immunity that is cross-protective between influenza strains with distinct HA and 
NA serotypes is termed heterosubtypic immunity. Importantly, CD4+ and CD8+ memory 
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T cell subsets generated following influenza infection (Figure 1.5f) in mouse models 
have been demonstrated to mediate heterosubtypic immune responses to distinct viral 
strains via the targeting of conserved viral proteins (228-230). In contrast to secondary 
antibody responses which provide sterilizing immunity by preventing viral infection of 
host cells, heterosubtypic protection is characterized by limited infection leading to 
inflammatory responses (231, 232). Consequently, although heterosubtypic responses 
may protect from mortality, they may not completely prevent morbidity associated with 
secondary infection.  
Following secondary influenza challenge, relative to naïve mice, primed mice or 
mice receiving memory CD4+ cells significantly upregulate proinflammatory cytokines 
and chemokines including IFN-gamma, TNF-alpha, IL-6, IL-12, CXCL9 and CXCL10 
and this correlates with early viral control during secondary infection (233). In primary 
influenza infection, IFN-gamma is not required for protection from infection and the 
development of CTL or antibody responses are not reduced in IFN-gamma knockout 
mice compared to WT (122). However, protection to influenza challenge mediated by 
memory CD4+ T cells is dependent on the presence of IFN-gamma as neutralization of 
IFN-gamma abrogates protection (123, 232, 234). In addition, in human influenza 
challenge studies, early responses to virus infection were characterized by CD4-
mediated production of IFN-gamma (235). In contrast to naïve T cells, which begin to 
upregulate IFN-gamma production in a T-bet-mediated fashion over the course of days 
following activation, the production of IFN-gamma by memory CD4+ T cells occurs 
rapidly via an NF-kappa-B-mediated transcriptional program (236). The functional 
	  
	  59	  
characteristics of memory T cell responses, compared to primary responses, in 
influenza infection are detailed in Table 1.5. 
 
Section 1.5.4.3: TRM in influenza infection 
In recent years, non-circulating, lung influenza-specific CD4+ and CD8+ TRM 
populations have been identified both in mice and in humans and it is now understood 
that a significant fraction of T cell memory generated following experimental infection in 
mice is of this subset (198, 202, 213, 237). In mouse models of influenza infection, 
populations of virus-specific CD4+ and CD8+ TRM persist in the lungs for extended 
periods following infection (198). Influenza-specific CD4+ and CD8+ T cells with TRM 
phenotypes have been further identified in human lung tissue (203, 205, 213, 237) 
suggesting the conserved nature of this subset.  
While the developmental pathways for TRM following influenza infection have yet 
to be completely elucidated, it has been demonstrated that CD4+ T cells within the lung 
assist in the establishment of CD8+ TRM cells during infection (104). Furthermore, 
when lung-derived memory T cells obtained from previously influenza-infected mice are 
transferred into secondary recipients, they preferentially recirculate back to the lungs, 
suggesting that this subset has an intrinsic mechanism for specific homing to and/or 
retention in the lung (198). In human tissue studies lung-derived CD4+ and CD8+ T 
cells, but not CD4+ or CD8+ cells from blood responded to stimulation with influenza 
virus (238, 239). In addition, influenza-specific CD8+ T cells identified by tetramer 
staining were enriched within the lung while memory CD8+ T cells specific for the 
systemic virus Cytomegalovirus (CMV) were distributed in both the lungs and spleen 
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(203) suggesting localization of pathogen-specific T cells based on sites of pathogen 
encounter. Similarly, intranasal, but not intraperitoneal inoculation with influenza virus 
results in the establishment of lung TRM while both routes generate virus-specific TEM 
(200). Taken together, these results indicate that TRM generation following influenza 
infection requires site-specific antigen introduction and/or infection. 
Significantly, in mouse models of influenza infection, virus-specific lung TRM 
have been shown to mediate enhanced viral clearance and increased survival following 
lethal challenge, and to provide protection against heterosubtypic viral challenge (198, 
200, 202). In humans, functional studies of lung-derived TRM have demonstrated that 
these cells rapidly acquire effector function and respond vigorously to secondary 
stimulation with influenza virus (203, 238), potentially suggesting an analogous 
protective function upon viral reencounter in vivo. Precise knowledge, however, of the 
inflammatory cytokines and chemokines mediating lung TRM generation and protective 





Table 1.5: Mechanisms of protection mediated by primary effectors and memory T 
cells during influenza infection 
Key immune responses and characteristics of primary effectors T cells and 
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Section 1.6: Immune responses to influenza vaccines 
Section 1.6.1: Influenza vaccine formulations 
There are currently two broad classes of influenza vaccines available: inactivated 
influenza virus vaccines (IIVs), which include split-virion and subunit vaccines, and, 
more recently, live-attenuated influenza virus vaccines (LAIVs). Inactivated influenza 
vaccines are based either on killed virus formulations or on recombinantly generated 
purified surface proteins. Traditionally, killed virus vaccines are produced by growing 
virus in eggs or cell culture, then collecting and inactivating viral particles with formalin 
followed by chemical disruption with a detergent such as Triton X-100. Killed virus 
formulations containing the full complement of disrupted viral proteins are referred to as 
split-virion vaccines. Subunit vaccines may be generated from killed virus by further 
purification of viral surface proteins, particularly HA due to its surface localization and 
important role in host cell binding and entry. In contrast, recombinant vaccines are 
another form of subunit vaccine generated by purification of viral surface proteins, 
again, generally HA, expressed by a heterologous vector, such as baculovirus, grown in 
culture (240, 241). 
Regardless of their source and type, IIVs contain antigen from three or four 
distinct seasonal viral strains – two influenza A strains and one to two influenza B 
strains which are selected based on patterns of viral circulation as determined by WHO 
surveillance data (http://www.who.int/influenza/vaccines/virus/recommendations/en/). 
IIVs are standardized by the amount of viral HA delivered with 1.5ug of HA per viral 
strain per dose being the standard for adult vaccines. IIVs are delivered by 
intramuscular injection to the deltoid muscle, or more recently, by intradermal injection 
	  
	  63	  
to the skin in the region of the deltoid. Though patterns of antigen drainage following 
influenza vaccination are not definitively known, it is thought that by this route, antigen 
drains to the axillary lymph nodes and that these are the sites of initiation of anti-viral 
immune responses (242, 243). 
In contrast to IIVs, LAIVs are based on cold-adapted viral strains which have 
restricted replicative ability in vivo resulting in limited infection. LAIV are generated by 
engineering HA and NA antigens from selected viral strains onto cold-adapted viral 
backbones designed for optimal growth at 25°C and are restricted to temperatures 
below 35°C (240). Commercially available LAIVs contain four viral strains based on 
WHO surveillance data. In a given influenza season, all IIV and LAIV formulations, 
regardless of manufacturer, are designed to be protective against the same viral strains 
with the exception that trivalent IIVs contain antigen to only one of the two suggested 
influenza B strains. LAIVs are delivered intranasally and, due to their temperature 
restricted growth, the cold-adapted viral particles primarily infect the nasopharyngeal 
epithelium, where body temperature is typically 3 to 4 degrees cooler, rather than the 
epithelium of the lung as is typical of wild-type influenza virus (240). Via this route of 
administration, vaccine specific immune responses are initiated in the tonsils, which are 
a collection of mucosa-associated lymphoid tissues serving the upper respiratory tract 





Table 1.6: Attributes of inactivated and live attenuated influenza vaccines 
Functional characteristics and contraindications of seasonal inactivated influenza 
vaccines (IIV) and live attenuated influenza vaccines (LAIV). 
	  
	  
Attribute IIV LAIV 
Attenuation Killed and Chemically Inactivated Cold-Adapted 
Number of Viral 
Strains 
3 to 4 
2 influenza A and 
1 or 2 influenza B) 
4 
(2 influenza A and 






Initiation Site Axillary Lymph Nodes Tonsils 
Approved Age Over 6 months 2 to 49 years 
Contraindications 













Section 1.6.2: Antibody responses to influenza vaccines 
The ability of influenza vaccines to protect against infection has been traditionally 
thought to rely on the generation of neutralizing antibodies directed toward the antigenic 
viral surface glycoproteins HA and NA. The generation of detectable circulating HA-
neutralizing antibodies following vaccination is currently the gold standard by which 
vaccine responses are assessed with titers ≥40 generally providing protection against 
homosubtypic vaccine viral strains (245). Significantly, such antibodies are only 
protective against identical or highly similar viral strains with little cross-protection 
conveyed even to related strains of the same HA and NA subtypes. Changes in HA and 
NA molecules driven by the combined forces of antigenic drift and antigenic shift lead to 
antigenic mismatch between circulating and vaccine viral strains resulting in poor 
vaccine efficacy. These mutagenic processes occur fairly rapidly, even within influenza 
seasons, necessitating the generation of new, revised influenza vaccines annually. 
Both IIV and LAIV formulations have been shown to elicit HA neutralizing 
antibodies in the serum of vaccinated individuals (246-249) although titers are generally 
higher following IIV vaccination compared to LAIV. However, IIV and LAIV exhibit 
similar protection against influenza-like illness in adults (246-250). Interestingly, LAIV 
appears to be slightly more protective in children (251) or in seasons with poorly 
matched circulating and vaccine viral strains suggesting that, in addition to neutralizing 






Section 1.6.3: T cell responses to influenza vaccines 
Whether protective influenza-specific T cells are generated in humans following 
vaccination has been difficult to establish (252, 253), partially because analysis of 
vaccine responses is generally limited to peripheral blood. Assessment of circulating T 
cell responses in the blood following vaccination suggests that IIVs do not generate 
significant virus-specific T cell responses while LAIVs elicit detectable circulating T cell 
responses in children, but not adults (252, 254) which can be detected even one year 
post-vaccination in some cases (255). However, whether circulating T cell responses 
following vaccination contribute to protection from influenza infection is not confirmed. 
Recent studies using tonsillar tissues obtained from children undergoing routine 
tonsillectomy following receipt of LAIV have demonstrated increased markers of B and 
T cell activation in these samples compared to unvaccinated controls (244, 256), though 
the nature of these cells remains unclear. It is further not known whether lung-localized 
T cell responses or T cell memory populations are established following vaccination with 
either IIVs or LAIVs. Animal studies have demonstrated that cold-adapted influenza 
strains made to resemble commercially available LAIV can elicit heterosubtypic 
protection (257-259); typically attributed to T cell responses. The nature of this 
protection, however, remains undefined. 
 
Section 1.6.4: TRM generation following vaccination 
In addition to differences in vaccine formulation, there is evidence that the route 
of administration of vaccines may affect memory T cell generation. Intranasal, but not 
parenteral, delivery of a cancer vaccine was able to inhibit mucosal tumor growth with 
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only intranasal vaccination eliciting CD8+ T cell populations expressing both CD49a, 
and CD103, molecules important in lung homing and retention, respectively (260). The 
ability of vaccines to establish TRM populations protective against mucosal pathogens 
has been demonstrated in several experimental models. In a herpes simplex virus type 
2 (HSV-2) model, parenteral vaccination with viral antigens was coupled with topical 
chemokine application to recruit virus-specific T cells to the genital mucosa (220). This 
‘prime and pull’ strategy resulted in the establishment of virus-specific TRM populations 
capable of providing protective immunity against viral challenge (220). Similarly, 
intravaginal immunization was capable of generating CD8+ TRM protective to human 
papilloma virus (HPV) (261) and intranasal vaccination with a UV-inactivated chlamydia 
trachomatis vaccine was able to generate CD4+ effectors which homed to the vaginal 
mucosa and were able to establish protective CD4+ TRM (262). 
Importantly, these studies demonstrate a link between the route of vaccination, T 
cell tissue homing and the development of protective memory responses. In particular, 
mucosal vaccination seems to most effectively generate mucosally-localized TRM. 
Enhanced understanding of the immunogenic properties of current influenza vaccines 
as well as the design of new vaccines based on our mechanistic knowledge of TRM 
generation will likely be key to the development of lasting, heterosubtypic protection 
against infection following vaccination.  
 
Section 1.7: Immune responses in early life 
Following birth, neonates transition from a largely sterile environment to one 
where they are rapidly exposed to novel innocuous antigens derived from commensal 
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organisms and food, representing substantial potential for inflammation, particularly in 
the respiratory and digestive tracts. At the same time, neonates are exposed to an 
abundance of potentially pathogenic organisms via these same tissue sites. How the 
early immune system balances the conflicting demands of tolerance to harmless 
antigens but responsiveness to those derived from pathogens remains unclear. The 
need for functionally limited immune responses early in life, combined with the 
observation that infants are generally more susceptible to infections has led to the 
prevailing view that the early immune system is largely unresponsive or is intrinsically 
suppressed. Indeed, a variety of studies have demonstrated multiple differences in both 
the innate and adaptive immune systems between early life and adulthood.  
 
Section 1.7.1: Innate immunity in neonates and infants 
The innate immune system represents the first line of host defense following 
pathogen encounter, providing rapid recognition and responses against defined 
molecular moieties. Studies of various cellular subsets within the neonatal innate 
immune system have generally demonstrated reduced overall inflammatory responses.  
Macrophages derived from cord blood and neonatal airways are less effective at 
phagocytosing and eliminating antigens compared with their adult counterparts and 
produce reduced levels of inflammatory cytokines, including IL-12, following stimulation 
(263-266). Similarly, NK cells derived from cord blood and the peripheral blood of 
infants, although greater in overall number than adults, are less functionally mature than 
their adult counterparts, with increased percentages of the poorly cytotoxic CD56(hi) 
CD16- subset, and increased inhibitory receptor expression (267-269). Reduced 
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numbers of neutrophils precursors in neonates leading to neutropenia, as well as 
defects in their adhesion, migration and function have also been reported (270, 271).  
DCs also differ in early life both in subset composition and function. Neonates 
and infants have reduced numbers of plasmacytoid DCs, important producers of type I 
interferon in response to viral infection, and reduced tissue-localized CD11b+ DC 
populations relative to adults (272). In addition, the maturation and migration of lung 
CD103+ DCs to the MdLN following infection, thought to be an important step in the 
activation of pathogen specific CD8+ T cells, is reduced in early life compared to 
adulthood (272). Functionally, DCs derived from cord blood express reduced levels of 
costimulatory molecules, including MHC-II, CD40, CD80 and CD86 compared to adults 
following stimulation (273, 274) and further have a reduced capacity to secrete IL-12 
upon TLR stimulation, necessary for the generation of effective type I T cell responses, 
although IL-12 secretion by neonatal cells can be restored to adult levels by the addition 
of IFN-gamma during stimulation.  
 
Section 1.7.2: Adaptive immune responses in neonates and infants 
Section 1.7.2.1: B cells and antibody responses 
At birth, neonatal B cells express reduced levels of costimulatory molecules 
including CD40 and CD80/86 (275) which are important for T cell activation. Reduced 
ability to provide efficient costimulation to cognate T cells further leads to reduced B cell 
help by these cells. Indeed, GC reactions are reduced in early life and B cells from 
neonates are less likely to differentiate into long-lived plasma cells (276). The ability of 
plasma cells in early life to be retained within the bone marrow niche may further be 
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affected (277). Furthermore, relative to adults, antibodies generated by neonates 
demonstrate reduced somatic hypermutation (278), necessary for the production of 
high-affinity antibody responses. A combination of these factors contributes to reduced 
overall magnitude, quality and duration of antibody responses in early life. 
Neonates additionally have higher levels of innate-like B1 B cells that 
spontaneously secrete antibodies to broadly-expressed polysaccharide antigens and do 
not form lasting memory. In contrast, B2, or traditional B cells, predominate in adults; 
these cells respond in an antigen-dependent manner to highly variable protein antigens 
and generate lasting memory responses to these antigens. Furthermore, B2 cells from 
neonates also have a limited capacity to respond to T cell independent antigens (279), 
generally polysaccharides, which are of particular importance in protection to 
encapsulated bacteria including Haemophilus influenzae and Streptococcus 
pneumonia. Consequently, children are more susceptible to these pathogens 
necessitating the use of alternative strategies to induce protective humoral immune 
responses. Current vaccines to these pathogens are based on protein conjugates 
composed of capsular polysaccharides linked to toxoids, which are T cell dependent 
antigens and better recognized by the early immune system (280). However, generation 
of antibody responses to capsular antigens elicits protection only to vaccine strains. 
Strategies promoting responses to proteins conserved between strains and preferably 
those eliciting both antibody and T cell-mediated responses will likely providing optimal 





Section 1.7.2.2: T cell populations and phenotype 
T cells in early life display marked phenotypic and functional differences 
compared to those of adults and have a distinct distribution pattern. Infants have a clear 
CD4+ bias which is gradually reduced over early life into adulthood (283). Similar to 
studies in blood, the majority of peripheral tissue T cells in neonates and infants further 
show signs of being recent thymic emigrants with increased expression of CD31 and 
high T cell receptor excision circle (TREC) content (283, 284) relative to adults, 
presumably due to lack of division associated with antigen encounter and homeostatic 
proliferation necessary for their long-term maintenance. Furthermore, peripheral T cell 
populations early in life are predominantly naïve in contrast to adults which have 
significant proportions of memory T cells present in the tissues (283). These naïve T cell 
populations in the periphery progressively transition to a memory-dominated phenotype 
with age (283), likely due to gradual antigen encounter over time. 
 
Section 1.7.2.3: T cell function 
In addition to phenotypic differences, T cells derived from neonates and infants 
also demonstrate differences in function relative to adults. Stimulation of T cells derived 
from cord blood and fetal tissues have demonstrated that these cells have a strong 
tendency to proliferate and are significantly more susceptible to apoptosis than cells 
derived from adults (285-288). This increased susceptibility to apoptosis, however, can 
be ameliorated by addition of common gamma chain cytokines including IL-2, IL-7 and 
IL-15 in vitro (285, 286, 289-291). Distinct cytokine responses following activation have 
also been observed in neonatal and infant T cells. Cord blood-derived CD4+ T cells 
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produce lower levels of IFN-gamma compared to adults and can additionally produce 
both IL-4 and IFN-gamma simultaneously, which is not generally observed in adult cells 
(292-294). This reduced production of IFN-gamma has been associated with 
hypermethylation of the IFN-gamma promoter locus in neonatal T cells (295).  
While these findings initially suggested that T cell responses in early life are Th2-
biased and functionally limited, further studies have demonstrated that infant cells can 
indeed generate robust Th1 responses under inflammatory activating conditions. While 
cord blood CD4+ T cells produce less IFN-gamma relative to adults following stimulation 
without additional cytokines, inclusion of exogenous IL-12 during stimulation restores 
IFN-gamma production to adult levels (294). In later in vivo studies it was demonstrated 
that infection of neonates with low doses of Cas-Br-M murine leukemia virus generated 
protective cytotoxic T cell responses. However high dose infection preferentially 
generated non-protective Th2 responses (296). In vaccine studies of neonatal mice it 
was further shown that the use of different adjuvants during immunization (incomplete 
versus complete Freund’s adjuvant) resulted in distinct immune responses with 
incomplete Freund’s adjuvant biasing toward Th2 responses by complete Freund’s 
adjuvant promoting Th1-polarized responses (297). Significantly, complete Freund’s 
adjuvant contains killed mycobacteria and it is now understood that neonatal T cells are 
capable of generating robust Th1 responses to certain classes of molecules, including 
mycobacterially-derived components and CpG motifs. Relatedly, following immunization 
with the live-attenuated bacterial vaccine BCG, T cells of very young children have been 
shown to robustly produce IFN-gamma (298) – possibly due to the presence of 
mycobacterial components and CpG (299). 
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Neonates may further have distinct inflammatory responses which provide 
protection from infection that are not typically observed in adults. In studies of cord 
blood, T cells derived from premature infants spontaneously secrete IL-8, a potent 
chemoattractant and activator of neutrophils and gamma-delta T cells, and further 
generate robust IL-8 responses upon stimulation, a function not observed in adults 
(300). Taken together, these results suggest that infants are indeed capable of 
mounting inflammatory responses and that early life T cell responses in both canonical, 
and distinct ways, rather than simply intrinsically dampened.  
 
Section 1.7.2.4: Active suppression of early life T cells 
Evidence suggests that robust inflammatory responses early in life may be 
actively suppressed by cell-extrinsic mechanisms. Erythroid-lineage CD71+ cell 
populations have been described in both neonatal mice and human cord blood with 
suppressive abilities based on depletion of L-arginine, which is an essential factor for T 
cell responses (301). In fetal and early life increased percentages of Tregs present in 
the blood and peripheral tissues have been described (283, 302) and the function of 
these Tregs is enhanced relative to Tregs derived from adults. Significantly, depletion of 
these cells leads to restoration of robust IFN-gamma responses in stimulated infant 
CD4+ and CD8+ T cells suggesting that the ability of these T cells is not intrinsically 
compromised, but rather inhibited (283). Furthermore, relative to adults, infant T cells 
are more likely to differentiate into Tregs following stimulation in a process mediated by 
the RNA-binding protein Lin28b and TGF-beta signaling (303, 304) suggesting an 
additional mechanism by which early life inflammatory responses can be dampened. 
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Importantly, such suppressive mechanisms may be necessary to limit potentially 
detrimental inflammatory responses following the rapid exposure to antigen occurring 
immediately after birth. 
 
Section 1.7.3: Early life responses to Influenza infection and vaccination  
 In adults, influenza infection elicits both protective humoral and T cell-
mediated responses. Significant gaps exist, however, in our understanding of adaptive 
immune responses to influenza infection and vaccination in early life, including the 
extent to which such responses are generated as well as their protective capacities. In 
mouse models of influenza infection, neonates exhibit both delayed CD8+ T cell 
responses as well as reduced overall accumulation of CD8+ T cells around the lung 
airways which represent primary sites of influenza infection and replication (305, 306). 
Additionally, neonatal CD8+ cells secrete less IFN-gamma in response to infection 
compared to adults (305).  
While these findings suggest reduced overall responses to influenza infection in 
early life. Significant differences in lymphocyte populations, however, exist between 
neonatal mice and humans with neonatal mice being profoundly lymphopenic at birth 
through the first two weeks of life (307). In contrast, humans are born with a full 
complement of peripheral lymphocytes. Therefore this model may not accurately 
recapitulate primary T cell responses of humans in early life following influenza 
infection. In a study of natural IAV infection, viral load in respiratory secretions was 
similar between children and adults and did not correlate with clinical outcomes. 
Secretions from infants and young children did, however, have increased levels of 
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inflammatory cytokines compared to adults (308), suggesting that enhanced 
inflammation may actually be a mediator of exacerbated illness. Whether this translated 
to differences in lymphocyte responses and their protective abilities, however, is not 
clear. 
Vaccine responses in young children are, in general, reduced compared to older 
children and adults (309, 310). In studies of primary responses to influenza vaccination, 
children under four receiving IIV demonstrated reduced induction of serum neutralizing 
antibody responses and antibody secreting cells compared to older children and adults 
(246). Additional studies have demonstrated impairments in the phenotype, localization 
and function of Tfh in neonates after immunization (311) suggesting a possible 
mechanism for the distinct responses to vaccination. Interestingly, the oil-in-water 
adjuvant MF59 was identified to enhance antibody responses via the induction of Tfh 
cells and administration of HA in combination with MF59 promoted protection against 
influenza infection in infant mice similar to that observed in adult controls (312).  
Studies comparing T cell responses in children and adults vaccinated with IIV 
found little to no evidence of circulating virus-specific T cells in the peripheral blood 
following vaccination in either group (313). However, vaccination with LAIV protective 
against the identical influenza strains resulted in the inducting of circulating virus-
specific T cell responses in children, but not adults (313), suggesting differences in 
immune responses between distinct vaccine formulations which are additionally 
influenced by age. Vaccination with LAIV was further demonstrated to protect against 
the incidence of laboratory confirmed influenza and influenza-like illness in young 
children and this protection was superior to that observed in adults (251). These 
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findings led to the preferential recommendation by the AAP for the use of LAIV in 
children 2 and over. However, due to poor vaccine efficacy for the H1N1pdm09 and 
H3N2 strains among all age groups for the 2013-2014, 2014-2015 and 2015-2016 
influenza seasons, LAIV is no longer recommended as of the 2016-2017 season (314). 
Taken together, these findings suggest that neonates and infants are capable of 
responding effectively following vaccination, further supporting that they are not 
inherently less functional than adult cells, however, that responsiveness appears to be 
highly dependent on vaccine formulation and the conditions of vaccination. Identifying 
the immune mechanisms underlying the host response to influenza infection and how 
these factors differ between young children and adults is therefore a priority in the 
rational design of future vaccines and therapeutics for this disease.  
 
Section 1.8: Thesis objectives 
While influenza and other respiratory viruses are an important cause of morbidity 
and mortality in early life there is a lack of mechanistic understanding of the factors 
contributing to reduced immune responses of infants following infection. Therefore, 
identifying the immune mechanisms underlying the host response to influenza infection 
and how these factors differ between young children and adults is a priority in the 
rational design of future vaccines and therapeutics for this age group. This body of work 
investigates the hypothesis that robust tissue-localized immune responses are 
necessary for protective TRM generation and that intrinsic defects in early life 
responses to infection or vaccination limit T cell memory establishment. 
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It is well established that T cell responses, Th1-type responses in particular, play 
an important role in protection from influenza illness. The current paradigm that infant T 
cell responses are diminished and Th2-biased therefore suggests that infants may not 
generate protective primary T cell responses to influenza infection. Our first objective, 
therefore, is to determine whether infants are able to generate protective primary 
immune responses to influenza infection and to assess the nature of the primary 
T cell response relative to adults .  
It is additionally known that infants are more likely to suffer repeated influenza 
infections, suggesting poor establishment of immune memory. Whether infants generate 
T cell memory subsets, including tissue-resident memory, following influenza infection 
which are protective upon secondary infection, is unknown. In our second objective, we 
assess the generation and phenotype of T cell memory following influenza 
infection in infancy and determine whether infants are protected from 
heterosubtypic reinfection in a T cell-dependent manner. 
Furthermore, overall vaccine responses are reduced in the very young compared 
to older children and adults, resulting in reduced protection in this vulnerable population 
(315, 316). Promoting demonstrable T cell-mediated protection through vaccination, 
however, has remained elusive. The protective capacities of tissue-resident memory T 
cells, however, suggest that vaccination strategies targeting their generation and 
persistence may provide enhanced immunity compared to vaccines relying on 
circulating responses. In our final objective, we evaluate neutralizing antibody and T 
cell-mediated immune responses to commercially available inactivated influenza 
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and live attenuated influenza vaccines in adults and infants and examine their 
mechanisms of protection. 
In total, this body of work contributes an enhanced understanding of the ability of 
infants to generate T cell responses and T cell memory following influenza infection and 
vaccination. This work reveals that while infants generate robust primary T cell 
responses following influenza infection, they establish reduced protective lung tissue-
resident memory T cells (TRM), limiting protection upon viral reinfection. It further 
identifies TRM as an important mediator of protection following live-attenuated influenza 
vaccination (LAIV), but not inactivated influenza vaccination (IIV) in adults. Significantly, 
the reduced ability of infants to generate TRM limits LAIV-mediated protection in this 
group, relative to adults. However, LAIV still provides superior protection in infants 
relative to IIV. The reduced generation of TRM in early life appears to be T cell-intrinsic. 
Importantly, this reduction in TRM can be ameliorated by reduced expression of the Th1 
lineage defining transcription factor T-bet during the primary response. Taken together, 
the findings support a model where dysregulation of key transcription factors by infant T 
cells following activation results in terminal differentiation and subsequent failure to be 
maintained as memory. These results have potentially important implications in the 
development of vaccines and therapeutics to promote the establishment of protective 




CHAPTER 2: Materials and Methods 
 
Section 2.1: Animal breeding and maintenance  
Section 2.1.1: Mouse strains and genotyping 
C57BL/6 or BALB/c mice were purchased (Charles River Laboratories, 
Wilmington, MA) or were bred within Columbia University Medical Center (CUMC) 
animal facilities. TS1 (HA TCR) mice, which express a transgene-encoded T cell 
receptor (TCR) specific for S1 (peptide 110-119 (SFERFEIFPK)), the major MHCII I-Ed-
restricted determinant of PR8 influenza hemagglutinin (HA) (317), were maintained and 
bred on a BALB/c Thy1.1 Rag2-/- background within CUMC animal facilities. Breeders 
were periodically screened for the TS1 TCR present on CD4+ T cells by flow cytometry 
using the anti-clonotypic antibody 6.5 conjugated to allophycocyanin (APC) (317). T-bet 
heterozygous mice were bred and maintained in CUMC animal facilities by crossing 
male Tbx21-/- mice, generated via targeted deletion of Tbx21 exons 2-6 and 
backcrossed onto a C57BL/6 background for >10 generations, (164) with wild-type (WT) 
C57BL/6 females. T-bet-null breeders and heterozygous mice were screened for the 
exon 2-6 deletion by PCR of genomic DNA extracted from ear punches using the 
Clontech Terra PCR Direct Polymerase Mix kit (Takara Bio, Mountain View, CA). 
Genotyping reactions were performed according to kit specifications using the following 
primers: 
(1 - Forward) 5’- TAT GAT TAC ACT GCA GCT GTC TTC AG -3’ 
(2 - WT Reverse) 5’- CAG GAA TGG GAA CAT TCG CCT GTG -3’ 
(3 - Null Reverse) 5’- CTC TGC CTC CCA TCT CTT AGG AGC -3’ 
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In these reactions, primers 1 and 2 generate a 298bp band representing the WT 
allele, while primers 1 and 3 generate a 400bp T-bet null band. T-bet heterozygous 
mice are identified by the presence of both bands (Figure 2.1). All experimental mice 
were maintained under specific pathogen-free conditions in a BSL-2 bio-containment 
room within CUMC animal facilities and all adult mice were used between 8-12 weeks of 
age unless otherwise noted. All animal studies and procedures were conducted 
according to the NIH guidelines for the care and use of laboratory animals, and were 
approved by the CUMC Institutional Animal Care and use Committee (IACUC). 
 
Section 2.1.2: Infant animal breeding and usage 
Infant mice were bred in a BSL-2 bio-containment room within CUMC animal 
facilities. WT and TS1 (HA TCR) mice were obtained by crossing two homozygous 
adults. To obtain T-bet heterozygous pups and WT pups within the same litter, male 
Tbx21+/- mice were crossed with WT C57BL/6 females. In all studies and for all strains, 
infant mice were used between 10-14 days after birth. For infection and vaccination 
experiments, pups were infected between 10-14 days of age and allowed to remain with 
their mothers for an additional 14 days so that weaning was delayed from 21 days after 





Figure 2.1: Genotyping PCR for T-bet exon 2-6 deletion 
 Gel indicating bands obtained following genotyping PCR for WT, T-bet null and 




































Section 2.2: Reagents  
Section 2.2.1: Influenza viruses 
PR8 (influenza A/Puerto Rico/8/34(H1N1)) and X31 (influenza A/Hong 
Kong/1/68-x31(H3N2), a reassortant virus containing the six internal genes of PR8, and 
the surface HA and neuraminidase (NA) from the influenza A/Hong Kong/1/68(H3N2) 
virus) were used for infection studies. Influenza viruses were generated by propagation 
in nine- to eleven-day-old embryonated chicken eggs as described (318). Briefly, fertile 
eggs were inoculated into the allantoic cavity with 200uL of a 1x103 TCID50 stock of 
influenza virus and incubated at 34-35°C for 72 hours. Eggs were then cooled overnight 
to 4°C, the virus-containing allantoic fluid harvested and centrifuged for 10 minutes at 
500xg at 4°C prior to storage in 1mL aliquots at -80°C. 
 
Section 2.2.2: Influenza vaccines 
The following influenza vaccine formulations were purchased from Moore 
Medical (Farmington, CT): FluMist® Quadrivalent, 2014-2015, live-attenuated vaccine 
(MedImmune, Gaithersburg, MD) and Fluzone® Quadrivalent, 2014-2015, inactivated 
virus vaccine (Sanofi Pasteur, Lyon, France) containing A/California/7/2009 
(H1N1)pdm09, A/Texas/50/2012 (H3N2), B/Massachusetts/2/2012, and 
B/Brisbane/60/2008; as well as 2015-2016 FluMist® Quadrivalent and Fluzone® 
Quadrivalent formulations containing A/California/7/2009 (H1N1)pdm09, 
A/Switzerland/9715293/2013 (H3N2), B/Phuket/3073/2013, and B/Brisbane/60/2008 




Section 2.2.3: Pharmaceuticals 
FTY720 (Fingolimod), a sphingosine 1-phosphate receptor agonist was 
purchased from Cayman Chemical Company (Ann Arbor, MI) for use in heterosubtypic 
infection animal studies. Phorbol 12-myristate 13-acetate (PMA) and Ionomycin were 
purchased from Sigma-Aldrich (St. Louis, MO) for use in T cell activation and 
intracellular cytokine studies. The protein transport inhibitor Brefeldin A, used in 
intracellular cytokine studies, was purchased from BD Biosciences (GolgiPlug, San 
Diego, CA). To remove non-specific inhibitors of hemagglutination from serum in 
hemagglutination inhibition assays, serum was treated with Receptor Destroying 
Enzyme (RDE, Denka Seiken, Tokyo, Japan). 
 
Section 2.2.4: Antibodies and Tetramer Reagents 
Anti-CD3e (clone 145-2C11) and anti-CD28 (clone 37.51) monoclonal antibodies were 
purchased as azide-free, low-endotoxin formulations from BD Biosciences for use in T 
cell activation assays. Fluorescently conjugated antibodies for cell surface phenotypic 
staining, cell sorting and intracellular staining were purchased from BD Biosciences, 
BioLegend (San Diego, CA) and eBioscience (San Diego, CA) and are listed, including 
target, clone, color and manufacturer, in Table 2.1. The influenza nucleoprotein-specific 
(NP366-374 ASNENMDAM) MHCI H-2Db tetramer, the influenza RNA-dependent RNA 
polymerase PB1 subunit-specific (PB1703-711 SSYRRPVGI) MHCI H-2Kb tetramer, and 
the influenza hemagglutinin-specific (HA533-541 IYSTVASSL) MHCI H-2Kd tetramer, all 




Table 2.1: Fluorophore-conjugated antibodies used for flow cytometry 
 Antibodies used for flow cytometric analyses separated by cell surface 
phenotype stains (top), intracellular stains (middle), and cell sorting stains (bottom), 
which are further subdivided by those used for in vitro activation sort studies and those 
used for HA T cell adoptive transfer sort studies. Each listing includes antibody target, 




CELL SURFACE PHENOTYPE STAIN 
Target Clone(s) Fluorochrome(s) Manufacturer 
CD3 145-2C11, 17A2 PE, PE-Cy7 BioLegend, eBioscience 
CD4 RM4-5, GK1.5 Alexa Fluor 700, eFluor 450 BioLegend, eBioscience 
CD8 53-6.7 BV650, eFluor 450 BioLegend, eBioscience 
CD11a M17/4 eFluor 450, PerCP eFluor710 eBioscience 
CD11c HL3 FITC BD 
CD19 6D5 FITC BioLegend 
CD44 IM7 APC-Cy7 BioLegend 
CD45 30-F11 APC, Pacific Blue BioLegend 
CD62L MEL-14 BV605 BioLegend 
CD69 H1.2F3 PE-Cy7 BioLegend 
CD90.1 (Thy1.1) HIS51, OX-7 APC, PE eBioscience, BD 
CD90.2 (Thy1.2) 53-2.1 APC, PE BioLegend 
CD103 2E7 APC, PerCP eFluor 710 BioLegend, eBioscience 
CD127 A7R34 PerCP-Cy5.5 eBioscience 
F4/80 BM8 Alexa Fluor 488 BioLegend 
KLRG1 2F1 APC, PerCP eFluor 710 eBioscience 
INTRACELLULAR STAIN 
Target Clone Fluorochrome Manufacturer 
Bcl2 10C4 RUO PE-Cy7 eBioscience 
IFN-gamma XMG1.2 PerCP eFluor 710 eBioscience 
T-bet 4B10 PE, PE-Cy7 BioLegend, eBioscience 
TNF-alpha MP6-XT22 Alexa Fluor 647 eBioscience, BD 
CELL SORTING STAIN (in vitro Activation) 
Target Clone Fluorochrome Manufacturer 
CD3 145-2C11 PE BioLegend 
CD4 RM4-5 FITC eBioscience 
CD8 53-6.7 FITC BD 
CELL SORTING STAIN (Sorted D13 Transferred HA T cells) 
Target Clone Fluorochrome Manufacturer 
CD3 145-2C11 PE BioLegend 
CD4 RM4-5 BV650 BioLegend 
CD11c HL3 FITC BD 
CD19 6D5 FITC BioLegend 
F4/80 BM8 Alexa Fluor 488 BioLegend 





Section 2.3: Lymphocyte isolation from tissues 
Lymphocytes were prepared from mediastinal lymph nodes (MdLN) and spleens, 
as outlined in Figure 2.2. Briefly, tissues were first disrupted by pressing through a 
70micron filter with the plunger of a clean 3mL syringe to generate cell suspensions in 
complete RPMI (RPMI 1640 (Thermo Fisher Scientific, Waltham, MA) containing 10% 
Fetal Bovine Serum (FBS, Thermo Fisher Scientific), 5nM 2-mercaptoethanol (Sigma-
Aldrich), 2mM L-glutamine (Thermo Fisher Scientific), 10u/mL penicillin (Thermo Fisher 
Scientific) and 10ug/mL streptomycin sulfate (Thermo Fisher Scientific)). Spleen cell 
suspensions were further depleted for red blood cells by incubation with ACK Lysing 
Buffer (Corning Cellgro, Manassas, VA) for 5 minutes at room temperature. Cells were 
then washed, resuspended in complete RPMI and filtered through a 40micron filter to 
remove debris prior to use.  
Lung lymphocytes were prepared as outlined in Figure 2.2 first by mechanically 
dicing tissues with sharp scissors. Tissue homogenates were then incubated for 30 
minutes at 37°C with digestion medium (Hank's buffered saline solution (HBSS, Thermo 
Fisher Scientific) containing 0.1mg/mL DNase I (Roche, Indianapolis, IN), 1mg/mL 
collagenase D (Roche) and 1mg/mL trypsin inhibitor (Invitrogen, Carlsbad, CA)). Tissue 
homogenates were further disrupted by passing through a 70micron filter to remove 
debris and the resulting suspensions depleted for red blood cells by incubation with 
ACK Lysing Buffer for 5 minutes at room temperature. Cells were then washed, 
resuspended in complete RPMI and filtered through a 40micron filter to remove debris 




Figure 2.2: Lymphocyte isolation strategies from tissues 
 Flowchart outlining the methods used for the isolation of lymphocytes from the 

























Section 2.4: T cell phenotypic and functional assays 
Section 2.4.1: Tetramer and antibody staining for flow cytometry 
Cell suspensions were surface stained with combinations of fluorochrome-
conjugated antibodies (for clone, fluorochrome and manufacturer information, see Table 
2.1) as indicated within the experimental results for a minimum of 45 minutes at 4°C in 
the dark in fluorescence-activated cell sorting (FACS) buffer (Phosphate Buffered Saline 
(PBS, Thermo Fisher Scientific) with 1% FBS and 0.02% sodium azide (Sigma-
Aldrich)). For tetramer staining, cells were incubated for an additional 30 minutes at 
room temperature (19-25°C) in the dark with a tetramer reagent with one of the 
following specificities: influenza NP366-374 (C57BL/6), influenza PB1703-711 (C57BL/6), or 
the influenza HA533-541.  
For intracellular staining, cells were first surface-stained with antibody and 
tetramer reagents, then fixed for 30 minutes at room temperature (19-25°C) in the dark 
or overnight at 4°C in the dark with FoxP3 Fixation/Permeabilization Buffer 
(eBioscience), then washed with Permeabilization Buffer (eBioscience) and stained with 
fluorescently-conjugated antibodies to the transcription factor T-bet, the anti-apoptotic 
factor Bcl2 or the cytokines IFN-gamma or TNF-alpha (Table 2.1) diluted in 
Permeabilization Buffer. Staining was performed for 30 minutes at room temperature 
(19-25°C) in the dark followed by a minimum of 30 minutes at 4°C protected from light 
prior to washing with FACS buffer. Prepared cells were analyzed using LSRII or 
Fortessa flow cytometer instruments (BD Biosciences), and data assessed using 




Section 2.4.2: Intravascular labeling for identification of tissue-resident T cells 
For in vivo antibody labeling, mice were given 3ug fluorochrome-conjugated anti-
Thy1.2 or anti-CD45 antibody (Table 2.1) by intravenous (i.v.) injection 10 minutes prior 
to tissue harvest. Lungs were then perfused with 15-20mL PBS via instillation of the 
right ventricle of the heart. Lungs were collected and lymphocytes isolated as previously 
described. 
 
Section 2.4.3: T cell stimulations 
For PMA/Ionomycin stimulation studies, a total of 2x105 purified lymphocytes in 
100uL complete RPMI were added to individual wells of 96-well flat-bottomed plates. 
PMA and Ionomycin were added to wells to final concentrations of 100ng/mL and 
1ug/mL, respectively, in a total volume of 200uL. For intracellular cytokine staining 
studies 1uL/mL Brefeldin A was also added. Samples were incubated at 37°C for 4-6 
hours prior to antibody staining for surface and intracellular markers for flow cytometric 
analysis. 
 
Section 2.4.4: T cell activation studies 
Naïve (CD44(lo)) CD4+ and CD8+ T cells were enriched from prepared 
lymphocyte pools using MagniSort CD4+ or CD8+ naïve T cell negative selection kits 
(eBioscience), counted and resuspended in complete RPMI. For cell proliferation 
studies, cells were further labeled at 2x107 cells/mL with 2.5uM carboxyfluorescein 
succinimidyl ester (CFSE, eBioscience) or 10uM eFluor® 450 Cell Proliferation Dye 
(eBioscience) at 37°C for 15 minutes in the dark just prior to activation. To activate cells 
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with anti-CD3/anti-CD28 monoclonal antibodies, 96-well flat-bottomed plates were 
prepared prior to stimulation by overnight incubation at 4°C with 200uL of a combined 
solution of 5ug/mL anti-CD3 and 5ug/mL anti-CD28 in PBS per well. The antibody 
cocktail was then aspirated and a total of 2x105 purified naïve T cells in 200uL complete 
RPMI were added to each well and incubated at 37°C for 24 to 72 hours.  
 
Section 2.5: Influenza infections and vaccinations 
Section 2.5.1: Influenza virus infections 
Adult and infant mice were lightly anesthetized by inhalation of isofluorane (5% 
induction/2% maintenance) delivered through a vaporizer within CUMC animal facilities. 
Once anesthetized, mice were infected intranasally (i.n.) by direct delivery of virus 
diluted in PBS to the nares with a micropipette. This route establishes viral infection 
throughout the total respiratory tract (nose, throat and lungs). Adult doses were 
delivered in a 20uL final volume while infant mice received weight-adjusted doses of the 
same viral dilution for a reduced total infection volume (approximately 6-9uL).  
Appropriate viral doses were determined based on mouse age and strain, viral 
strain and primary versus heterosubtypic infection as listed in Table 2.2. Morbidity 
following infection was monitored by daily examination and weight assessment. Mice 





Table 2.2: Influenza viral doses used in infections 
 Influenza viral strains and doses used in primary and heterosubtypic infection 
studies. Doses are given by viral strain for adult and infant mice receiving primary or 
heterosubtypic infections. Doses for C57BL/6 mice are listed in the upper section while 
doses for BALB/c mice are listed in the lower section. 
 
 
Mouse Strain: C57BL/6 
Age Infection Virus Strain Dose (TCID50) 
Adult 
Primary 












Mouse Strain: BALB/c 
Age Infection Virus Strain Dose (TCID50) 
Adult 
Primary 
PR8 250 to 325 
X31 N.D.2 
Heterosubtypic 




PR8 70 to 91 
X31 N.D.2 
Heterosubtypic1 
PR8 2500 to 5000 
X31 4000 
 
1Heterosubtypic protection studies were performed 6-12 weeks post-initial infection, therefore mice 
initially infected as infants were adults during heterosubtypic infection and received the same dose as 






Section 2.5.2: Live-attenuated and inactivated influenza vaccinations 
For FluMist® live-attenuated influenza virus vaccinations, adult or infant mice 
were administered 20uL of 2014-2015 or 2015-2016 FluMist® vaccine (1:10th the adult 
human dose) i.n. or intraperitoneally (i.p.) for a final dose of 105.5-6.5 FFU/viral 
strain/mouse. Identical volumes of live attenuated vaccine were used for infant and 
adult mice because human infants also receive the same dose (in terms of volume and 
FFU) of FluMist® vaccine as adults. For Fluzone® inactivated influenza virus 
vaccinations, adult mice received 50uL of 2014-2015 or 2015-2016 Fluzone® (1:10th the 
adult human dose) i.p. or subcutaneously (s.c.) in the neck scruff or i.n. for a final dose 
of 1.5ug of HA/viral strain/mouse. Infant mice received either 25uL or 50uL of 2014-
2015 or 2015-2016 Fluzone® i.p. as children under the age of three typically receive 
only one-half of the adult vaccine dose while individuals three and over receive the full 
adult dose (319). 
 
Section 2.5.3: FTY720 treatment 
For experiments evaluating TRM-mediated control of heterosubtypic infection, 
mice infected or vaccinated 6-12 weeks prior were treated with the spingosine-1-
phosphate receptor agonist FTY720 (197, 202, 320). Mice received daily i.p. injections 
of 1mg/kg FTY720 (25ug/mouse) or PBS beginning 2-3 days prior to heterosubtypic 
infection and continuing daily throughout the course of infection. FTY720-mediated 
depletion of peripheral lymphocytes was confirmed in treated mice by flow cytometric 
assessment of lymphocyte populations in peripheral blood and by comparing labeled 
(circulating) and unlabeled (tissue-localized) lung T cells at sacrifice by flow cytometry. 
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Section 2.6: Virus titration and hemagglutination inhibition assays 
Section 2.6.1: Virus titrations from lung tissue  
Influenza titers in lung homogenates of infected mice were measured by a 50% 
tissue culture infective dose (TCID50) assay as outlined in Figure 2.3. Lungs were 
isolated from infected mice at defined timepoints post-infection and homogenized in 
1mL of complete RPMI using a Closed Tissue Grinder System (Thermo Fisher 
Scientific). Debris was pelleted and supernatants stored at -80°C until analysis.  
For the titration assay, thawed supernatants were diluted serially 10-fold in 100uL 
of Dulbecco’s Modified Eagle Medium (DMEM, Thermo Fisher Scientific) supplemented 
with 5% FBS, 2mM L-glutamine, 10U/mL penicillin and 10ug/mL streptomycin sulfate 
(DMEM-5). Diluted supernatants were plated into 96-well U-bottom plates with 100uL of 
Madin Darby Canine Kidney (MDCK) cells at 2.5x106 cells/mL (2.5x105 total cells) and 
incubated overnight at 37°C. After 24 hours, the culture medium was removed and 
replaced with 200uL of serum-free DMEM supplemented with 2mM L-glutamine, 
10U/mL penicillin, 10ug/mL streptomycin sulfate and 0.0002% trypsin (Thermo Fisher 
Scientific) (DMEM+Trypsin) and cultures returned to 37°C for 72 hours.  
To assess viral content in cell supernatants, 50uL of 0.5% chicken red blood cells 
(Lampire Biological Laboratories, Everett, PA) in PBS were added to each well. 
Hemagglutination was recorded after 1 hour of incubation at room temperature (19-
25°C). Viral titers were expressed as the reciprocal of the dilution of lung extract that 
corresponded to 50% virus growth in MDCK cells, as assessed by positive 




Figure 2.3: Influenza virus titration from lung homogenates 
 Schematic of the viral titer assay used to titrate influenza virus in the lungs 
following infection. Briefly, lung homogenates were serially diluted and plated with 
Madin Darby Canine Kidney (MDCK) cells. In wells containing viral particles, cells 
become infected and the virus is propagated. After 72 hours red blood cells (RBCs) are 
added. Influenza hemagglutinin (HA) present in infected wells causes RBCs to 

























Section 2.6.2: Hemagglutination inhibition assay 
Serum neutralizing antibodies titers following infection or vaccination were 
measured by hemagglutination inhibition (HAI) assay. Blood was collected from 
previously infected or vaccinated mice by cardiac puncture or by tail-vein bleed into 
untreated microcentrifuge tubes. To isolate serum, blood was allowed to clot at room 
temperature (19-25°C) for 60 minutes then centrifuged at 13000rpm for 20 minutes at 
4°C. Isolated serum was then frozen at -80°C until analysis. To remove non-specific 
inhibitors of hemagglutination prior to assay, one part thawed serum was incubated at 
37°C overnight (18-20 hours) with 3 parts Receptor Destroying Enzyme (RDE). RDE 
was then heat-inactivated for 30 minutes at 56°C and PBS added for a final serum 
dilution of 1:10.  
For the HAI assay, RDE-treated serum was serially diluted to a final volume of 
25uL in 96-well V-bottom plates and incubated for 30 minutes with 25uL of 
hemagglutinin diluted in PBS to 8 hemagglutination units (HAU)/50uL. HA sources used 
included Fluzone® vaccine (2014-2015 or 2015-2016 formulation to match that used for 
vaccination), or PR8 or X31 whole-virus particles. Afterward, 50uL of 0.5% chicken red 
blood cells in PBS were added to each well and incubated at room temperature (19-
25°C) for 30 minutes. Titers were expressed as the reciprocal of the last dilution of 
serum that completely inhibited hemagglutination. 
 
Section 2.7: T cell adoptive transfer studies 
For reciprocal adoptive transfer experiments, CD90.1+ TS1 CD4+ T cells specific 
to the S1 peptide (110-119 - SFERFEIFPK) from PR8 influenza hemagglutinin in 
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BALB/c mice, were isolated from the spleens of 10-14 day old (infant) or 8-16 week old 
(adult) TS1 (HA TCR) mice. Naïve (CD44(lo)) splenocytes were purified using the 
MagniSort CD4+ naïve T cell enrichment kit (eBioscience) and 1.5-5 x 105 purified cells 
were transferred by i.p. injection into naïve, congenic (CD90.2+) 10-14 day old infant or 
8-12 week old adult recipients 24 hours prior to infection. The following day, recipient 
mice were infected i.n. with 10-13 TCID50/g PR8 influenza (250-325 TCID50 for adults 
and 70-91 TCID50 for infants). For primary response studies, mice were sacrificed at 
D13 post-infection. For TRM analysis studies, mice were allowed to rest for a total of 6-
12 weeks following infection prior to tissue harvest. 
 
Section 2.8: Cell sorting, RNA preparation and RNA-Seq analysis 
Section 2.8.1: Cell populations and sorting 
Whole transcriptome profiling studies were conducted using adult or infant-
derived TS1 (HA TCR) CD4+ naïve spleen-derived T cells adoptively transferred to 
adult hosts and sorted from the lung 13 days following influenza infection (Figure 2.4) as 
described in the T cell adoptive transfer study section. Harvested lungs were processed 
as described and single lymphocyte suspensions stained in FACS Sort Buffer with 
antibodies to CD3, CD4, CD90.1 and CD19, CD11c, F4/80 in the same channel to 
further exclude non-T cells (Table 2.1). Samples were maintained and sorted in FACS 
Sort Buffer using a BD Influx Cell Sorter (BD Biosciences). Sorted T cells were 





Figure 2.4: T cell populations isolated for RNA-Seq analysis 
 (A) Schematic representation of experimental workflow used to generate in vivo 
activated T cell samples for RNA-Seq analysis. Naive TS1 (HA TCR) CD4+ T cells were 
isolated from adult or infant spleens and adoptively transferred to congenic adult hosts. 
24 hours post-transfer, mice were infected with PR8 influenza. At D13 post-infection, 
lungs from each group were collected and donor CD90.1+ T cells sorted by FACS and 






























Section 2.8.2: RNA isolation and RNA sequencing 
RNA from sorted cells was isolated using the Qiagen RNeasy Mini Kit (Hilden, 
Germany), flash frozen and stored at -80°C prior to quality analysis and library 
generation. Samples were prepared in duplicate or triplicate and RNA integrity and 
concentration for all samples were assessed using an Agilent 2100 Bioanalyzer 
instrument (Agilent Technologies, Santa Clara, CA) and all samples had RNA Integrity 
Number (RIN) values of near 8 or above (see Figure 2.5 for sample RNA quality 
curves). Library preparation and RNA sequencing were performed by the Columbia 
Genome Center using an Illumina HiSeq 2500 instrument (San Diego, CA). RNA 
samples were sequenced in a single-read manner with a sequencing depth of 30 million 
reads.  
Mapping of reads to a mouse reference genome was performed with TopHat 
(322), with downstream estimation of gene abundance using cufflinks (323). Differential 
gene expression was determined using the R-based package DESeq2 (324) available 
from Bioconductor (325). We generated heatmaps of gene expression using Morpheus 
(software.broadinstitute.org/morpheus); with a p-value cutoff of 0.05 and sorting genes 
by log fold change (logFC). STRING (326, 327) was used to evaluate potential protein-
protein interactions and assign Gene Ontology (GO) terms to likely pathways affected 
by differential gene expression patterns among the top 200 differentially expressed 
genes in each dataset. Ingenuity Pathway Analysis software (Qiagen) was used to 
predict potential upstream transcriptional regulators using all differentially expressed 
genes with a p-value of 0.10 or lower and selecting “transcriptional regulators” from the 
upstream regulators tab. 
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Figure 2.5: Bioanalyzer evaluation of RNA quality and concentration  
 Representative histograms indicating RNA integrity, purity and concentration for 
RNA samples used in subsequent RNA-Seq analysis. Plots included are from adult 
CD4+ T cells activated in vitro for 24 hours with anti-CD3 and anti-CD28 antibodies 
(top), infant CD4+ T cells activated in vitro for 24 hours with anti-CD3 and anti-CD28 
antibodies (second from top), transferred adult CD4+ HA effectors sorted from adult 
recipient lungs D13 post-influenza infection (third from top) and transferred infant CD4+ 
HA effectors sorted from adult recipient lungs D13 post-influenza infection (bottom). 
 







Fragment table for sample 2  :  KDZ-044 Adult CD4
Name Start Time [s] End Time [s] Area % of total Area
18S 42.04 43.33 11.5 16.0
28S 47.96 50.83 16.7 23.2
KDZ-044 Adult CD4
Overall Results for sample 2  :  KDZ-044 Adult CD4
RNA Area: 72.1 
RNA Concentration: 24 ng/µl
rRNA Ratio [28s / 18s]: 1.5 
RNA Integrity Number (RIN): 8.4   (B.02.08) 
Result Flagging Color:
Result Flagging Label: RIN: 8.40 
2100 Expert (B.02.08.SI648) © Copyright 2003 - 2009 Agilent Technologies, Inc. Printed: 5/4/2015 9:28:46 AM
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Fragment table for sample 5  :  KDZ-044 Infant CD4
Name Start Time [s] End Time [s] Area % of total Area
18S 41.99 43.02 24.1 23.7
28S 47.68 51.35 39.9 39.2
KDZ-044 Infant CD4
Overall Results for sample 5  :  KDZ-044 Infant CD4
RNA Area: 101.7 
RNA Concentration: 34 ng/µl
rRNA Ratio [28s / 18s]: 1.7 
RNA Integrity Number (RIN): 9.6   (B.02.08) 
Result Flagging Color:
Result Flagging Label: RIN: 9.60 
2100 Expert (B.02.08.SI648) © Copyright 2003 - 2009 Agilent Technologies, Inc. Printed: 5/4/2015 9:28:46 AM
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Fragment table for sample 1  :  Sample 1
Name Start Time [s] End Time [s] Area % of total Area
18S 40.92 42.99 5.3 12.8
28S 49.15 51.92 6.9 16.5
Sample 1
Overall Results for sample 1  :  Sample 1
RNA Area: 41.6 
RNA Concentration: 130 pg/µl
rRNA Ratio [28s / 18s]: 1.3 
RNA Integrity Number (RIN): 8.3   (B.02.08) 
Result Flagging Color:
Result Flagging Label: RIN: 8.30 
2100 Expert (B.02.08.SI648) © Copyright 2003 - 2009 Agilent Technologies, Inc. Printed: 9/14/2015 2:45:31 PM
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Overall Results for sample 3  :  Sample 3
RNA Area: 35.8 
RNA Concentration: 112 pg/µl
rRNA Ratio [28s / 18s]: 1.2 
RNA Integrity Number (RIN): 8.1   (B.02.08) 
Result Flagging Color:
Result Flagging Label: RIN: 8.10 
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9/14/2015 12:43:55 PMData Path:
Eukaryote Total RNA Pico
C:\...Eukaryote Total RNA Pico_DE13805982_2015-09-14_12-21-00.xad
Assay C ass:
Electropherogram Summary Continued ...
Adult in vitro 
activated CD4+ T cells 
Infant in vitro 
activated CD4+ T cells 
Adult adoptively 
transferred CD4+ HA 
primary effectors 
Infant adoptively 




Differentially expressed gene data was further assessed for enrichment of 
signatures of T-bet regulation by Gene Set Enrichment Analysis (GSEA) using a 
previously published dataset (328) of targets putatively up- or down-regulated by T-bet 
to create sets of up- and down-regulated genes. A ranking statistic was computed for 
each gene that passed the default independent filtering criteria (329) of DESeq2 
(alpha=0.1) by multiplying the log of its p-value with the sign of its logFC. This ranked 
list was then tested for enrichment of the T-bet regulated gene sets by applying 
GSEA-Preranked (330) using a weighted scoring scheme and 1000 permutations. 
Enrichment “mountain” plots were produced using the desktop GSEA application. 
 
Section 2.9: Statistics 
Section 2.9.1: Justification of animal numbers 
 For phenotype analysis studies: In preliminary studies we observed an effect size 
for differences in mean T cell memory frequencies between mice infected as infants or 
as adults of approximately 10-20% with a variation of approximately 5% within each 
group. Based on these values, we used the pwr package for R 
(github.com/heliosdrm/pwr) to calculate an estimated required sample size. To 
determine statistical significance between these groups by two-tailed t test at a power of 
80% and type 1 error set to 0.05, it would be necessary to include between 3 to 5 mice 
per group for most studies. 
For body weight assessment studies: Based on previous heterosubtypic infection 
studies we estimated that the maximum difference in mean weight changes between 
infected mice (mice infected as infants or as adults for adult and infant comparisons, or 
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mice receiving live-attenuated or inactivated vaccines for IIV and LAIV comparisons) at 
any day of infection would be between 5 and 10% with a variation of approximately 5% 
within each group. Based on these values, we used the pwr package for R to calculate 
a group size between 4 and 13 animals necessary to determine statistical significance 
between groups by one-tailed t test at a power of 80% and type 1 error set to 0.05. 
 
Section 2.9.2: Data analysis and visualization 
Flow cytometry, weight loss, lung viral titer and neutralizing antibody data were 
compiled and statistical analyses were performed using Prism software (GraphPad 
Software, San Diego, CA). Results are expressed as the mean value from individual 
groups ± SEM, unless otherwise designated, indicated by error bars. Significance 
between experimental groups was determined by one or two-way ANOVA or Student’s t 
test and corrected for multiple comparisons as indicated, assuming a normal distribution 





CHAPTER 3: Vaccine-Generated Lung Tissue-Resident Memory T cells Provide 
Heterosubtypic Protection to Influenza Infection 
 
Tissue-resident memory T cells (TRM) are a recently defined subset with the 
potential for rapid in situ protective responses, although their generation and role in 
vaccine-mediated immune responses is unclear. We assessed TRM generation and 
lung-localized protection following administration of licensed influenza vaccines, 
including injectable inactivated influenza virus (IIV, Fluzone®) and intranasally-delivered 
live-attenuated influenza virus (LAIV, FluMist®) vaccines. We found that, while IIV 
induced robust, strain-specific neutralizing antibodies, LAIV generated lung-localized, 
virus-specific T cell responses. Importantly, LAIV, but not IIV, generated lung CD4+ and 
virus-specific CD8+ TRM, similar in phenotype to those generated by influenza 
infection. Vaccine-generated TRM mediated cross-strain protection, independent of 
circulating T cells or neutralizing antibodies. Intranasal administration of IIV or injection 
of LAIV failed to elicit T cell responses or protect against viral infection, demonstrating 
requirements for respiratory targeting and a live-attenuated strain to establish TRM. The 
ability of LAIV to generate lung TRM capable of providing long-term protection against 
non-vaccine viral strains, as demonstrated here, has implications for providing 
protection against emergent influenza pandemics by direct fortification of lung immunity. 
 
Zens KD, Chen JK, Farber DL. Vaccine-Generated Lung Tissue-Resident Memory T 




Section 3.1: Introduction 
Influenza virus is a severe, acute respiratory pathogen with the potential to 
generate novel strains capable of global pandemics. Current vaccines protect against 
disease by eliciting neutralizing antibodies to the strain-specific glycoproteins 
hemagglutinin (HA) and neuraminidase (NA). Such neutralizing antibodies are the 
correlate of protection by which current vaccines are assessed (227, 250). However, 
antigenic shift and drift drive alterations in these molecules limiting protective efficacy of 
antibody responses and necessitating the annual production of new vaccines (227). 
Developing vaccines which provide universal protection to current and emerging 
influenza strains remains a major public health challenge. 
Influenza infection generates both lasting antibody and T cell responses (332). 
While antibody responses are strain-dependent, virus-specific T cells recognize 
epitopes derived from conserved internal viral proteins in both mice and humans (333-
335), and have been shown to provide heterosubtypic, cross-strain protection in animal 
models (228, 332). Promoting T cell-mediated protection through vaccination, however, 
has remained elusive, and the precise subsets involved in protection are still being 
defined. We and others have identified subsets of non-circulating, lung tissue-resident 
memory CD4+ and CD8+ T cells (TRM) generated following influenza infection, which 
mediate enhanced viral clearance, survival to lethal challenge, and protection to 
heterosubtypic challenge (198, 200, 202).  Establishment of TRM which mediate 
protection against site-specific infection have also been described in other tissues 
including skin, the female reproductive tract and brain (195, 220, 221, 336). The 
protective capacities of TRM suggest that vaccination strategies targeting their 
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generation and persistence may provide enhanced immunity compared to vaccines 
relying on circulating responses. However, the potential role of circulating versus tissue-
localized immunity in vaccine-mediated protection remains undefined.   
Two classes of influenza vaccines are currently available: injectable inactivated 
influenza (IIV) vaccines, and live-attenuated influenza (LAIV) vaccines administered 
intranasally. Both generate HA-specific neutralizing antibodies and exhibit similar 
protection against influenza-like illness (246-250), with LAIV more efficacious in children 
(251). Whether protective influenza-specific T cells are generated in humans following 
vaccination has been difficult to establish (252, 253). Moreover, it is not known whether 
influenza vaccines promote TRM development in humans or animal models.    
Here, we evaluated the capacity of currently used Fluzone® IIV or FluMist® LAIV 
vaccines to promote lung T cell responses and protective TRM. We found that 
vaccination with LAIV, but not IIV, elicited robust lung T cell responses while IIV 
promoted primarily neutralizing antibody responses as observed by hemagglutination-
inhibition assay (HAI). Importantly, LAIV, but not IIV, elicited the establishment of long-
term, virus-specific lung TRM, and provided heterosubtypic protection to non-vaccine 
viral strains similar to previous influenza infection. Vaccine-mediated lung T cell 
responses and protection required both the live-attenuated strain and respiratory 
targeting revealing a requirement for site-specific productive infection for establishing 
lung TRM.  Our findings demonstrate that LAIV may be an effective strategy to generate 





Section 3.2: Results  
Section 3.2.1: Distinct localization of primary responses generated from 
vaccination with IIV and LAIV  
We compared primary immune responses, including T cell and antibody 
responses, in mice vaccinated intraperitoneally (i.p.) or subcutaneously (s.c.) with 
Fluzone® IIV versus intranasally (i.n.) with FluMist® LAIV. The injection routes (i.p. and 
s.c.) for IIV were chosen based on patterns of antigen drainage with i.p. immunization 
draining to the lung-draining, mediastinal lymph nodes (MdLN) (337, 338) and s.c. 
immunization at the base of the neck draining to the axillary lymph nodes similar to 
intradeltoid injection in humans (242, 243). We observed increased numbers of CD3+ T 
cells in the lungs and MdLN and increased percentages of CD44+CD62L(lo) 
effector/memory CD4+ and CD8+ T cells in the lungs of i.n. LAIV mice compared to i.p 
or s.c. IIV mice or unvaccinated groups (Figure 3.1a,b, Figure 3.2). The majority of T 
cells in the lungs of LAIV mice expressed the early activation marker CD69 while T cells 
in the lungs of IIV or unvaccinated mice were CD69-negative (Figure 3.1c,d), indicating 
generation of tissue-localized, effector CD4+ and CD8+ T cells following administration 
of LAIV, but not IIV.  These results demonstrate that vaccination with LAIV promotes the 




Figure 3.1: Distinct localization of primary T cell responses following vaccination 
with IIV or LAIV 
(A) CD3+ cells in the lung and MdLN of mice 10 days post-vaccination with 2014-
2015 IIV or LAIV. Graph displays mean absolute CD3+ cell numbers ± SEM. (n=5-10 
mice per group compiled from 2 independent experiments; significance determined by 
multiple Student’s t tests with Welch’s correction, ***p<0.001). (B) Lung effector/memory 
T cells 10 days post-vaccination with 2014-2015 IIV or LAIV. Left: Representative flow 
cytometry plots displaying percentages of cells with naïve (CD44(lo)CD62L(hi)) and 
effector/memory (CD44(hi)CD62L(lo)) phenotypes. Right: Individual percentages of lung 
CD4+ and CD8+ effector/memory phenotype T cells ± SEM. (n=5 mice per group, 
representative of 3 experiments; significance determined by two-way ANOVA with 
Holm-Sidak’s multiple comparisons test, ****p<0.0001). (C) CD69 expression by lung T 
cells 10 days post-vaccination with 2014-2015 IIV or LAIV. Left: Representative flow 
cytometry plots showing percentages of cells with CD44(hi)CD69hi phenotype. Right: 
Individual percentages of lung CD4+ and CD8+ T cells expressing CD69 ± SEM. (n=5 
mice per group, representative of 3 experiments; significance determined by two-way 
ANOVA with Holm-Sidak’s multiple comparisons test, ****p<0.0001). (D) CD69 
expression by lung T cells 10 days post-vaccination with 2014-2015 IIV i.n. or i.p. or 
LAIV i.n. or i.p. Graph displays individual percentages of lung CD4+ and CD8+ T cells 
expressing CD69 ± SEM. (n=4-5 mice/group; significance determined by two-way 
ANOVA with Holm-Sidak’s multiple comparisons test, ****p<0.0001). (E) Influenza-
specific CD8+ T cells in the lungs 10 days post-vaccination with 2015-2016 IIV or LAIV. 
Top: Representative flow cytometry plots with percentages of lung NP366-374-specific 
	  
	  112	  
CD8+ T cells. Bottom: Individual percentages of lung NP366-374-specific CD8+ T cells ± 
SEM. (n=5 mice per group, representative of 2 experiments; significance determined by 











































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.2: Similar primary T cell responses following vaccination with 
intraperitoneal (i.p.) or subcutaneous (s.c.) IIV 
(A) Flow cytometric analysis of CD4+ and CD8+ T cells 10 days post-vaccination 
in the lung, MdLN and pooled cervical/axillary lymph nodes of mice vaccinated 
intraperitoneally (i.p.) or subcutaneously (s.c.) at the base of the neck with 2014-2015 
IIV. Top: Representative percentages of cells with naïve (CD44(lo)CD62L(hi)) and 
effector/memory (CD44(hi)CD62L(lo)) phenotypes. Bottom: Individual percentages of 
effector/memory phenotype in each tissue ± SEM. (n=5 mice per group; significance 
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We further investigated whether the increased lung T cell response from LAIV, 
compared to IIV, was due to direct targeting of vaccine into the respiratory tract. 
However, respiratory targeting of IIV by i.n. administration did not generate increased 
numbers of lung or MdLN CD3+ T cells (Figure 3.3a) or increased percentages of 
CD69+ or CD44+ effector/memory CD4+ and CD8+ T cells observed with i.n. LAIV 
(Figure 3.1d, Figure 3.3b), indicating that mucosal administration alone is not sufficient 
to promote lung T cell responses. Conversely, i.p. or systemic administration of LAIV 
failed to promote lung T cell responses (Figure 3.1d, Figure 3.3b). These results 
demonstrate that both the live-attenuated vaccine formulation and respiratory targeting 
are required for the generation of lung-localized primary T cell responses.   
Our initial studies used commercially available IIV and LAIV vaccines from the 
2014-2015 season directed against the following four strains: A/California/7/2009 
(H1N1) pdm09, A/Texas/50/2012 (H3N2), B/Massachusetts/2/2012, and 
B/Brisbane/60/2008. However, since vaccine formulations are changed annually, it was 
important to establish whether the distinct responses observed with 2014-2015 IIV and 
LAIV were to due differences in vaccine type and not specific to the vaccine strains. We 
therefore assessed the primary responses to vaccination using the current 2015-2016 
quadrivalent IIV and LAIV formulations directed against new 
A/Switzerland/9715293/2013 (H3N2) and B/Phuket/3073/2013 strains in addition to 
A/California/7/2009 (H1N1)pdm09 and B/Brisbane/60/2008 similar to the 2014-15 
version. In agreement with our results using 2014-2015 vaccines, we observed 
increased percentages of CD44+CD62L(lo) effector/memory and CD69-expressing 
CD4+ T cells in the lungs of mice vaccinated with 2015-2016 LAIV compared to 2015-
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2016 IIV and unvaccinated mice (Figure 3.4a,b). Vaccination with LAIV also resulted in 
the accumulation of influenza nucleoprotein (NP)-specific CD8+ T cells in the lung, 
which was not observed in IIV-vaccinated or unvaccinated mice (Figure 3.1e). Together, 
these results demonstrate that i.n. administered LAIV generates influenza-specific 
primary lung T cell responses while IIV immunization does not result in significant lung-




Figure 3.3: Effect of vaccine formulation and administration route on lung-
localized T cell responses to vaccination 
(A) Absolute numbers of CD3+ T cells in the lung and MdLN 10 days post-
vaccination in i.n. or i.p. 2014-2015 IIV-vaccinated and i.n. or i.p. 2014-2015 LAIV-
vaccinated mice. Graph displays mean absolute cell numbers ± SEM. (n=4-5 mice per 
group; significance determined by two-way ANOVA with Holm-Sidak’s multiple 
comparisons test, ****p<0.0001, *p<0.05). (B) Percentage of CD44+ CD4+ and CD8+ T 
cells in the lung 10 days post-vaccination with 2014-2015 IIV given i.n. or i.p or 2014-
2015 LAIV given i.n. or i.p. Graph displays individual percentages of CD44(hi) CD4+ 
and CD8+ T cells ± SEM. (n=4-5 mice per group; significance determined by two-way 















































































Figure 3.4: Primary lung T cell responses following vaccination with 2015-2016 IIV 
or LAIV 
(A) Flow cytometric analysis of lung CD4+ and CD8+ T cells 10 days post-
vaccination with 2015-2016 IIV or 2015-2016 LAIV compared to unvaccinated mice. 
Left: Representative flow plots with percentages of cells with naïve (CD44(lo)CD62L(hi)) 
and effector/memory (CD44(hi)CD62L(lo)) phenotypes. Right: Individual percentages of 
lung CD4+ and CD8+ effector/memory phenotype T cells ± SEM. (n=5 mice per group, 
representative of 3 experiments; significance determined by two-way ANOVA with 
Holm-Sidak’s multiple comparisons test, ****p<0.0001, ns p>0.05). (B) Frequencies of 
lung CD4+ and CD8+ T cells expressing CD69 10 days post-vaccination with 2015-
2016 IIV or 2015-2016 LAIV compared to unvaccinated mice. Left: Representative flow 
plots with percentages of CD44(hi)CD69(+) cells. Right: Individual percentages of lung 
CD4+ and CD8+ CD44(hi)CD69(+) cells T cells ± SEM. (n=5 mice per group, 
representative of 3 experiments; significance determined by two-way ANOVA with 




























































































































































































































































































































































































































































































































































































































































































































































































































































































Serum neutralizing antibody responses, as measured by hemagglutination 
inhibition (HAI) assay, are currently the gold-standard for assessing vaccine efficacy 
with titers ≥40 generally protective against homologous infection in humans (339). 
Given the disparate primary T cell responses to vaccination with IIV and LAIV, we 
further assessed serum HAI titers during the primary response at day 10 post-
vaccination with 2014-2015 IIV or LAIV by different routes. Significant HAI titers were 
only observed in mice administered IIV by i.p. or s.c.-vaccination, with minimal titers in 
i.n. IIV recipients, or in i.n. or i.p. LAIV-vaccinated mice (Figure 3.5a,b) demonstrating 
the importance of both vaccine formulation and route of vaccination in this response. 
For the 2015-2016 formulations, HAI titers were higher in mice vaccinated with i.p. IIV 
compared to i.n. LAIV (Figure 3.5c), although HAI titers were generally higher in mice 
vaccinated with 2015-16 LAIV compared to 2014-15 LAIV on an absolute scale, 
although the lack of concurrent availability of both seasonal vaccines precluded direct 
comparisons. Taken together, IIV and LAIV generate dichotomous primary immune 
responses with IIV inducing predominantly humoral immunity and LAIV generating 





Figure 3.5: Distinct primary serum neutralizing antibody responses following 
vaccination with IIV or LAIV 
(A) Serum HA-neutralizing antibody titers to vaccine antigen 10 days post-
vaccination in mice receiving 2014-2015 IIV i.n. or i.p. or LAIV i.n. or i.p.. Graph shows 
individual HAI titers ± SEM. (n=5-10 mice per group compiled from 2 independent 
experiments; significance determined by one-way ANOVA with Holm-Sidak’s multiple 
comparisons test, ****p<0.0001). (B) Serum HA-neutralizing antibody titers to vaccine 
antigen 10 days post-vaccination in mice administered 2014-2015 IIV i.p. or s.c. Graph 
shows individual HAI titers ± SEM. (n=5 mice per group; significance determined by 
two-tailed Student’s t test with Welch’s correction, ns p>0.05). (C) Serum HA-
neutralizing antibody titers to vaccine antigen 10 days post-vaccination in mice receiving 
2015-2016 i.p. IIV or i.n. LAIV. Graph shows individual HAI titers ± SEM. (n=3-8 mice 
per group compiled from 2 independent experiments; significance determined by one-

























































Section 3.2.2: LAIV generates persisting lung TRM 
We next assessed whether immunization with IIV or LAIV generated persisting 
lung TRM assessed at longer times (>6 weeks) post-vaccination. To distinguish 
circulating T cells from tissue-localized TRM, we used an intravenous in vivo antibody 
labeling technique (i.v. Ab) whereby i.v. infusion of fluorescently-conjugated anti-T cell 
antibodies results in fluorescent labeling of circulating T cells while T cells retained 
within tissues are protected from antibody binding (201, 202). “Protected” and “labeled” 
T cells revealed by i.v. Ab, exhibit phenotypic markers of TRM and circulating T cells, 
respectively, and segregate into distinct niches of the lung (201, 202). Using this 
technique, we found that the majority of lung CD4+ and CD8+ T cells (>75%) in mice 
vaccinated with LAIV were protected from i.v. Ab labeling compared to only 20% 
protected in IIV-vaccinated mice and 5% protected in unvaccinated mice, on average 
(Figure 3.6a). The majority of lung T cells in IIV and unvaccinated groups were labeled, 
indicating that they comprised circulating subsets (Figure 3.6a). Similar patterns of lung 
T cell segregation to protected and labeled niches were observed following vaccination 
with both 2014-2015 and 2015-2016 IIV and LAIV formulations (not shown). Protected 
CD4+ and CD8+ T cells in the lungs of mice vaccinated with LAIV were present in 
similar numbers and upregulated the TRM marker CD69 to similar extents as those 
resulting from live PR8 influenza infection (Figure 3.6b,c,d).  These results demonstrate 
that TRM generated following vaccination with LAIV are similar in phenotype and 




Figure 3.6: LAIV-vaccination generates lung TRM  
(A) Lung T cells labeled by i.v. anti-Thy1 antibody in mice 6 weeks post-
vaccination with 2014-2015 IIV or LAIV. Left: Representative flow cytometry plots 
displaying CD4+ and CD8+ cells in tissues (“Protected”) or circulating (“Labeled”). 
Right: Individual percentages of protected T cells ± SEM. (n=5 mice per group, 
representative of 2 experiments; significance determined by two-way ANOVA with 
Holm-Sidak’s multiple comparisons test, ***p<0.0001, ***p<0.001, *p<0.05). (B) 
Protected lung CD69+ T cells in mice 16 weeks post-vaccination with 2014-2015 IIV or 
LAIV or post-infection with PR8 influenza. Graph displays protected CD69+ cell 
numbers ± SEM. (n=4-5 mice per group, representative of 2 experiments; significance 
determined by multiple Student’s t tests with Welch’s correction, *p<0.05, ns=p>0.05). 
(C) CD69 expression by protected versus circulating lung T cells 16 weeks after 2014-
2015 LAIV-vaccination or PR8 infection. Top: Representative histogram of CD69 
expression by protected/labeled lung T cells post-PR8 infection. Bottom: CD69 
expression by protected/labeled lung T cells post-LAIV vaccination. (D) TRM marker 
expression in protected lung T cells 6 weeks post-vaccination with 2015-2016 IIV or 
LAIV. Left: Representative flow cytometry plots displaying protected CD4+ and CD8+ T 
cells with CD44(hi)CD69+ phenotypes or protected CD8+CD44+ T cells with 
CD69+CD103hi phenotype. Right: Individual percentages of protected CD4+ or CD8+ T 
cells expressing CD69 or protected CD8+CD44+ T cells expressing CD103 ± SEM. 
(n=5 mice per group, representative of 3 experiments; significance determined by 
multiple Student’s t tests with Holm-Sidak’s correction, ***p<0.0001, ***p<0.001). (E) 
Protected lung influenza-specific CD8+ T cells in mice 5 weeks post-vaccination with 
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2015-2016 IIV or LAIV. Left: Representative flow cytometry plots displaying protected or 
labeled lung NP366-374-specific CD8+ T cells. Right: Individual percentages of protected 
lung NP366-374-specific CD8+ T cells ± SEM. (n=3-5 mice per group; significance 
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We further investigated whether LAIV-generated CD8+ TRM cells also expressed 
the canonical CD8+ TRM marker CD103 and/or were enriched for influenza-specific T 
cells as found with influenza-generated TRM (104, 198, 202). Protected CD8+ TRM 
generated following vaccination with LAIV expressed CD103 while lung T cells in mice 
vaccinated with IIV were CD103-negative (Figure 3.6d). In addition, NP-specific lung 
CD8+ memory T cells were readily detected in mice vaccinated with LAIV, but not IIV, 
and nearly all of these NP-specific cells were protected from i.v. Ab labeling (Figure 
3.6e) indicating that they belonged to the TRM subset. Thus, vaccination with LAIV, but 
not IIV, generates lung-localized memory CD4+ and influenza-specific CD8+ lung TRM 
populations.   
Persisting serum HAI antibody titers specific for vaccine viral strains were detected in 
the sera of mice 6 weeks post-vaccination with IIV and LAIV (Table 3.1, columns 1 and 
2). Vaccination with IIV generated higher titers than LAIV for both 2014-2015 and 2015-
2016 formulations (Table 3.1, columns 1 and 2). We did not detect neutralizing HAI 
titers specific for the non-vaccine influenza strains PR8 or X31 in any of the vaccinated 
mice at any timepoint (Table 3.1, columns 3 and 4 and data not shown), further 
confirming the strain-specific nature of vaccine-elicited antibody responses.  These 
results indicate key differences in the persisting memory immune response following 
immunization with IIV and LAIV, with high levels of durable, strain-specific antibodies 





Table 3.1: Serum hemagglutination inhibition titers in memory mice 
Hemagglutination inhibition titers, in HAI units, to whole-virus or vaccine antigen 
in the serum of memory mice following infection or vaccination 6 weeks prior. 
 






Vaccine AntigenB PR8 Virus X31 Virus 
Unvaccinated <20C <20 <20 <20 
2014-2015 
Fluzone® 832 ± 97.8 ND <20 <20 
2014-2015 
FluMist® 240 ± 61.1 ND <20 <20 
2015-2016 
Fluzone® ND
D 130 ± 14.6 <20 ND 
2015-2016 
FluMist® ND 75 ± 5.0 <20 ND 
PR8-Infected <20 <20 576 ± 64.0 <20 
 
An = 5-10 mice per group, means given ± SEM 
 
BFluzone® was used as vaccine antigen as FluMist® is a whole-virus preparation and may contain 
additional antibody epitopes not present in the Fluzone® vaccine 
 







Section 3.2.3: LAIV-generated TRM mediate heterosubtypic protection  
In order to assess whether vaccine-generated, lung-localized memory T cell 
responses were protective, we challenged mice vaccinated with IIV and LAIV with X31 
or PR8 heterosubtypic strains of influenza virus. These stains are known to be 
serologically distinct from the vaccine strains and vaccinated mice lack neutralizing 
antibodies to X31 and PR8 HA (Table 3.1). To specifically assess TRM-mediated 
protection independent from that mediated by circulating T cells, we treated mice 
throughout infection with the sphingosine 1-phosphate receptor-1 agonist FTY720, 
which sequesters circulating T cells within the secondary lymphoid tissues, while TRM 
within the lung remain intact (202). We also challenged PBS-treated vaccinated mice to 
assess total T cell-mediated protection from both resident and circulating subsets.   
Following X31 challenge, mice vaccinated with LAIV (and mice previously infected with 
PR8 influenza as a positive control) were fully protected from morbidity of infection as 
measured by weight loss in both PBS- and FTY720-treated groups. In contrast, mice 
vaccinated with IIV and unvaccinated mice exhibited similar kinetics of weight loss and 
recovery over 7 days post-challenge in PBS-treated groups; however, in FTY720-
treated groups recovery was only observed by IIV-immunized mice while unvaccinated 
mice exhibited worsening morbidity throughout the infection course (Figure 3.7a).  
These results demonstrate that vaccination with LAIV protects form morbidity of 
infection independent of circulating lymphocytes, while IIV does not, although it may 




Figure 3.7: LAIV generates TRM-mediated heterosubtypic protection 
(A) Morbidity following heterosubtypic X31 (H3N2) infection in unvaccinated mice 
or mice vaccinated 6 weeks prior with 2014-2015 IIV or LAIV or infected with PR8 
(H1N1) influenza. Left: Mean percentage weight retention in infected mice receiving 
daily PBS treatment ± SEM. Right: Mean percentage weight retention in infected mice 
receiving daily FTY720 treatment ± SEM. (n=5 mice per group, representative of 2 
experiments; significance determined by multiple Student’s t tests comparing i.n. LAIV-
vaccinated to i.p. IIV-vaccinated, **p<0.01, *p<0.05). (B) Viral clearance 5 days post-
X31 infection in mice administered 2014-2015 IIV or LAIV or infected with PR8 influenza 
6 weeks prior. Left: Individual D5 lung viral titers in infected mice receiving daily PBS 
treatment ± SEM. Right: Individual D5 lung viral titers in infected mice receiving daily 
FTY720 treatment ± SEM. (n=5 mice per group, representative of 3 experiments; 
significance determined by one-way ANOVA with Holm-Sidak’s multiple comparisons 
test, *p<0.05, ns p>0.05). (C) Morbidity following X31 infection in mice vaccinated with 
i.n. 2014-2015 IIV or i.n. or i.p. LAIV 6 weeks prior. Left: Mean percentage weight 
retention in infected mice with daily PBS treatment ± SEM. Right: Mean percentage 
weight retention in infected mice with daily FTY720 treatment ± SEM. (n=5 mice per 
group; significance determined by multiple Student’s t tests comparing i.n. LAIV-
vaccinated to other recipient groups with the least significant p value reported, 
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In terms of lung viral clearance, mice vaccinated with LAIV exhibited enhanced 
lung viral clearance both PBS- and FTY720-treated groups (Figure 3.7b), indicating that 
protection is independent of circulating responses. By contrast, mice vaccinated with IIV 
exhibited viral clearance in PBS-treated, but not FTY720-treated, groups (Figure 3.7b), 
suggesting that while the circulating T cell response induced by IIV (340, 341) could 
provide a degree of protection, lung-resident protection was not generated. Additionally, 
targeting IIV to the lung through i.n. administration did not result in protection in either 
FTY720 or PBS-treated mice demonstrating that respiratory targeting of antigen alone 
even in the form of inactivated, split virions, does not promote long-term protective 
immunity (Figure 3.7c).  
We further investigated the breadth and persistence of lung-specific protection 
generated by LAIV. Mice vaccinated with LAIV (and treated with FTY720) were also 
protected against challenge with PR8 influenza (Figure 3.8a,b) and this protection 
persisted 45 weeks (10 months) post-vaccination (Figure 3.8c). Furthermore, 
vaccination with 2015-2016 LAIV or IIV resulted in a similar pattern of lung-specific 
protection in the presence of FTY720, with LAIV providing enhanced protection from 
weight loss compared to IIV (Figure 3.8d). Together, these results demonstrate that 




Figure 3.8: LAIV-formulations establish long-term TRM-mediated protection 
against multiple viral strains 
(A) Percentage weight retention following heterosubtypic PR8 (H1N1) influenza 
infection 12 weeks post-vaccination with 2014-2015 IIV or 2014-2015 LAIV or post-
infection with X31 (H3N2) influenza, compared to unvaccinated, in mice receiving daily 
FTY720 treatment. Mean percentage weight retained shown ± SEM. (n=4-5 mice per 
group; significance determined by multiple Student’s t tests comparing i.n. LAIV-
vaccinated to i.p. IIV-vaccinated groups, *p<0.05). (B) Viral titers 5 days post-PR8 
infection in unvaccinated mice or mice vaccinated with 2014-2015 IIV or 2014-2015 
LAIV or infected with X31 influenza 12 weeks prior. Animals received daily FTY720 
treatment throughout infection. Graph show individual titers ± SEM. (n=4-6 mice per 
group; significance determined by one-way ANOVA with Holm-Sidak’s multiple 
comparisons test, *p<0.05, ns p>0.05). (C) Percentage weight retention following PR8 
infection in unvaccinated mice or mice receiving 2014-2015 LAIV 45 weeks prior. 
Animals received daily FTY720 treatment throughout infection. Mean percentage weight 
retained shown ± SEM. (n=4-5 mice per group, significance determined by multiple 
Student’s t tests comparing i.n. LAIV-vaccinated and unvaccinated groups, *p<0.05). (D) 
Percentage weight retention following X31 infection 6 weeks post-vaccination with 
2015-2016 IIV or 2015-2016 LAIV, compared to unvaccinated, in mice receiving daily 
FTY720 treatment. Mean percentage weight retained shown ± SEM. (n=5-12 mice per 
group; significance determined by multiple Student’s t tests comparing i.n. LAIV-
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We investigated whether the putative TRM-mediated protection to heterosubtypic 
challenge in FTY720-treated, vaccinated mice was associated with a virus-specific 
recall response in the lung. We detected substantial percentages (>30%) of influenza-
specific CD8+ T cells in the lung at early timepoints after heterosubtypic challenge with 
PR8 or X31 in mice vaccinated with LAIV. In contrast, low to negligible virus-specific 
CD8+ T cells were observed in the lungs of similarly challenged IIV-vaccinated or 
unvaccinated mice (Figure 3.9a,b). The preferential mobilization of a lung-localized 
influenza-specific CD8+ T cell recall response in LAIV, compared to IIV-vaccinated mice 
was observed with both 2014-2015 and 2015-2016 vaccine formulations (Figure 
3.9a,b), as further evidence that i.n. administered live-attenuated vaccines promote lung 
TRM. Taken together, these results demonstrate that LAIV promotes generation and 
long-term persistence of lung TRM capable of controlling both viral load and preventing 
infection morbidity.   
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Figure 3.9: Heterosubtypic infection induces a significant lung influenza-specific 
CD8+ T cell recall response in LAIV-vaccinated mice 
(A) Influenza-specific CD8+ T cells in the lungs 5 days post-PR8 (H1N1) 
influenza infection in unvaccinated mice or mice vaccinated with 2014-2015 IIV or LAIV 
6 weeks prior. Animals were treated daily throughout infection with FTY720. Left: 
Representative flow cytometry plots showing percentages of influenza NP366-374-specific 
CD8+ T cells in the lungs. Right: Individual percentages of lung NP366-374-specific CD8+ 
T cells ± SEM. (n=5-6 mice per group; significance determined by one-way ANOVA with 
Holm-Sidak’s multiple comparisons test, ***p<0.001). (B) Influenza-specific CD8+ T 
cells in the lungs 6 days post-X31 (H3N2) influenza infection in unvaccinated mice or 
mice vaccinated with 2015-2016 IIV or LAIV 6 weeks prior. Animals were treated daily 
throughout infection with FTY720. Left: Representative flow plots showing percentages 
of NP366-374-specific CD8+ T cells in the lungs. Right: Individual percentages of lung 
NP366-374-specific CD8+ T cells ± SEM. (n=5-9 mice per group; significance determined 






























































































































































































































































































































































































































































































Section 3.3: Discussion 
The identification of TRM and their robust protective capacities to site-specific 
infections has provided a new paradigm by which to assess T cell-mediated responses 
(342) and an important new target for vaccine design (220, 262). Here we compared the 
ability of commercially available influenza vaccines Fluzone® Quadrivalent IIV, and 
FluMist® Quadrivalent LAIV to generate lung T cell responses and establish protective 
lung TRM. We demonstrate that vaccination with LAIV elicits lung CD4+ and virus-
specific CD8+ T cell responses and ultimately establishes lung TRM capable of 
providing long-term, heterosubtypic protection to multiple, non-vaccine influenza strains. 
In contrast, vaccination with IIV generates durable, strain-specific humoral immunity, but 
does not promote the establishment of significant lung TRM or heterosubtypic 
protection. Our results have important implications in the testing, monitoring and 
administration of different influenza vaccine formulations for promoting protection from 
seasonal and pandemic strains.  
Influenza-specific T cells in mice and humans recognize conserved internal viral 
proteins that are similar in diverse serotypes (333, 343) and could therefore promote 
universal protection to new and emerging influenza strains – the ultimate goal of a 
successful influenza vaccine. Importantly, mouse studies of T cell-mediated protection 
now indicate that the tissue location of persisting memory T cells greatly impacts their 
protective capacities. Lung TRM have been shown to provide enhanced protective 
immunity to influenza infection compared to circulating T cells (198) and are necessary 
for effective heterosubtypic protection (200). These findings raise the question of 
whether vaccines can promote TRM-mediated long-term immunity – an issue that is not 
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currently possible to address in humans. By administering clinically available influenza 
vaccines (IIV and LAIV) to mice, we were able to recapitulate the distinct systemic 
humoral responses observed in humans with IIV promoting enhanced HAI titers 
compared to LAIV (246-249), indicating that this system may provide an effective model 
by which to examine potential TRM formation to vaccines.  
Factors necessary for the establishment of TRM are not currently well 
understood. Both the route of antigen encounter as well as the nature of the antigen 
itself may play critical roles in this process. Recent vaccine studies have demonstrated 
that mucosal administration of antigen is important for the establishment of localized T 
cell responses which may go on to establish TRM (220, 259, 262, 344-346). We found 
that a single intranasal vaccination with LAIV from either of two seasonal vaccine 
formulations was sufficient to generate lung CD4+ and CD8+ TRM, enriched in 
influenza-specific T cells, which provided long-lasting protection to heterosubtypic 
challenge. By contrast, vaccination with IIV by systemic or intranasal routes was not 
sufficient to promote lung TRM generation, or lung-specific protection from infection. 
Moreover, systemic administration of LAIV similarly did not generate lung TRM, 
indicating an essential role for tissue-targeting. These results demonstrate that a site-
specific infection is necessary for TRM generation, while antigen introduced at the 
tissue site, even in the context of the PAMPS present within inactivated virus 
preparations for activation of innate immunity, was not sufficient for TRM establishment. 
Our influenza challenge studies with FTY720 treatment indicate that LAIV-
mediated protection is targeted to the lung and can occur independent of circulating T 
cell responses or infiltration from the lymphoid tissue. The enrichment of significant 
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influenza-specific lung memory CD8+ T cells following heterosubtypic influenza 
challenge in FTY720-treated, LAIV-vaccinated mice suggests in situ expansion of 
influenza-specific lung TRM. Focused, local responses by TRM involving rapid cytokine 
production have been observed in skin and the female reproductive tract following 
secondary challenge (220, 222, 223, 225), although expansion was not assessed in 
those studies.  We propose that local and limited expansion of lung TRM may be 
responsible for the enhanced viral clearance and protection from morbidity of infection 
that we observed in mice vaccinated with LAIV.  
While studies of TRM generation and protection have been limited to mouse 
models, TRM-phenotype cells are present in human lymphoid and mucosal tissues and 
represent the majority of memory T cells in tissues (205, 347).  Moreover, analysis of 
human lung samples has revealed that influenza-specific memory T cells are present in 
most healthy humans (238, 239), with a proportion of these lung virus-specific T cells 
expressing CD69 (202), representing putative TRM. Whether TRM in human lungs were 
generated in response to infection or vaccination, however, is unknown. In general, 
studies of human influenza-specific T cell responses to infection and vaccines have 
largely been limited to the analysis of peripheral blood subsets. Circulating virus-specific 
T cells in the peripheral blood of children following LAIV, but not IIV vaccination (251, 
252), although whether such responses provide protection is unclear. In human 
influenza infection the presence of virus-specific CD4+ T cells in circulation has been 
correlated to reduced overall disease severity (235). Whether circulating T cell 
responses predict lung TRM generation will be important to establish to improve vaccine 
response monitoring.  
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We propose that assessing the relative contribution of TRM versus systemic T 
cells and humoral responses for clinical vaccine strains in a mouse model can be 
informative for predicting protective efficacy required for different conditions of seasonal 
or pandemic infections. Our findings here highlight the differing mechanisms of 
protection between LAIV and IIV vaccines and establish TRM as an important correlate 
of vaccine-mediated protection to influenza virus, with potential implications for the 





CHAPTER 4: Infant Tissue-Resident Memory Generation Following Influenza 
Infection or Vaccination is Influenced by the Th1 Transcription Factor T-bet 
 
Infants are disproportionately affected by respiratory infection and suffer more 
repeated infections relative to adults suggesting poor establishment of protective 
immunity. Mechanisms for the worsened outcomes of infants to infection, as well as 
their diminished vaccine responses, however, remain incompletely defined. It is now 
understood that the majority of pathogen-specific memory T cells generated by many 
respiratory infections are non-circulating, tissue-resident cells (TRM). In mice, TRM are 
generated in response to influenza infection or live-attenuated influenza vaccination 
(LAIV) and provide superior protection to heterosubtypic challenge compared to 
circulating antibody or T cell responses. Mechanisms for TRM generation are not 
completely elucidated, although roles for the Th1 lineage-defining transcription factor T-
bet have been implicated. 
We hypothesized that distinct immune responses in early life limit establishment 
of protective immune memory and investigated the capacity of infant mice to generate T 
cell responses and protective T cell memory following influenza infection or vaccination. 
Infants mounted robust, lung-localized primary T cell responses to both infection and 
LAIV. However, these cells were inefficiently maintained as protective TRM. By 
transferring adult or infant T cells to adult and infant hosts, we determined that reduced 
TRM formation by infants is T cell-intrinsic and transcriptional profiling studies revealed 
enhanced expression of T-bet-regulated genes by infant effectors. Strikingly, reducing 
T-bet expression in infection by utilizing T-bet heterozygous infant mice restored lung 
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TRM generation to adult levels. Our findings identify the reduced generation of TRM in 
early life as a contributing factor to reduced protection from heterosubtypic reinfection 
with influenza virus and provide mechanistic insight into the process of TRM 
establishment with potential applications in vaccine design. 
 
Zens KD, Chen JK, Cvetkovski F, Miron M, Wu FL, Guyer RS and Farber DL (in 
Preparation) Infant Tissue-Resident Memory Generation Following Influenza Infection is 





Section 4.1: Introduction  
Infants are disproportionately affected by respiratory infections and are 
susceptible to multiple viral and bacterial pathogens. Infants are additionally more likely 
to suffer repeated respiratory infections suggesting ineffective establishment of 
protective immunity. The worsened outcomes of infants to infection, as well as their 
limited or delayed responses to vaccines, have been primarily attributed to immaturity of 
their immune systems. Reduced functional responses by T lymphocytes have been 
specifically implicated due to their role in coordinating many aspects of adaptive 
immunity. It has become increasingly clear, however, that infant T cell and other 
immune responses are not simply ‘reduced’ compared to adults. Neonates and infants 
generate adult-like T cell responses to certain antigens such as those derived from 
mycobacteria (298, 348). Furthermore, evidence suggests that T cells in early life 
generate distinct protective responses not typically observed in adults (300). Factors 
controlling the establishment of protective T cell responses and lasting T cell memory in 
early life remain, however, poorly understood. In order to develop therapies to better 
treat respiratory infections and promote robust, protective responses to vaccines, it is 
essential to define the mechanisms that control T cell differentiation and function at the 
earliest life stages. 
It is now understood that, following respiratory infection, a significant fraction of 
total pathogen-specific T cell memory in both mice and humans is comprised of non-
circulating, lung-tissue resident memory (TRM) T cells (198, 202, 238, 349). In addition 
to the lung, TRM are established at multiple tissue sites including the brain, skin, gut 
and female reproductive tract, where they mediate robust protection against local 
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pathogen encounter (197, 198, 214, 220, 336). TRM populations specific to the lung-
localized viral respiratory pathogen influenza are generated following infection or live-
attenuated influenza vaccination in mouse models (198, 202, 331) and have been 
shown to provide superior protection from heterosubtypic viral reinfection and lethal 
challenge compared to circulating antibody or T cell responses (198, 331). In humans, 
influenza-specific CD4+ and CD8+ T cells have been further identified localized 
specifically within the lungs (202, 238, 239), highlighting the site-specific nature of these 
cells. The mechanisms underlying TRM establishment are incompletely understood 
although TRM have a distinct transcriptional profile (214, 350). Master regulators of 
TRM generation have not yet been identified, though it is known that altering the 
expression of the transcription factor T-bet, which controls Th1 effector and memory 
differentiation, impacts TRM generation in mice (104). 
Importantly, how the distinct nature of the infant immune system affects primary 
T cell responses to respiratory pathogens and the generation of immune memory 
following infection or vaccination is unclear. Neonates vaccinated with BCG at birth 
generate circulating T cells which produce adult-like Th1-mediated IFN-gamma 
responses upon stimulation. However, the protective function of these cells is not known 
(298). Additionally, following receipt of live-attenuated influenza virus vaccine (LAIV), 
infants generate circulating, virus-specific T cell responses not observed in adults (313) 
and LAIV was further demonstrated to provide enhanced protection in children 
compared to inactivated influenza vaccine (IIV) (251), although the nature of this 
protection is not clear. Despite their capacity to generate robust immune responses 
under certain circumstances, and despite early life exposures to multiple vaccines and 
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pathogen encounters, T cells derived from most tissues in early life demonstrate a 
predominantly naïve phenotype in contrast to adults which have a predominance of 
memory, and TRM specifically (283), possibly suggesting a reduced capacity to 
generate lasting tissue-localized T cell memory in early life. 
We hypothesized that infant-intrinsic defects in primary T cell responses limit the 
capacity to generate lasting, protective T cell memory populations in response to 
infection and vaccination. Using an infant mouse model of influenza infection we found 
that infants mount robust primary responses to infection and LAIV. However, these cells 
were inefficiently maintained as lung TRM. By adoptively transferring adult or infant T 
cells to adult and infant hosts, we determined that reduced TRM formation by infants is 
T cell-intrinsic rather than a consequence of the infant lung environment. Through 
transcriptional profiling studies we identified enhanced expression of T-bet-regulated 
genes by infant effectors during the primary response. We further observed enhanced 
expression of T-bet at the protein level following activation of infant T cells from mice 
and humans. Strikingly, reducing T-bet expression during infection by utilizing T-bet 
heterozygous infant mice restored establishment of lung TRM to near adult levels. 
These findings identify the reduced generation of TRM following infection during early 
life as a contributing factor to reduced protection from subsequent heterosubtypic viral 
infection and provide mechanistic insight into the process of TRM establishment with 





Section 4.2: Results  
Section 4.2.1: Infants generate robust, lung-localized primary T cell responses to 
influenza infection 
We utilized an infant mouse model to assess tissue-localized immune responses 
following influenza infection. To most accurately recapitulate the immune environment 
of humans during early life, we elected to use mice at 2 weeks of age for two primary 
reasons. First, mice, unlike humans, are profoundly lymphopenic at birth and 
consequently lack much of the cellular complement necessary for mounting robust 
adaptive immune responses. Second, a significant fraction of peripheral T cells in the 
first week of murine life have a memory phenotype due to recent homeostatic expansion  
(307, 351) and at two weeks of age the peripheral T cell compartment begins to 
resemble that of humans in early life with predominantly naïve T cells in all tissues 
(283), unpublished data).  
 To evaluate the primary response to influenza infection we infected 2 week-old 
infant mice and 8-12 week-old adult mice for comparison with weight-adjusted sublethal 
doses of influenza. We then analyzed T cell responses in the lung at different timepoints 
post-infection. Throughout the course of infection, infant mice had similar overall lung 
viral burdens compared to adults with peak viral loads between days 3 and 5. The 
kinetics of viral clearance were, however, slightly delayed (D9 vs D11) in infants relative 
to adults (Figure 4.1a). 
Overall percentages of CD4+ and CD8+ T cells with an effector phenotype 
(CD44+CD62L(lo)) in the lung 10-15 days post-infection were remarkably similar in 
infected infants and adults (Figure 4.1b). Comparable percentages of lung influenza-
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specific CD8+ T cells for immunodominant epitopes in nucleoprotein (NP), polymerase 
basic protein 1 (PB1), and hemagglutinin (HA) were also observed in infants and adults 
(Figure 4.1c). We further found that CD4+ and virus-specific CD8+ T effectors were 
present in both adult and infant spleens at similar levels that were significantly reduced 
compared to lungs (not shown). Although peak T cell responses (D7-15) were 
comparable in infant and adult mice we found that, relative to adults, infants displayed a 
marked reduction in percentages of lung virus-specific T cells the contraction phase of 
the response (D16-21) (Figure 4.1d). 
Taken together, these data demonstrate that infant mice are capable of mounting 
productive, protective immune responses following influenza infection characterized by 
lung viral clearance comparable to adults, as well as the robust expansion of lung-
localized, virus-specific T cells. That comparable responses were observed with CD8+ T 
cells of multiple viral antigen specificities and in two distinct mouse strains highlights the 
durability of our findings. Although early T cell responses appeared similar between 
adults and infants, reduced percentages of virus-specific T cells in infants later in 





Figure 4.1: Comparable primary lung T cell responses in infants and adults 
following influenza infection  
Infant (2 week old) and adult (8-12 week old) mice were infected with weight-
adjusted, sublethal doses of PR8 influenza and lung viral titers and T cell responses 
assessed. (A) Kinetics of lung viral clearance in adult and infant mice expressed as 
TCID50/g of lung tissue at indicated timepoints following infection ± SEM. *p<0.05. 
(n=3-5 mice per timepoint, per group compiled from 2 independent experiments). (B) 
Lung CD4+ and CD8+ T cells in adult and infant mice 15 days post-infection or in 
uninfected controls. Top: Representative plots showing percentages of CD4+ and CD8+ 
cells with an effector/memory (CD44(hi)CD62L(lo)) phenotype. Bottom: Graph displays 
individual percentages of effector/memory phenotype populations with means ± SEM 
(n=8 mice per group compiled from 2 independent experiments; significance determined 
by two-tailed Student’s t test with Welch’s correction, ns p>0.05). (C) Influenza-specific 
CD8+ T cells in the lung 12-15 days post-infection in adult and infant C57BL/6 and 
BALB/c mice as indicated. Top: Representative plots showing percentages of lung 
NP366-374-specific (left), PB1703-711-specific (middle), or HA533-541-specific (right) CD8+ T 
cells in infected adults and infants. Bottom: Graphs display individual percentages of 
corresponding lung virus-specific CD8+ T cells ± SEM (n=4-8 mice per group compiled 
from 3 independent experiments; significance determined by two-tailed Student’s t test 
with Welch’s correction, ns p>0.05). (D) Kinetic analysis of HA533-541 virus-specific lung 
CD8+ T cell percentages in adult or infant mice at indicated timepoints post-infection ± 
SEM. (n=5 mice per group, representative of 2 experiments; significance determined by 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Section 4.2.2: Protective lung TRM are reduced following infection in infancy 
To assess whether infection during infancy results in the generation of persisting 
T cell memory we infected infant and adult mice with PR8 influenza similar to our 
primary response studies and analyzed T cell populations in the lung 6 weeks later. Due 
to the importance of TRM in protection from heterosubtypic influenza infection (198, 
331), we specifically investigated the establishment of this subset. To distinguish 
circulating T cells from tissue-localized TRM, we used an intravenous in vivo antibody 
labeling technique (i.v. Ab) whereby i.v. infusion of fluorescently-conjugated anti-T cell 
antibodies results in fluorescent labeling of circulating T cells while T cells retained 
within tissues are protected from antibody binding (201, 202). “Protected” and “labeled” 
T cells distinguished by i.v. Ab, exhibit phenotypic markers of TRM and circulating T 
cells, respectively, and are localized to distinct niches of the lung (201, 202).  
Using this technique, we found the majority of lung CD4+ and CD8+ T cells 
(>75%) in adult mice were protected from i.v. Ab labeling in contrast to only 35-45% 
protected in mice infected as infants, on average (Figure 4.2a). Furthermore, 
percentages of protected lung T cells were similar between mice infected as infants and 
in uninfected controls (Figure 4.2a). Similarly, percentages of protected NP-specific lung 
CD8+ memory T cells were increased in mice infected as adults compared to those 
infected in infancy (90% versus approximately 75%, respectively, Figure 4.2b).  
We further investigated whether protected lung T cell in infants expressed the 
canonical TRM markers CD69 and CD11a (CD4+ TRM) or CD103 (CD8+ TRM) (204, 
352). Consistent with previous studies, a significant fraction of protected CD4+ and 
CD8+ T cells in adults expressed both CD69 and CD11a (>60% of CD4+) or CD69 and 
	  
	  154	  
CD103 (approximately 50% of CD8+). In contrast, only 40% of protected CD4+ T cells 
and 15% of protected CD8+ T cells in previously infected infants and 15% of protected 
CD4+ and 3% of protected CD8+ T cells in uninfected controls expressed these 
markers (Figure 4.2c).  
Taken together, these data demonstrate that mice infected in infancy retain 
reduced percentages of CD4+ and virus-specific CD8+ T cells within the lung following 
infection. A greater percentage of virus-specific CD8+ T cells are circulating in infant 
memory mice, possibly indicating a bias toward circulating memory subsets rather than 
simply a failure to generate memory. In addition, lung-localized T cells from previously 
infected infants have reduced expression of canonical TRM markers suggesting that 
these tissue-localized cells are distinct from comparable populations established by 
adults. Overall, these findings demonstrate reduced establishment of canonical lung 
TRM following influenza infection in infants. 
Given that TRM are important mediators of protection against heterosubtypic 
influenza infection and that infants generate reduced lung TRM relative to adults, we 
hypothesized that mice infected initially as infants would be less protected against 
heterosubtypic reinfection later in life. Alternatively, infants may preferentially establish 





Figure 4.2: Reduced lung TRM in infants relative to adults after influenza infection 
Infant and adult mice were infected with PR8 influenza as in Figure 4.1 and lung 
T cell populations assessed 6 weeks post-infection. (A) Lung CD4+ or CD8+ T cells 
labeled by (labeled), or protected from (protected), i.v. anti-Thy1 Ab in previously 
infected adult or infant mice or in uninfected controls. Top: Representative flow plots 
showing percentages of labeled and protected lung CD4+ or CD8+ T cells. Bottom: 
Individual percentages of lung protected CD4+ or CD8+ T cells in previously infected 
adult or infant mice ± SEM. (n=15-18 mice per group, compiled from 4 independent 
experiments; significance determined by two-way ANOVA with Holm-Sidak’s multiple 
comparisons test, ***p<0.001). (B) Lung NP366-374-specific CD8+ protected T cells in 
previously infected adult or infant mice. Top: Representative flow plots showing 
percentages of labeled and protected lung NP366-374-specific CD8+ T cells. Bottom: 
Individual percentages of protected lung NP366-374-specific CD8+ T cells from previously 
infected adult or infant mice ± SEM. (n=15-18 mice per group, compiled from 4 
independent experiments; significance determined by Student’s t test with Welch’s 
correction, ***p<0.001). (C) Expression of TRM phenotype markers (CD11a, CD69, 
CD103) by protected lung CD4+ or CD8+ T cells in previously infected adult or infant 
mice or in uninfected controls Left: Representative flow plots with percentages of 
protected CD4+ cells expressing CD11a and CD69 (top) or protected CD8+ cells 
expressing CD69 and CD103. Right: Individual percentages of lung CD4+ TRM 
(CD69+CD11a+) or CD8+ TRM (CD69+CD103+) in mice previously infected adult or 
infant mice or in uninfected ± SEM. (n=5-15 mice per group, compiled from 3 
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experiments; significance determined by two-way ANOVA with Holm-Sidak’s multiple 
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To assess the capacity of infants to generate protective T cell memory we 
infected mice initially as infants or adults with PR8 (H1N1) influenza as in our previous 
experiments. After 6 weeks we challenged infant and adult memory mice and naïve 
adults as controls with the heterosubtypic H3N2 viral strain X31 and assessed weight 
loss and lung viral burden. As the majority of anti-viral antibody responses are directed 
toward surface HA and NA proteins, this system allows us to assess T cell-mediated 
protection from reinfection. To further assess TRM-mediated protection independent of 
that mediated by circulating T cells, we treated mice throughout infection with the 
sphingosine 1-phosphate receptor-1 agonist FTY720, which sequesters circulating T 
cells within the secondary lymphoid tissues, while TRM within the lung remain intact 
(202, 331, 353). We also challenged PBS-treated infant or adult memory mice to assess 
total T cell-mediated protection from both resident and circulating subsets.  
We found that FTY720-treated infant memory mice lost significantly more weight 
following heterosubtypic infection compared to adult memory and that overall weight 
loss was similar to naïve controls (Figure 4.3a, left). Lung viral burden at D5 post-
challenge was increased in infant memory relative to adult memory mice and not 
statistically different from naïve controls (Figure 4.3b, left). Furthermore, in contrast to 
infant memory mice, several adult memory mice completely cleared infection. In PBS-
treated cohorts, neither adult memory nor infant memory mice lost weight in response to 
heterosubtypic infection (Figure 4.3a, right). Additionally, there was no statistically 
significant difference in D5 lung viral burden, although there was a trend toward 
clearance in the adult memory group (Figure 4.3b, right).  
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Figure 4.3 Reduced lung TRM-mediated heterosubtypic protection in mice 
infected initially as infants versus as adults 
(A) Morbidity following heterosubtypic X31 (H3N2) challenge of mice infected 
previously with PR8 (H1N1) as in Figure 4.2. Left: Mean percentage weight retention in 
infected mice with daily PBS treatment ± SEM. Right: Mean percentage weight retention 
in infected mice with daily FTY720 treatment ± SEM. (n=4-9 mice per group compiled 
from 2 independent experiments; significance determined by multiple Student’s t tests 
comparing infected-as-adult to infected-as-infant, *p<0.05). (B) Viral clearance 5 days 
post-X31 infection in mice infected as adults or infants with PR8 influenza 6 weeks prior, 
compared to naïve mice. Left: Individual D5 lung viral titers in infected mice receiving 
daily PBS treatment ± SEM. Right: Individual D5 lung viral titers in infected mice 
receiving daily FTY720 treatment ± SEM. (n=4-9 mice per group, compiled from 2 
independent experiments; significance determined by one-way ANOVA with Holm-




























































































































































































The increased morbidity following heterosubtypic challenge observed in infant 
memory mice treated with FTY720 suggests a specific deficiency in protective lung 
TRM as circulating memory cells are retained in the lymph nodes. Interestingly, PBS-
treated infant memory mice are protected from weight loss and lung viral burden similar 
to adult memory mice. These findings suggesting that mice infected initially as infants 
are specifically deficient in TRM, and that circulating virus-specific T cell memory 
(Figure 4.2b), can provide some degree of protection, perhaps in concert with what lung 
TRM are generated by this group. 
 
Section 4.2.3: Reduced lung TRM establishment in LAIV-vaccinated infants 
We have previously shown in adult mice that current live-attenuated influenza 
virus (LAIV) and inactivated influenza virus (IIV) vaccines elicit distinct mechanisms of 
immune protection with IIV generating predominantly neutralizing antibodies and little 
lung-localized T cell memory and LAIV generating lung TRM protective to 
heterosubtypic reinfection (331). We hypothesized, therefore, that the reduced ability of 
infants to generate TRM in response to infection may affect their ability to generate 
protective responses to influenza vaccines.  
We vaccinated infant mice i.n. with LAIV or i.p. with IIV and analyzed lung T cell 
populations 10 days or 6 weeks post-vaccination. As positive and negative controls for 
lung T cell responses and TRM generation, we included adult LAIV and IIV-vaccinated 
controls, respectively. As in our previous study, adult LAIV-recipients generated robust 
primary lung CD4+ and CD8+ effector (CD44+CD62L(lo)) responses. Minimal lung T 
cell responses were observed in adult IIV recipients (Figure 4.4a). We observed that 
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primary vaccine responses in infants were consistent with those of their adult 
counterparts. LAIV-vaccinated infants further had percentages of lung CD4+ and CD8+ 
effectors similar to adult recipients while infant IIV recipients had only low percentages 
of lung effectors, similar to IIV-vaccinated adults.  
When we further assessed persisting lung T cell populations and associated 
protection 6 weeks post-infection we found that adult LAIV, but not IIV, recipients 
generated protected, lung CD69-expressing CD4+ and CD8+ T cells and CD103-
expressing CD8+ T cells (Figure 4.4b), as in our previous studies. Despite robust 
primary lung T cell responses, infant LAIV recipients had only low frequencies of 
protected lung T cells expressing CD69 and/or CD103 comparable to adult IIV 
recipients (Figure 4.4b), which do not generate significant lung TRM (331). Infant IIV 
recipients additionally generated only low frequencies of protected TRM (Figure 4.4b). 
Both infant LAIV and IIV recipients generated persisting neutralizing to vaccine viral 
strains, however, demonstrating that they are able to respond to vaccination (not 
shown). 
To determine whether the reduced generation of lung TRM by vaccinated infants 
resulted in reduced heterosubtypic protection, we challenged adult and infant vaccine 
memory mice after 6 weeks with PR8 influenza which is serologically distinct from 
vaccine viral strains (331). To specifically assess TRM-mediated protection We treated 
mice with FTY720 during infection. Compared to adult LAIV recipients, infant LAIV 
recipients and infant and adult IIV recipients all lost significantly more weight following 
challenge (Figure 4.4c). Furthermore, weight loss was equivalent between these 
groups. Interestingly, lung viral burden at D7 was significantly higher in IIV-treated 
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adults and infants compared to both infant and adult LAIV recipients which had similar 
D7 viral titers (Figure 4.4d).  
Together, these results demonstrate that LAIV, but not IIV-vaccination elicits lung 
effector T cell responses in infants. Furthermore, these responses are similar in 
frequency and phenotype to responses of adults. That IIV-vaccinated infants fail to 
generate significant lung responses but generate neutralizing antibodies is consistent 
with the systemic, rather than tissue-localized, nature of this vaccine. Despite robust 
primary responses to LAIV, infant mice fail to establish lung TRM comparable to that 
observed in LAIV-vaccinated adults and are less protected from subsequent influenza 
infection than adults in a TRM-dependent manner. LAIV-vaccinated infants are, 
however, protected from lung viral burden while IIV-vaccinated mice are not indicating 
that LAIV vaccination provides superior protection against heterosubtypic infection in 





Figure 4.4: Reduced TRM generation and TRM-mediated heterosubtypic 
protection in LAIV-vaccinated infants compared to adults 
Infant and adult mice were vaccinated i.p. with IIV or i.n. with LAIV (see methods) 
and lung T cell responses analyzed 10 days or 6 weeks later. (A) Frequency of lung 
effector/memory (CD44+CD62L(lo)) CD4+ and CD8+ T cells in adult or infant mice 
vaccinated 10 days prior with IIV or LAIV. (individual data ± SEM, n=4-5 mice per group, 
representative of 2 experiments; significance determined by two-way ANOVA with 
Holm-Sidak’s multiple comparisons test, ****p<0.0001, ns p>0.05). (B) Lung CD4+ and 
CD8+ TRM in mice vaccinated with IIV or LAIV as adults or infants 6 weeks prior. Top: 
Representative flow cytometry plots of lung CD4+ and CD8+ T cells protected from i.v. 
anti-Thy1 Ab (“protected”). Bottom: Protected lung CD4+ and CD8+ T cells expressing 
CD69 or CD103 ± SEM. (n=4-5 mice per group, representative of 2 experiments; 
significance determined by multiple Student’s t tests with Holm-Sidak’s comparisons 
correction, ***p<0.001). (C) Mice vaccinated as in (b) were challenged by 
heterosubtypic PR8 (H1N1) infection in the presence of FTY720. Graph shows 
morbidity expressed as mean percentage weight retention ± SEM. (n=5 mice per group, 
representative of 2 experiments; significance determined by multiple Student’s t tests 
comparing adult to infant LAIV-vaccinated, **p<0.01, *p<0.05). (D) Viral clearance 7 
days post-PR8 infection in mice challenged as in (c). (individual data ± SEM n=4-5 mice 
per group, representative of 2 experiments; significance determined by one-way 
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Section 4.2.4: Reduction in lung TRM establishment by Infants is cell-intrinsic 
We further asked whether the reduction in lung TRM observed in infant mice 
following influenza infection was due to the distinct lung environment of infants during 
infection or due to intrinsic differences between infant and adult T cells. We performed 
reciprocal adoptive transfers of infant or adult-derived influenza hemagglutinin (HA)-
specific CD4+ T cells (HA T cells) to WT congenic infant or adult recipients to generate 
four groups: adult HA-adult host, adult HA-infant host, infant HA-adult host, and infant 
HA-infant host. The resultant groups were subsequently infected with PR8 influenza. 
We assessed primary lung responses by transferred effectors at D13 and persistence of 
transferred cells in the lung as memory 6 weeks post-infection.  
During the primary response we found that all groups had similar percentages of 
transferred HA T cells in the lung with infant and adult-derived HA T cells present at 
comparable percentages in both host lung environments (Figure 4.5a). When we 
examined persistence of transferred cells as memory 6 weeks later we observed 
comparable low, but discernable, frequencies of adult HA T cells in the lungs of both 
adult and infant recipients (Figure 4.5b). However, we were not able to detect significant 
populations of persisting infant cells in the lungs of either host (Figure 4.5b). These 
results demonstrate that, while infant cells are capable of expanding and migrating to 
the lung in response to influenza infection comparable to adult cells, they are not 
efficiently maintained in the lung as long-term memory regardless of the host 




Figure 4.5: Reduced lung TRM generation by infants is T cell-intrinsic 
Naïve (CD44(lo)) influenza hemagglutinin (HA)-specific CD4+ T cells isolated 
from infant or adult TS1-transgenic mice were transferred to adult or infant congenic 
(Thy1.2) hosts which were subsequently infected with PR8 influenza and assessed 13 
days (a) or 6 weeks (b) post-infection (A) Representative flow cytometry plots of 
transferred adult or infant HA-specific T cells in the lungs of infant or adult recipient mice 
13 days post-infection with mean frequencies (bottom) ± SEM. (n=4-11 mice per group 
compiled from 3 independent experiments; significance determined by one-way ANOVA 
with Holm-Sidak’s multiple comparisons test, ns p>0.05). (B) Representative flow 
cytometry plots of transferred adult or infant HA-specific T cells in the lungs of infant or 
adult recipient mice 6 weeks post-infection with mean frequencies (bottom) ± SEM. 
(n=9-10 mice per group compiled from 3 independent experiments; significance 
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Section 4.2.5: Enhanced T-bet expression predicts transcriptional differences in 
infant and adult primary effectors 
Given that impaired lung TRM generation by infants is T cell-intrinsic, we 
hypothesized that distinct gene expression patterns between adult and infant T cells 
during the acute response might drive this difference. To test this, we assessed the 
transcriptional profiles of transferred infant and adult T cells isolated from the adult lung 
environment during primary influenza infection using RNA-Seq. We transferred infant or 
adult HA T cells to adult congenic mice and infected the resulting host mice with PR8 
influenza. We then isolated transferred infant or adult HA T cells (referred to as “HA 
effectors”) from host lungs 13 days later for whole-transcriptome profiling. We elected to 
isolate cells at D13 post-infection as this corresponds roughly to the initial phases of T 
cell contraction following influenza infection and reasoned that transcriptional 
differences in factors influencing memory establishment may occur at this time. 
A total of 634 genes were significantly differentially expressed (p<0.05) between 
infant and adult HA effectors (Tables 4.1 and 4.2). Among these, several well-
established molecules important for lung tissue homing and retention, including CCR2, 
CCR5, CXCR6, CCR8 and Itga1 (VLA-1) (216, 354-358), were observed. Interestingly, 
expression of these molecules was consistently enhanced in infant HA effectors relative 
to adult (Table 4.1). We further found that expression of transcription factors typically 
associated with effector T cell differentiation and function, including Blimp1, Id2 and T-
bet (164, 167, 169, 170), was consistently enhanced in infant cells compared to adult 
(Table 4.1). Correspondingly, expression of transcription factors associated with the 
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generation of T cell memory including Eomes, Bcl6 and Id3 (165, 167, 168, 170) was 
reduced in infants (Table 4.2).  
We further used Ingenuity Pathway Analysis (IPA, http://www.ingenuity.com) 
(359) to identify upstream transcriptional regulators of the genes differentially expressed 
between infant and adult HA effectors (Figure 4.6a). Based on our observation that 
expression of transcription factors promoting effector differentiation was increased in 
infant HA effectors relative to adult, we were interested to find that STAT4 and its major 
target T-bet (360) were predicted positive regulators of the differential gene expression 
profile of infant HA effectors. To further evaluate a role for T-bet in the regulation of our 
differentially expressed gene profile, we compared genes differentially expressed 
between infant and adult HA effectors (634 total) to a list of genes found to significantly 
positively or negatively regulated by T-bet in an independent study (430 total, (328)). 
We found a substantial degree of overlap between our gene set and identified T-bet-
regulated genes with 12% of our genes represented in the T-bet-regulated set (Figure 
4.6b,d). To determine whether the direction of gene expression in infant HA effectors 
was consistent with upregulated T-bet expression we used Gene Set Enrichment 
Analysis (361). We found a strong correlation (p<0.0001) with genes known to be 
positively regulated by T-bet also upregulated in infant HA effectors and genes known to 
be negatively regulated by T-bet also downregulated in infant HA effectors, relative to 
adult (Figure 4.6c), suggesting that enhanced T-bet may be a driver of the gene 




Table 4.1: Upregulated genes in infant primary HA effectors 
Genes significantly (p<0.05) upregulated in D13 infant HA TCR effectors relative 
to adult D13 HA TCR effectors (397 total) as described in Figure 4.6. Genes are listed 
by decreasing fold change and ordered by p value. Gene names and corresponding 






	   	  
Ltf 1.68 Mgat4a 0.65 Aak1 0.57 Gcnt1 0.51 Plek 0.48 Epsti1 0.43 Cd274 0.39
Krt19 1.47 Rxra 0.65 Sema4a 0.57 Lrrc1 0.51 Gbp7 0.48 Slc20a1 0.43 Btg2 0.39
Krt7 1.05 Itgb3 0.65 Fbxo30 0.56 Atrn 0.51 Gpr68 0.48 Clu 0.43 Atp2a2 0.39
Cxcr6 1.03 Pag1 0.65 Sorl1 0.56 Swap70 0.51 Inpp5d 0.48 Nedd9 0.43 P2ry10 0.39
Cdh1 0.95 Dennd1b 0.65 Rhbdf2 0.56 Parp12 0.51 Id2 0.48 Tnfaip3 0.43 Plk3 0.39
Ccr8 0.94 Ccdc88c 0.65 Camk2g 0.56 Amica1 0.51 Cish 0.48 Myst3 0.42 Fmnl1 0.39
Sytl2 0.94 Prex1 0.65 Herc1 0.56 Mfap3 0.51 Ctsd 0.48 Vgll4 0.42 Zc3h7a 0.39
Rasgef1b 0.90 Srgap3 0.64 Ppp1r12a 0.56 Trp53inp2 0.51 Tpcn2 0.47 Birc6 0.42 Akna 0.39
Trim36 0.90 Rtn4rl1 0.64 Fosb 0.56 Phf21b 0.51 Fbxo42 0.47 Zfp292 0.42 B4galnt4 0.38
Kcnk5 0.89 Mx1 0.64 Rgs1 0.56 Nlrc3 0.51 Anxa11 0.47 Otud4 0.42 Irgm1 0.38
Zfp862 0.88 Cpd 0.64 Traf3ip1 0.55 Ep300 0.51 Khnyn 0.47 Plac8 0.42 Ceacam1 0.38
Osgin1 0.88 Ccrl2 0.64 Dsp 0.55 Osbpl3 0.51 N4bp1 0.47 Arih2 0.42 B4galt1 0.38
C1qb 0.87 Entpd1 0.64 Ildr1 0.55 Kidins220 0.51 Perp 0.47 Cd40lg 0.42 Baz1a 0.38
Gsto1 0.86 Ly6a 0.64 Adssl1 0.55 Abr 0.51 Igf2r 0.47 Ctsw 0.42 Ms4a4b 0.38
Aqp3 0.86 BC013712 0.63 Pparg 0.55 Litaf 0.51 Errfi1 0.47 Trp53inp1 0.42 Hsp90b1 0.38
Calca 0.85 Vcl 0.63 Mmp14 0.55 Rgs2 0.51 Tigit 0.47 Mxi1 0.42 Gbp4 0.37
Chst11 0.84 H2-Ea-ps 0.63 Mll2 0.55 C1qc 0.50 AA986860 0.47 Ankrd11 0.42 Purb 0.37
Cd74 0.82 Atp8b4 0.63 Ccl5 0.55 Fam19a3 0.50 Cnnm3 0.46 Dgat1 0.42 Arl4c 0.37
Epcam 0.81 Itgav 0.63 Pmaip1 0.55 Pde8a 0.50 Heatr6 0.46 Tnfrsf1b 0.42 Tgoln1 0.37
Chi3l3 0.81 Gxylt1 0.63 Gzma 0.54 Braf 0.50 Rmi1 0.46 Mll1 0.41 Gpr183 0.37
Ppp2r2c 0.81 Gpr55 0.62 Gatm 0.54 Pip5k1a 0.50 Arntl 0.46 Rln3 0.41 Cep110 0.37
Lamc1 0.81 Gbp10 0.62 Fancm 0.54 Mafb 0.50 Ppp1r3b 0.46 Isg15 0.41 Gng2 0.37
Ptprj 0.81 Crebbp 0.62 Clock 0.54 Gbp6 0.50 Fcho2 0.46 Diap1 0.41 Amfr 0.37
Hip1 0.80 Rbpj 0.62 Gm16907 0.54 Plcd1 0.50 Antxr2 0.46 Prrc2b 0.41 Chd7 0.37
H2-Aa 0.78 Itgb5 0.61 Camk1d 0.54 Havcr2 0.50 Dennd4a 0.46 Nr6a1 0.41 Uhrf2 0.37
Il10ra 0.78 Scarb2 0.61 Asb1 0.54 Lamc2 0.50 Ski 0.46 Mndal 0.41 Ncor1 0.37
Ccr5 0.77 Smad3 0.61 Tmcc1 0.54 Plekhm1 0.50 Il18rap 0.46 Irf2 0.41 Il4ra 0.37
Itga1 0.77 Npc1 0.60 Acsbg1 0.54 Xpo7 0.50 Fli1 0.46 Gcn1l1 0.41 Nptn 0.36
Hsph1 0.77 Lgmn 0.60 Dennd5a 0.54 Ifitm1 0.50 Cmtm7 0.46 Trim30a 0.41 Cyld 0.36
Chsy1 0.76 Apobr 0.60 Msln 0.54 Fasl 0.50 Hilpda 0.46 Rfx1 0.41 Dock11 0.36
Oplah 0.73 Clec12a 0.60 Dopey2 0.54 Rbl2 0.50 Gzmb 0.46 Vps54 0.41 Atp8b2 0.36
Mx2 0.73 Fcgr2b 0.60 Egr1 0.54 Zyx 0.50 Cobll1 0.45 Pxn 0.41 Adcy7 0.36
Nupr1 0.73 Dpy19l1 0.60 Cxcl16 0.53 Arid1a 0.50 Ptpre 0.45 Lass4 0.41 Scd1 0.36
Vdr 0.73 Itch 0.60 Ly6c2 0.53 Kif21b 0.50 Fndc3a 0.45 Slc38a2 0.41 Ikzf3 0.36
Prdm1 0.73 H2-Eb1 0.60 Pgm2l1 0.53 Klf6 0.50 Ccl4 0.45 Per1 0.41 Dock8 0.36
Plin2 0.73 Gse1 0.60 Cass4 0.53 Itsn1 0.49 Evi2b 0.45 Myo1f 0.41 Tab2 0.36
Rhoq 0.72 Tnk2 0.60 Lyst 0.53 Spg11 0.49 Rnf125 0.45 Pld3 0.41 Pde4b 0.36
Slc16a6 0.72 Dusp5 0.60 Itgae 0.53 Cd200r4 0.49 Asph 0.45 S1pr4 0.40 Lasp1 0.35
Runx2 0.72 Ahnak 0.60 Dyrk3 0.53 Anxa3 0.49 Akap9 0.45 Ifitm3 0.40 Gpx2 0.35
Ctsc 0.72 H2-T24 0.59 Serinc3 0.53 Arsb 0.49 Lgals3 0.45 Scaf8 0.40 Pmepa1 0.35
Tlr2 0.71 Galnt3 0.59 Gm20199 0.52 Zfp873 0.49 Smg1 0.45 Nsd1 0.40 Atxn2l 0.35
St14 0.71 Frmd4a 0.59 Ap4e1 0.52 Sdc1 0.49 Ppp1r16b 0.45 Ppp1r9b 0.40 Grina 0.35
Adam19 0.70 Prcc 0.59 Trip10 0.52 Taok1 0.49 Thy1 0.45 Gna15 0.40 Cldn3 0.35
Gp49a 0.70 Lilrb4 0.59 Gpr56 0.52 Ccdc6 0.49 Rprd2 0.44 Cln3 0.40 Icos 0.34
Atp2b4 0.70 Zfp36l2 0.59 Notch2 0.52 Gsta4 0.49 Arid2 0.44 Zfp658 0.40 Rab8b 0.33
Dock5 0.69 Anxa1 0.59 Krt18 0.52 Gbp9 0.49 Adam8 0.44 Kdm6b 0.40 Mxd1 0.33
Tgfbi 0.69 Myadm 0.58 Wdr81 0.52 Kndc1 0.49 Atxn1 0.44 Htra3 0.40 Snrnp70 0.33
Atf3 0.68 Mef2a 0.58 Taf15 0.52 Tacc1 0.49 Tmem33 0.44 Picalm 0.40 Cyfip2 0.33
Sfn 0.67 Golim4 0.58 Fam38a 0.52 Ugcg 0.49 Lyz2 0.44 Pde4d 0.40 Gabrp 0.33
Rab11fip4 0.67 F2r 0.58 Plec 0.52 Abca2 0.49 Smad7 0.44 Tsc22d3 0.40 Sh2d2a 0.32
Hyou1 0.67 Sik1 0.58 Gpr65 0.52 Ifngr1 0.49 Fosl2 0.44 Phip 0.39 Rgs16 0.32
Ccr2 0.67 Nbeal2 0.58 Evi2a 0.52 Mllt6 0.49 Cd28 0.44 Klf13 0.39 Btg1 0.32
Hip1r 0.67 Nkg7 0.58 Txnip 0.52 Senp5 0.48 Il2rb 0.44 Esyt1 0.39 Srrm2 0.31
Padi2 0.66 Lyn 0.57 Tbx21 0.52 Eif2ak3 0.48 Ctla4 0.44 Eif2c4 0.39 Ripk4 0.29
Ifit1 0.66 Slc16a10 0.57 Tor1aip2 0.52 Plxnb1 0.48 Pik3r5 0.43 Axin1 0.39 Mbnl1 0.29
Clec7a 0.66 Sos2 0.57 Samd9l 0.52 Usp20 0.48 Agap2 0.43 Akap13 0.39
Nfat5 0.66 Herc6 0.57 Tpp2 0.52 Dbf4 0.48 Med13l 0.43 Stk10 0.39











Table 4.2: Downregulated genes in infant primary HA effectors 
Genes significantly (p<0.05) downregulated in D13 infant HA TCR effectors 
relative to adult D13 HA TCR effectors (237 total) as described in Figure 4.6. Genes are 
listed by decreasing fold change and ordered by p value. Gene names and 
corresponding log2 fold change (L2FC) are indicated. Genes of interest mentioned in 




	   	  
Lrig1 -1.23 Tnfrsf25 -0.62 Satb1 -0.52 Cep63 -0.46 Prkcq -0.36
A↵3 -1.19 Id3 -0.62 Gpx1 -0.51 Timp2 -0.45 Rpl13a -0.35
Slamf6 -0.97 Plxnc1 -0.62 Tuba1b -0.51 Ndufa4 -0.45 Armcx6 -0.34
Ntrk3 -0.94 Casp4 -0.61 Cxcr5 -0.51 Rps19 -0.45 Tnfrsf4 -0.34
Mapk11 -0.89 Asap1 -0.61 Mif -0.51 Hap1 -0.45 Ccm2 -0.34
Dennd2d -0.88 As3mt -0.61 Sh2d1a -0.51 Hvcn1 -0.45 Relb -0.34
Coro2b -0.86 Ext1 -0.61 Plcb2 -0.51 Actn1 -0.45 Fyn -0.33
Adck3 -0.84 Cd22 -0.60 C1qbp -0.51 Parp8 -0.45 Rpl32 -0.33
Fam49a -0.84 Egln3 -0.60 Abhd11 -0.51 Snrpd2 -0.45 Ldha -0.33
Srm -0.82 Nsg2 -0.60 Echs1 -0.51 Stat5a -0.45
Slc2a6 -0.81 Slc1a4 -0.60 Nrn1 -0.51 Rpl41 -0.45
Tbc1d4 -0.80 Synpo -0.60 Cbr1 -0.51 Raf1 -0.44
Trib2 -0.80 Dbi -0.60 Naprt1 -0.51 Mcm2 -0.44
Penk -0.79 Mgrn1 -0.60 Galk1 -0.51 Ftl1 -0.44
Trerf1 -0.79 P2rx7 -0.59 Mvk -0.51 Pqlc1 -0.44
Il1r2 -0.78 BC021614 -0.58 Tha1 -0.51 Rgs10 -0.44
Il21 -0.76 Usp33 -0.58 Ptrh1 -0.51 Ispd -0.44
S1pr1 -0.76 Dtx1 -0.58 Zmynd19 -0.51 Tbl3 -0.44
St3gal2 -0.75 Fam162a -0.57 Timeless -0.51 Socs3 -0.43
Slc43a1 -0.75 Rundc3a -0.57 Rrm2 -0.50 Tnfaip8 -0.43
Marcksl1 -0.74 Bcat1 -0.57 Shmt2 -0.50 Nt5c3l -0.43
Cd83 -0.74 Adi1 -0.56 Uck2 -0.50 Suclg1 -0.43
Tnfrsf26 -0.74 Eomes -0.56 Rps15 -0.50 Wdr46 -0.43
Ramp3 -0.74 Tnfrsf14 -0.56 Rcl1 -0.50 Nme1 -0.42
Rnf157 -0.73 Socs1 -0.56 D8Ertd82e -0.50 H2afv -0.42
Fbxo17 -0.73 Ccnb2 -0.56 Abcb8 -0.50 Sidt1 -0.42
Pou2af1 -0.73 Clpb -0.56 Bphl -0.50 Plekhj1 -0.42
Tspan32 -0.73 Rgs11 -0.56 Gm14085 -0.50 Nop10 -0.42
Pkp4 -0.72 Fas -0.55 Ankrd46 -0.49 Cdk2ap2 -0.41
Gypc -0.71 Bcl6 -0.55 Ipo5 -0.49 Atp5e -0.41
Adk -0.71 Sparcl1 -0.55 Cpsf3 -0.49 Ier5l -0.41
Nav2 -0.71 Atad3a -0.55 Evl -0.49 Dapp1 -0.41
Dph5 -0.71 Art2a-ps -0.55 Mrpl52 -0.49 Rplp1 -0.40
Stx11 -0.69 Hmgn1 -0.55 Polr2e -0.48 Pkm2 -0.40
Cdk5r1 -0.69 Setd4 -0.55 Por -0.48 Rpa1 -0.40
Folr4 -0.67 Sh3bp5 -0.55 Nolc1 -0.48 Tmsb10 -0.40
Tspan3 -0.67 Ankrd37 -0.55 Bzw2 -0.48 Slc25a11 -0.40
Nbn -0.67 Sssca1 -0.55 Parp1 -0.48 Mybbp1a -0.40
Tnfsf8 -0.66 Ipmk -0.55 Tpi1 -0.48 Ikbke -0.40
Tspan5 -0.66 Batf -0.54 Vav2 -0.48 Il6st -0.40
Nefh -0.66 Prelid2 -0.54 Heatr3 -0.48 Lsm4 -0.40
Tox2 -0.66 Maged1 -0.54 Gm5424 -0.48 Cdk4 -0.40
Usp6nl -0.65 Gltp -0.54 Fam18b -0.48 Tubb5 -0.39
Btla -0.65 Fbn2 -0.53 Bckdk -0.48 Eif5a -0.39
Myc -0.65 Fam43a -0.53 Gar1 -0.48 Park7 -0.39
Cd200 -0.65 Decr1 -0.53 Sh2b3 -0.48 Rpl8 -0.38
Slc39a11 -0.65 Abhd8 -0.53 Als2cl -0.48 Casp1 -0.38
Filip1l -0.65 Phb -0.53 Stx6 -0.47 Mcm5 -0.38
Il1r1 -0.65 Pecam1 -0.53 Ica1l -0.47 Nhsl1 -0.38
Tspan13 -0.64 Fgfr1op -0.53 Saa3 -0.47 Prdx1 -0.38
Zan -0.64 Lta -0.52 Hdac10 -0.47 Slc41a1 -0.38
St6gal1 -0.63 Mpp1 -0.52 Fam108c -0.47 Rps20 -0.37
Lif -0.63 Cdca8 -0.52 Cyb5r3 -0.46 Mcm6 -0.37
Matk -0.63 Inadl -0.52 Gfra4 -0.46 Cs -0.37
Gpm6b -0.62 Fah -0.52 Gart -0.46 Emd -0.37
Cxcl10 -0.62 Limd2 -0.52 Ccr6 -0.46 Rnf145 -0.36
Icam2 -0.62 Igf1r -0.52 Rapgef4 -0.46 Cnn2 -0.36






Figure 4.6: Gene expression analysis of infant versus adult lung CD4 effectors 
reveals a T-bet signature 
 Influenza HA-specific CD4+ T cells (HA T cells) isolated from infant or adult TS1 
mice (Thy1.1+) were transferred to adult congenic hosts which were subsequently 
infected with PR8 influenza. Lung Thy1.1+ cells were sorted 13 days later for whole 
transcriptome profiling by RNA-Seq (sorted cells hereafter referred to as ‘lung HA T 
cells’). (A) Top predicted upstream transcriptional regulators, determined using the 
Ingenuity Pathway Analysis tool, based on differential gene expression patterns 
between adult and infant lung HA T cells. Top 20 upstream regulators as assessed by 
p-value, sorted by z-score. (B) Venn diagram depicts overlap of genes significantly 
(p<0.05) differentially expressed between adult and infant lung HA T cells (634) and 
those previously determined (328) to be regulated by the transcription factor T-bet 
(430). (C) Gene Set Enrichment Analysis comparing genes significantly differentially 
expressed between adult and infant lung HA T cells with independently identified T-bet-
regulated genes (328). (D) Heatmap of genes significantly (p<0.05) differentially 
expressed between adult and infant lung HA T cells. Results represent differential gene 
expression from 3 independent isolations (designated 1,2,3) of adult and infant HA T 
cells pooled from 5-10 mice per experiment. Rightmost column: Genes (78) regulated 
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We then specifically evaluated T-bet expression by flow cytometry in infant and 
adult CD4+ effectors following activation both in vitro and in vivo. We performed 
polyclonal in vitro stimulation of sorted naïve (CD44(lo)) CD4+ T cells from either infant 
or adult mice or from infant or adult human spleen. We found in both infant mice (Figure 
4.7a) and in human infants (Figure 4.7b) that increased percentages of stimulated cells 
were T-bet(hi) compared to adults. In mice, infant CD4+ T cells upregulated T-bet more 
rapidly than did adult cells, although levels were comparable by 72 hours post-
stimulation (Figure 4.7a). In contrast, in humans, infant and adult cells expressed T-bet 
with similar kinetics following stimulation but a greater percentage of infant cells 
sustained high levels of T-bet relative to adult-derived cells (Figure 4.7b). To evaluate T-
bet expression by infant and adult cells in vivo, we adoptively transferred infant HA T 
cells to infant or adult congenic mice or adult HA T cells to adult congenic mice and 
infected hosts with PR8 influenza. At D13 post-infection a greater percentage of infant 
cells expressed T-bet compared to adult cells. This enhanced expression of T-bet was 
further independent of the host environment with comparable percentages of T-bet(hi) 
infant HA T cells in both infant and adult hosts (Figure 4.7c) suggesting that enhanced 




Figure 4.7: Increased T-bet expression by infant T cells following in vitro 
activation or during primary influenza infection 
(A) T-bet expression following in vitro activation of mouse infant or adult naïve 
(CD44(lo)) CD4+ T cells isolated from spleen. Left: Representative flow cytometry 
histograms of T-bet expression following anti-CD3/anti-CD28 activation at indicated 
timepoints. Right: Percentages of stimulated adult or infant CD4+ T cells expressing T-
bet over unstimulated at indicated timepoints ± SEM. (n=3 replicate samples per group 
per timepoint with each group derived from the spleens of 4-10 mice; representative of 2 
experiments; significance assessed by multiple Student’s t tests with Welch’s correction, 
*p<0.05). (B) T-bet expression following in vitro activation of human infant or adult naïve 
(CD44(lo)) CD4+ T cells isolated from spleen. Left: Representative flow cytometry 
histograms of T-bet expression 72hr post-activation with anti-CD3/anti-CD28 by adult 
(blue) or infant (green) and unstimulated (black) cells at indicated timepoints. Right: 
Percentages of stimulated adult or infant CD4+ T cells expressing T-bet over 
unstimulated at indicated timepoints ± SEM. (n=4 replicate samples per group per time 
point with each group derived from a different human spleen; significance determined 
by Student’s t test, *p<0.05). (C) T-bet expression by transferred adult or infant HA T 
cells in the lungs of adult or infant recipients following PR8 influenza infection. Left: 
Representative flow cytometry histograms of T-bet expression in transferred adult or 
infant HA T cells in the lungs of recipients at D13 post-infection. Right: Compiled 
percentages of adult or infant HA T cells in adult or infant recipient lung with a T-bet(hi) 
(expression over naïve) phenotype ± SEM. (n=3-4 mice per group; significance 
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These data demonstrate that infant and adult lung effectors exhibit distinct 
transcriptional profiles during the primary responses to infection, which occur 
independent of environment. Significantly the distinct transcriptional responses 
observed between infant and adult cells during the primary response, including the 
enhanced expression of T-bet, may influence the subsequent generation of memory T 
cell subsets. 
 
Section 4.2.6: T-bet heterozygosity restores TRM generation in infants 
Our finding that transcriptional differences between infant and adult T cells in the 
primary infection response may be T-bet-regulated was of significant interest as robust 
T-bet expression by activated T cells promotes Th1-type responses and biases toward 
the generation of terminally-differentiated effectors while limiting memory establishment 
(85, 164). Recent studies have further demonstrated that CD8+ TRM are intermediate 
for T-bet expression and that intermediate levels of T-bet drive TRM differentiation (104, 
217). 
We hypothesized, therefore, that augmented T-bet expression by infant T cells in 
response to infection could alter T cell differentiation and consequently limit their ability 
to efficiently generate protective TRM. To test this, we used infant mice heterozygous 
for T-bet to effectively “modulate” T-bet expression. We infected 2 week-old T-bet+/- 
mice, age-matched WT infants, and WT adult controls with weight adjusted-sublethal 
doses of PR8 influenza and assessed lung TRM generation 6-8 weeks later. 
Importantly, as T-bet expression is co-dominant, deletion of a single allele effectively 
reduces expression on a per-cell basis (Figure 4.8c).  
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Consistent with our previous data, total numbers of lung CD4+ and CD8+ T cells 
protected from i.v. Ab labeling were reduced in WT memory infants compared to adults 
(Figure 4.8a). Significantly, T-bet+/- memory infants had similar or increased numbers of 
protected lung CD4+ and CD8+ T cells compared to adult memory controls (Figure 
4.8a). We further observed in both WT adult memory and T-bet+/- infant memory mice 
that the majority of protected lung CD4+ (approximately 60% in both groups) and CD8+ 
T cells (50% in WT adult and 45% in T-bet+/- infants) expressed canonical CD4+ and 
CD8+ TRM markers (Figure 4.8b). In contrast, only 40% of protected CD4+ T cells and 
20% of protected CD8+ T cells in WT memory infants expressed these markers 
(Fig.8b). We additionally confirmed that T-bet expression was reduced in both naïve 
CD4+ and CD8+ T cells and TRM in T-bet+/- infant memory mice compared to WT adult 
memory (Figure 4.8c). 
These data demonstrate distinct differences in the generation of lung-localized 
TRM between WT and T-bet+/- mice following infection during infancy. T-bet+/- mice 
infected as infants establish increased numbers of protected lung CD4+ and CD8+ T 
cells compared to WT infants. Furthermore, increased percentages of protected T cells 
in T-bet+/- mice express the canonical TRM markers CD69 and CD11a (CD4+) or 
CD103 (CD8+) compared to WT infant memory mice. Our results suggest that 
dysregulation of T-bet by infants during the primary response to influenza infection 
results in the reduced generation of lung TRM, which can potentially be restored 




Figure 4.8: T-bet heterozygous infants exhibit enhanced lung TRM establishment 
following influenza infection 
Wild-type (WT) adult mice and WT or T-bet+/- infant mice were infected with PR8 
influenza and lung T cells analyzed 6-8 weeks post-infection. (A) Numbers of CD4+ and 
CD8+ T cell in the lung protected from i.v. anti-Thy1 Ab (“protected”, as described in 
Fig.2) in previously infected WT adult or WT or T-bet+/- infants. Graph displays 
individual percentages of protected CD3+ cell numbers ± SEM. (n=4-7 mice per group 
compiled from 2 independent experiments; significance determined by multiple 
Student’s t tests with Welch’s correction, ***p<0.001, *p<0.05). (B) Expression of TRM 
phenotype markers (CD11a, CD69, CD103) by lung protected CD4+ or CD8+ T cells in 
previously infected WT adult and infant mice or T-bet+/- infants. Left: Representative 
flow cytometry plots with percentages of protected CD4+ cells expressing CD11a and 
CD69 (top) or protected CD8+ cells expressing CD69 and CD103. Right: Individual 
percentages of lung CD4+ TRM (CD69+CD11a+) or CD8+ TRM (CD69+CD103+) in 
previously infected WT adult or infant mice or T-bet+/- infant mice ± SEM. (n=7-10 mice 
per group, compiled from 3 experiments; significance determined by two-way ANOVA 
with Holm-Sidak’s multiple comparisons test, ****p<0.0001, ***p<0.001, **p<0.01). (C) 
T-bet expression by CD4+ and CD8+ naïve and TRM subsets in previously infected WT 
adult mice or T-bet+/- infant mice. Graph (bottom) displays individual T-bet mean 
fluorescence intensity values for lung CD4+ or CD8+ naïve or TRM T cells ± SEM. (n=3-
4 mice per group, representative of 2 independent experiments; significance determined 
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Section 4.3: Discussion 
Here we assessed the generation of lung primary and memory T cell responses 
following influenza infection or vaccination during infancy using a mouse model. In the 
primary response to infection we found that infant mice clear virus from the lungs with 
similar kinetics and viral burden compared to infected adults indicating the generation of 
protective immune responses. Significantly, infant mice generated robust lung-localized, 
influenza-specific T cell responses that were qualitatively and quantitatively similar to 
responses observed in adult mice. These findings are noteworthy because previous 
studies of infant infection have suggested reduced overall immune responses and 
studies of influenza infection, specifically, have reported delayed and quantitatively 
reduced CD8+ T cell responses with altered homing patterns relative to adults (305, 
306). Importantly, these studies used neonatal mice (<1 week of age) which are 
profoundly lymphopenic and have few CD8+ T cells, a finding not reflected in humans 
during the steady state or during acute viral respiratory infection (283, 362). For this 
reason, we elected to use mice at two weeks of age which are no longer lymphopenic 
and have a peripheral T cell compartment resembling that of humans in early life (307, 
351) (unpublished data). 
Although T cell responses at the peak of infection were similar between infants 
and adults, we observed a reduction in lung virus-specific T cells in infants at later 
stages of infection (>20 days) compared to adults. Following complete recovery (6 
weeks), we further found that mice infected as infants had significantly reduced lung 
TRM relative to adult controls and were consequently less protected from 
heterosubtypic influenza infection in a TRM-dependent manner. Interestingly, however, 
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in studies assessing protection mediated by both TRM and circulating memory, infant 
memory mice demonstrated protection greater than that observed in TRM-only 
protection studies suggesting that infants generate protective circulating memory T cell 
populations. Indeed, we find that an increased fraction of virus-specific memory T cells 
are circulating in infant memory compared to adult controls. Consistent with the 
reduction in TRM generation we observe in infant mice, proportions of CD103-
expressing CD8+ T cells in the peripheral tissues of young children and infants are 
reduced relative to adults, including in the lungs (283), suggesting reduced populations 
of TRM in humans during early life. However, it is not possible to distinguish whether 
this is due to and inability of generate TRM or due solely to reduced antigen exposure.  
In studies of adult mice, our lab has previously shown that vaccination with LAIV 
elicits lung TRM protective against heterosubtypic influenza infection. We asked 
whether influenza vaccination was also able to elicit comparable protective lung T cell 
responses in infants. Vaccination with LAIV, but not IIV, elicited primary lung effector T 
cell responses in infants, consistent with previous findings in adult mice (331). However, 
despite primary lung T cell responses comparable to adults, infant LAIV recipients 
generated reduced lung TRM and were less protected from heterosubtypic infection 
than LAIV-vaccinated adults in a TRM-dependent manner. Significantly, infant LAIV 
recipients were better protected than infants receiving IIV, suggesting that LAIV elicits 
superior protection from heterosubtypic in this age group. These results are consistent 
with vaccine studies in human infants demonstrating that LAIV, but not IIV, generates 
circulating, virus-specific T cell responses (313) and that LAIV better protects from 
influenza infection in children (251). Our finding that LAIV generates reduced protective 
	  
	  186	  
TRM in infant mice relative to adults suggests that the protection mediated by LAIV in 
children could be mediated by a distinct cell subset(s), such as circulating memory. 
However, other factors, such as preexisting antibody or T cell memory responses may 
limit LAIV efficacy in adult humans relative to mice. The efficacy of recent LAIV 
formulations in both children and adults has, however, come into question (314) 
suggesting that further studies into its mechanism of protection may be warranted. 
By transferring adult or infant virus-specific T cells to adult or infant hosts we 
determined that the reduction in infant TRM generation is cell-intrinsic. We further 
identified through transcriptional profiling studies of adult and infant primary effectors a 
differential gene expression signature consistent with enhanced T-bet expression by 
infant effectors. To ‘modulate’ T-bet expression in infants we infected T-bet 
heterozygous mice which express intermediate levels of T-bet due to gene dosage 
effects. Strikingly, we observed substantial restoration of TRM establishment in terms of 
both total lung protected cell numbers and phenotype. T-bet is a well-established driver 
of Th1-type inflammatory responses and acts to control cell fate decisions (85, 161). 
High levels of T-bet expression by primary effectors are associated with terminal 
differentiation leading to cell death rather than maintenance as memory (159). 
Intermediate expression of T-bet, however, promotes TRM establishment and TRM are 
intermediate for T-bet expression (104, 217) relative to naïve and TCM subsets, which 
are T-bet(lo), and effector and TEM subsets which are T-bet(hi). Based on our findings, 
we therefore suggest that increased expression of T-bet by infant T cells during the 
primary may result in their terminal differentiation and loss during T cell contraction at 
the expense of effective TRM generation.  
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What factors, then might promote strong Th1 responses and T-bet expression by 
infant effectors during influenza infection? It is known that Th1 responses are necessary 
for effective clearance of influenza infection (91) and that IFN-gamma is the major 
effector cytokine associated with Th1 responses. T-bet plays an essential role in IFN-
gamma expression by directly binding and remodeling the IFN-gamma (363). 
Interestingly, the IFN-gamma locus is hypermethylated in neonatal T cells. Therefore, 
robust expression of T-bet may be necessary to overcome transcriptional inhibition in 
neonates to promote protective levels of IFN-gamma, simultaneously promoting function 
while reducing the capacity of these cells to generate long-term protective memory.  
Alternatively, enhanced T-bet expression in infants may be related to the nature 
of T cell development. In humans, mature naïve T cells populate the periphery 
beginning at 10-12 weeks gestation (364). At this time, the peripheral tissues are 
completely lymphopenic and these T cells begin to homeostatically expand. A similar 
phenomenon occurs in mice in the first two weeks of life (307, 351). In both humans and 
mice, traces of this homeostatic proliferative profile remain in early life. T cells derived 
from fetal tissues or cord blood express increased Ki67 and have an increased 
tendency to proliferate in response to homeostatic cytokine signals such as IL-2, IL-7 
and IL-15 (287, 365). In mouse models, homeostatic proliferation depends on mTOR 
signaling (366), and further, that mTOR drives T-bet expression (367). Thus, the 
increased tendency of infant T cells to express T-bet may be related to their recent 
homeostatic expansion. Interestingly, the pharmacologic agents Sirolimus and 
Metformin act to limit mTOR signaling, both directly and indirectly, suggesting that 
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administration of these drugs during vaccination or infection may serve to enhance TRM 
generation by suppressing T-bet activity. 
In total, the work presented here contributes an enhanced understanding of early 
life immunity consistent with the emerging paradigm that infant responses are not 
simply intrinsically reduced but rather distinct compared to those of adults. Our findings 
demonstrating the ability of infant T cells to generate robust primary responses following 
influenza infection and vaccination further provides additional evidence to a growing 
body of work demonstrating an intact capacity to generate Th1-type responses in early 
life. Our results highlight differing abilities to generate functional lung TRM dependent 
on age and further provide mechanistic insight into this process identifying T-bet as a 
potential target to promote enhanced TRM formation following infection or vaccination in 
early life.  
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CHAPTER 5: Conclusion 
 
 Influenza is an important global health burden which disproportionately affects 
individuals with underlying immune conditions, including the very young. Although 
influenza is an important cause of morbidity and mortality in early life there is a lack of 
mechanistic understanding of factors contributing to the generation of durable protective 
immune responses in infants following influenza infection or vaccination. Identifying 
such factors and how they differ between young children and adults will aid in the 
rational design of future vaccines and therapeutics for this disease.  
Infection with influenza elicits robust antibody and T cell-mediated immune 
responses, both of which can provide long-lasting protective memory. While antibody 
responses provide sterilizing immunity against same viral strain, protection is limited 
due to the variable nature of viral surface HA and NA proteins. In contrast, T cell 
responses are directed toward conserved viral proteins and protect against viral strains 
of distinct HA and NA types. It is now understood that a significant fraction of the T cell 
memory generated following influenza infection is composed of non-circulating, lung-
tissue resident memory (TRM) T cells. TRM have been shown to provide superior 
protection from heterosubtypic viral reinfection and lethal challenge compared to 
circulating antibody or T cell responses. 
Due to their protective capacities, it is increasingly recognized that vaccination 
strategies promoting TRM establishment may convey enhanced protection from 
disease. However, whether TRM can be generated in response to current vaccination 
regimens and the factors necessary for their establishment, including the nature of the 
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immunizing antigen and route of administration have not been described. Additionally, 
whether individuals most susceptible to infection, including the very young, are capable 
of generating functional TRM is not known. The work presented here investigates the 
nature of T cell responses and TRM establishment following influenza vaccination and 
infection in both early life and adulthood with the hypothesis that tissue-localized 
immune responses are necessary for protective TRM generation and that intrinsic 
defects in early life responses to infection or vaccination limit T cell memory 
establishment.  
In studies comparing immune responses to influenza vaccination in adult mice, 
we identified distinct capacities of the two commercially available classes of influenza 
vaccines, inactivated influenza virus (IIV) and live-attenuated influenza virus (LAIV), to 
specifically elicit protective TRM. We found that, while IIV preferentially induced long-
lasting, strain-specific neutralizing antibodies, LAIV generated lung-localized, virus-
specific T cell responses and TRM, similar to those generated by influenza virus 
infection. LAIV-generated TRM further mediated heterosubtypic protection, independent 
of circulating T cells and neutralizing antibodies, which persisted long-term after 
vaccination. Interestingly, LAIV generated only limited circulating neutralizing antibody 
responses. Intranasal administration of IIV or injection of LAIV failed to elicit antibody or 
T cell responses or provide protection against viral infection, demonstrating that both 
targeting to the respiratory tract as well as the use of a live-attenuated viral strain are 
necessary for the effective establishment of lung TRM following vaccination. These 
findings are supported by recent vaccine studies demonstrating that mucosal 
	  
	  191	  
administration of antigen is important for the generation of localized T cell responses 
which may go on to establish TRM (220, 259, 262, 344-346).  
The IIV formulation used in this study is produced by chemically inactivating and 
disrupting whole influenza viral particles. While doses are standardized by the amount 
of viral HA per strain per dose, the vaccine contains additional viral proteins and RNA 
which can act as PAMPs. The amount and composition of these, however, are not 
assessed and may vary between preparations. It is noteworthy, then, that when IIV is 
introduced intranasally it is not sufficient to induce significant primary T cell responses, 
nor subsequent TRM establishment. This suggests that additional inflammatory signals 
are necessary for initial T cell lung recruitment and that this may be a prerequisite for 
TRM generation. While a live vaccine may provide these signals, establishment of 
protective TRM at the genital mucosa following administration of killed or inactivated 
vaccines has been demonstrated (220, 262), suggesting that live vaccines, per say, 
aren’t strictly necessary for this process. 
In studies of early life immune responses we found that mice infected with 
influenza or receiving LAIV in infancy generate robust primary lung T cell responses 
comparable to adults following both infection and vaccination. This finding was 
somewhat surprising given the current paradigm that T cell responses are reduced in 
early life relative to adults. Despite robust primary responses mice infected or 
vaccinated in early life failed to efficiently establish TRM and were subsequently less 
protected from later viral reinfection. Interestingly, proportions of CD103-expressing 
CD8+ T cells are reduced in the peripheral tissues of children relative to adults, 
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including in the lungs, (283) consistent with reduced TRM establishment in humans in 
early life as well.  
Adoptive transfer studies of adult and infant antigen-specific T cells to both adult 
or infant hosts, revealed that the failure of infants to efficiently establish TRM is cell-
intrinsic. Through transcriptional profiling studies, we further identified the Th1 lineage-
defining transcription factor T-bet as a potential mediator of the distinct gene expression 
pattern observed between adult and infant primary effectors. Our finding that infants 
upregulate T-bet in a T cell-intrinsic manner following activation is supported by a study  
demonstrating enhanced T-bet expression in activated neonatal effectors in a systemic 
infection model (368). Significantly, by utilizing T-bet heterozygous infant mice to control 
T-bet expression during the primary response to influenza infection we observed a 
restoration in TRM establishment to near adult levels, demonstrating a role for T-bet in 
TRM generation in early life. 
T-bet is a well-established driver of Th1-type inflammatory responses and is 
known to control T cell effector versus memory fate decisions with increasing levels of 
T-bet promoting effector differentiation and limiting the capacity to generate memory. 
The increase in T-bet expression by infant primary effectors may, therefore, result in 
their terminal differentiation and subsequent loss rather than maintenance as memory. 
Previous studies have demonstrated roles for T-bet in TRM generation with 
intermediate levels of T-bet promoting TRM establishment following infection while TRM 
themselves express intermediate levels of T-bet relative to naïve or effector or TEM 
subsets and (104, 217). This is consistent with our findings whereby controlling T-bet 
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expression during the primary immune response by utilizing T-bet heterozygous infant 
mice leads to enhanced TRM formation relative to WT infant controls.  
What factors promote T-bet expression by infants despite the fact that they are 
thought to be hyporesponsive and Th2-biased relative to adults? Enhanced expression 
of T-bet may be necessary to drive protective immune responses due to its role in 
regulating IFN-gamma expression. Previous work has demonstrated that the IFN-
gamma locus of cord blood-derived CD4+ T cells is hypermethylated relative to adults 
leading to reduced expression of IFN-gamma upon stimulation (295). However, under 
appropriate inflammatory conditions, this methylation is relieved and robust IFN-gamma 
production ensues. T-bet plays an essential role in IFN-gamma expression by directly 
binding the locus to enhance its expression (363). Thus, in situations where Th1-type 
immune responses are necessary, enhanced T-bet expression by infant T cells may 
restore IFN-gamma production to protective levels. The upregulated expression of T-bet 
may, however, simultaneously promote function while reducing the capacity of these 
cells to generate long-term protective memory. At the organismal level, however, this 
“choice” may be prudent as immediate survival should take precedence over 
unforeseen future dangers. 
Alternatively, the enhanced expression of T-bet by infant T cells may be related 
to the nature of T cell development and seeding of the peripheral tissues. During human 
development, mature naïve T cells begin to emerge from the thymus and populate the 
periphery as early at 10-12 weeks gestation (364). At this time, the peripheral tissues 
are completely lymphopenic and, as a result, new mature naïve T cells begin to 
homeostatically expand. A similar phenomenon occurs in mice in the first two weeks of 
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life (307, 351). Traces of a homeostatic proliferative profile remain in early life. T cells 
from fetal tissues or cord blood express increased Ki67, and exhibit a mature, 
CD44(hi)CD62lo, phenotype (287, 365), despite their lack of antigen encounter. T cells 
in early life further have an enhanced sensitivity to the survival cytokines IL-7 and IL-15, 
important drivers of homeostatic proliferation (287, 365). In mouse models, homeostatic 
proliferation has been shown to be driven by mTOR signaling (366) and mTOR, in turn, 
is an important driver of T-bet (367). Thus, the increased tendency of infant T cells to 
express T-bet following stimulation might be related to their recent homeostatic 
expansion. Interestingly, mTOR represents a drugable target, with the approved 
pharmacologic agents Sirolimus and Metformin acting on this pathway, both directly and 
indirectly. It is conceivable that administration of these drugs during vaccination or 
infection may serve to enhance TRM generation by suppressing T-bet activity.  
In summary, the studies presented here reveal several novel aspects of T cell-
mediated immunity in early life and adulthood. We demonstrate the generation of 
protective lung TRM following vaccination with LAIV and, of translational significance, 
establish TRM as an important correlate of vaccine-mediated protection to influenza 
virus. We further demonstrate differences in the ability to establish TRM dependent on 
age and provide mechanistic insight into this process, revealing T-bet as a possible 
target for improving early life vaccine responses. Importantly, this work contributes an 
enhanced understanding of the essential factors necessary for effective establishment 
of TRM, including 1) the route of antigen exposure, 2) the nature of the antigen, and 3) 
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Reduced Lung-Resident T cell Memory in Infants Following Influenza Infection 
 
KD Zens1,2 and DL Farber1,2,3 
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Immunology, 3Department of Surgery, Columbia University Medical Center, New York, 
NY 
 
For Keystone Viral Immunology Conference, Breckenridge, CO 2015 
 
Influenza is a major cause of morbidity and mortality in infants, who experience more 
severe primary infection and are more susceptible to reinfection. In adults, influenza 
generates robust, tissue-localized T cell memory which is protective in secondary 
infection. Using an infant mouse model, we investigated whether infants are able to 
establish functional, lung-resident T cell memory following influenza infection. We found 
that infants generate virus-specific, lung-homing primary T cell responses similar to 
adults. However, after resolution of infection, mice infected as infants exhibited a 
reduced frequency and number of lung tissue-resident memory (TRM) CD4+ and CD8+ 
T cells compared to mice infected as adults. Additionally, a reduced frequency of 
memory T cells from mice infected in infancy produce IFN-γ, known to be functionally 
important in secondary influenza infection. To determine whether age-dependent T cell-
intrinsic or environmental differences are responsible for the reduced TRM frequency in 
infants, we adoptively transferred hemagglutinin-specific CD4+ (HA) T cells derived 
from either adults or infants to both infant and adult recipients. We then challenged with 
influenza and assessed lung TRM establishment 6 weeks post-infection. In infant hosts, 
adult HA T cells were retained as TRM at a similar frequency as those transferred to 
adults. In contrast, reduced frequencies of infant HA T cells were maintained as TRM in 
both infant and adult hosts. Furthermore, adoptive transfer of adult HA T cells to infant 
hosts partially rescued endogenous (non-HA) TRM establishment compared to infants 
receiving infant cells. These results suggest T cell-intrinsic causes for the reduced TRM 
population in infants. Understanding factors contributing to the establishment of T cell 
memory in infants may have important implications in vaccine design and therapies for 
influenza in this population. 
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Tissue-resident memory T cells (TRM) comprise a non-circulating subset which 
provides robust in situ protection upon infection. It is increasingly recognized that 
vaccination strategies promoting TRM may convey enhanced protection from disease. 
However, it is unclear whether current vaccines elicit TRM and whether this is 
dependent on vaccine formulation or administration route. We assessed lung TRM 
generation and subsequent protection following vaccination with either injectable 
inactivated influenza virus (IIV, Fluzone®) or intranasal live-attenuated influenza virus 
(LAIV, FluMist®) vaccines. We found that IIV induced primarily neutralizing antibodies 
while LAIV generated robust lung T cell responses. Importantly, LAIV, but not IIV, 
established persisting lung CD4+ and CD8+ TRM similar in localization and phenotype 
to that generated by influenza infection. Furthermore, protection experiments utilizing 
FTY720, which sequesters circulating T cells in lymphoid tissues leaving lung TRM 
intact, demonstrated that only LAIV provided TRM-mediated protection to viral infection. 
Importantly, TRM generation and protection were dependent on both route and vaccine 
formulation. The ability of LAIV to generate lung TRM protective against non-vaccine 
viral strains may have important implications in providing protection in pandemic 
situations. 
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Influenza is a major cause of morbidity and mortality in infants, who suffer more severe 
disease and are more susceptible to reinfection. In adults, influenza generates robust 
lung tissue-resident T cell memory (TRM) which are protective upon subsequent 
infection. Using a mouse model, we investigated whether infants also establish lung-
TRM after influenza infection. We found that infants and adults mount similar primary 
lung T cell responses to influenza. However, following recovery, infected infants 
generated fewer lung TRM than mice infected as adults. Mice infected as infants also 
suffered greater weight loss and lung viral titers upon reinfection as adults in a TRM-
dependent manner. Reciprocal transfer of infant or adult CD4+ T cells to adult or infant 
hosts revealed that only adult cells are efficiently maintained as TRM after infection 
suggesting a cell intrinsic cause for reduced infant TRM. RNA-Seq analysis of infant 
and adult primary effectors revealed increased T-bet and strongly decreased levels of 
Eomes and the survival factor Bcl-2 in infant T cells while analysis of lung memory 
demonstrated lower levels of TRM-associated retention markers and survival factors 
Bcl-2 and Bcl-xL. Further pathway analysis implicated reduced IL-7 and IL-15 signaling 
in infant T cells suggesting a mechanism for their reduced TRM with important 
implications in vaccine design and therapies for influenza in this population. 
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Influenza is a major cause of disease in infants, who suffer enhanced illness and are 
more susceptible to reinfection than older children and adults. In adults, influenza 
generates robust lung tissue-resident T cell memory (TRM) protective in subsequent 
infection. Using a mouse model, we investigated whether infants also establish lung 
TRM after influenza infection. We found that infants and adults mount similar primary 
lung T cell responses to influenza. However, after recovery, infected infants had fewer 
lung TRM than mice infected as adults. Mice infected as infants suffered greater weight 
loss and viral burden upon reinfection as adults in a TRM-dependent manner. Transfer 
of infant or adult hemagglutinin-specific CD4+ T cells to adult or infant hosts revealed 
that only adult cells are maintained as TRM after infection suggesting a cell-intrinsic 
cause for reduced infant TRM. Following in vitro stimulation or influenza infection, infant 
T cells expanded more than adult cells. RNA-Seq analysis of infant and adult effectors 
demonstrated increased levels of the Th1 lineage-defining transcription factor T-bet and 
decreased expression of the survival factor Bcl-2 in infants. More infant effectors also 
expressed KLRG1, associated with short-lived effector cells, following infection. These 
findings suggest primary infant effectors expand and differentiate but may undergo 
apoptosis rather than retention as memory with implications in influenza vaccine and 
therapeutic design. 
 





Infant Lung-Resident T cell Memory Generation Following Infection is Controlled 
by T-bet Expression 
 
KD Zens1,2, JK Chen1,3, F Cvetkovski1,2, FL Wu3, RS Guyer4 and DL Farber1,2,3,5 
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Infants suffer increased morbidity and mortality following viral respiratory tract infection 
compared to older children or adults and are prone to repeated infections suggesting 
inefficient establishment of protective immune memory. Results in mouse models have 
established the importance of T cell responses targeted to and maintained as resident 
populations in the lung in mediating long-term protection to respiratory viruses. Here we 
evaluated the generation of lung T cell responses and establishment of lung tissue-
resident memory (TRM) T cells following influenza infection in infant mice. We found 
that infants mount robust primary (D7-15) lung T cell responses to influenza with CD4+ 
and CD8+ effector populations similar to adults. During contraction (D16-21), however, 
infant mice have markedly reduced lung virus-specific T cells compared to adults and, 
following recovery, significantly fewer lung TRM. Accordingly, mice infected initially as 
infants suffer greater weight loss and increased viral burden upon heterosubtypic 
reinfection as adults in a TRM-dependent manner. While transferred infant and adult 
hemagglutinin-specific (HA) CD4+ T cells expand similarly in infant or adult hosts 
following infection, only adult cells are maintained as TRM suggesting a cell-intrinsic 
cause for reduced infant TRM generation. We found infant HA T cells expressed more 
Th1 lineage-associated genes following RNA-Seq analysis of transferred primary 
effectors and predictive analysis of transcriptional regulators identified enhanced 
expression of T-bet as a potential upstream regulator of the gene expression pattern 
observed in infants. Significantly, lung TRM generation following influenza infection was 
nearly completely restored in T-bet heterozygous infant mice suggesting a model 
whereby dysregulation of T-bet by infant effectors prevents their efficient retention as 
memory with significant implications in our understanding of the infant immune 
response to infection and potential application in vaccine and therapeutic design. 
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